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The vast demand for ostrich meat has made South Africa the leader in not only the 
production of ostrich meat but also ostrich associated products such as feathers and 
leather. Ostrich specific mycoplasmas (referred to as Ms01, Ms02 and Ms03) cause 
respiratory tract infections with subsequent reduction in physical growth rate and 
therefore reduced production. To date no vaccines are available to combat these 
infections in ostriches. In this laboratory three DNA vaccines (pCI-neo, VR1012 and 
VR1020) have been developed with each containing the Ms01 oppA gene as antigen. 
The aim of this study was to evaluate these developed DNA vaccines in a mammalian 
cell culture based system as well as an ostrich vaccination trial.  
COS-1 cells were transfected with the three developed DNA vaccines. Transcription of 
the oppA gene was proven for all the plasmids. Translation into the OppA protein was 
shown to be limited to the VR1020_oppA plasmid. The protein was visualised by SDS-
PAGE and detected by western blot using chemiluminescence.  
Two of the vaccines, VR1020_oppA and pCI-neo_oppA, were administered in three 
concentrations (100 μg/ml, 300 μg/ml and 600 μg/ml) to ostriches during a vaccination 
trial followed by a booster injection. The ability of the vaccines to elicit anti-OppA 
antibodies was measured using ELISA. The pCI-neo_oppA vaccine failed to induce an 
immune response against the antigen after both the first and booster vaccinations. The 
VR1020_oppA vaccine on the other hand was able to elicit an anti-OppA immune 
response. 
  




Die groot aanvraag vir volstruisvleis het Suid-Afrika die leier in nie net die produksie van 
volstruisvleis nie, maar ook volstruis-geassosieerde produkte soos vere en leer gemaak. 
Volstruis-spesifieke mikoplasmas (verwys na as Ms01, Ms02 en Ms03) veroorsaak 
lugweginfeksies wat lei tot ‘n afname in fisiese groei tempo en gevolglike daling in 
produksie. Tot op hede is daar geen entstowwe beskikbaar om hierdie infeksies in 
volstruise te bekamp nie. In hierdie laboratorium is drie DNS-entstowwe (pCI-neo, 
VR1012 en VR1020) ontwikkel wat elk die Ms01 oppA geen bevat as antigeen. Die doel 
van hierdie studie was om hierdie DNS-entstowwe in 'n selkultuur-gebaseerde sisteem, 
sowel as 'n volstruis inentingproef te evalueer. 
COS-1-selle was getransfekteer met die drie DNS-entstowwe. Transkripsie van die oppA 
geen is bewys vir al die plasmiede. Translasie na die OppA proteïen was getoon, maar 
was beperk tot die VR1020_oppA plasmied. Die protein was gevisualiseer deur middel 
van SDS-PAGE en opgespoor deur middel van western-klad met behulp van 
chemiluminessensie. 
Twee van die entstowwe, VR1020_oppA en pCI-neo_oppA, was toegedien in drie 
konsentrasies (100 μg/ml, 300 μg/ml en 600 μg/ml) in volstruise tydens 'n inentingsproef, 
gevolg deur 'n skraagdosis. Die vermoë van die entstowwe om anti-OppA teenliggame 
te ontlok is gemeet deur middel van ELISA. Die pCI-neo_oppA entstof was nie daartoe 
in staat om na beide die eerste en skraag inentings 'n immuunrespons teen die antigeen 
te induseer nie. Die VR1020_oppA entstof daarenteen, was daartoe in staat om 'n anti-
OppA immuunrespons te ontlok. 
  




I would like to thank the following people/organizations for the technical, financial and 
emotional support. Without the following the thesis would not have been possible: 
Dr. A. Botes, Thank you for the opportunity given to me to complete this degree. Thank 
you for all the patience, time and your continuous efforts to assist me. The time spend 
here was an absolute joy and I learnt so much from you. 
Prof. Dirk U. Bellstedt, Thank you for all the advice, support and leadership throughout 
my degree.  
Mrs Coral de Villiers I want to thank you for not only the technical guidance and the 
welfare of our laboratory but also for the encouragement, life lessons and help during 
field trials. It made the time within the Laboratory an absolute joy. 
Mr W. Botes for the statistical analysis of the ELISA data. 
I would like to thank everyone within the “Struismoere” Laboratories and in particular 
Mariet Wium and Hestie Jonker for not only the “Sit die ketel aan” moments, but the 
friendships, support and encouragements throughout the degree. It made the 
environment very pleasant and day to day activities a lot of fun. 
National Research Foundation and Ostrich chamber, for the financial support 
throughout the degree.  
I want to say a special thanks to my Family for the support, love, encouragements as 
well as example they gave me to complete this degree. 
A big thank you to Samantha Jane Aldum, for the continuous support, love, care and 
encouragement. I appreciate everything you do, and look forward to the next book I’m 
writing that will be our life journey together.  
The biggest thank you must go to the Lord Jesus Christ, my rock and my best friend for 
the energy, strength and joy given every day (Psalm 106:1). 
 
 




ABC   ATP-binding cassette 
ABTS   2,2'-azino-bis(3-ethylbenzothiazoline-6-suphonic acid) 
Ag   antigen 
ampR   ampicillin resistance gene 
APC   antigen presenting cell 
ATP   adenosine triphosphate 
bp   base pair(s) 
kb   kilobase pairs 
BSA   bovine serum albumin 
CMV   cytomegalovirus 
CTL   cytotoxic T lymphocyte 
DAFF   department of agriculture, forestry & fisheries 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleotide 
DTT   dithiothreitol 
EDTA   ethylene diamine tetra-acetic acid di-sodium salt 
ELISA   enzyme-linked immunosorbent assay 
G+C   guanine and cytosine 
GOI   gene of interest 
GST   glutathione S-transferase 
g   gram(s) 
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h   hours 
Ig   immunoglobulin 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
kanR   kanamycin resistance gene 
kDa   kilo Dalton 
LB   Luria-Bertani 
M   molar 
mM   milimolar 
μg   microgram 
mg   milligram 
ml   milliliter 
μl   microliter 
MHC   major histo-compatability complex 
min   minutes 
mRNA  messenger ribonucleic acid 
NaCl   sodium chloride 
NCBI   National Centre for Biotechnology Information 
Opp   oligopeptide permease 
ORF   open reading frame 
ori   origin of replication 
PAP   peroxidase anti-peroxidase 
PBS    phosphate buffered saline  
Stellenbosch University  https://scholar.sun.ac.za
VIII 
 
PBS-T  phosphate buffered saline tween 
PCR   polymerase chain reaction 
RE   restriction endonuclease 
rRNA   ribosomal ribonucleic acid 
rpm    refs per minute 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
%T   acrylamide present 
%C   amount of cross-linker 
SV40   simian virus 40 
TB   terrific broth 
TEMED  tetramethylethylenediamine 
Th   T helper cell 
UV   ultraviolet 
X-ray   X-radiation 
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1 General introduction 
South Africa’s ostrich industry 
South Africa is the world leader in ostrich production and with 75% of the global market 
share it provides the country’s economy with an annual income of R1.2 billion. 
Domestication of ostriches started in 1860 in the Oudtshoorn district of the ‘Klein Karoo’ 
region of South Africa for feather production and later for leather. Today ostrich farms are 
found throughout South Africa, except in Kwazulu–Natal Province. The dry climate 
conditions, as well as the winter rainfall encountered in the Western Cape province, 
provide perfect breeding conditions for ostriches, making Oudtshoorn the capital of the 
ostrich industry in South Africa. More than 588 ostrich farms are registered in South 
Africa, the Western Cape has 453, 103 in the Eastern Cape and 33 farms in the rest of 
the country. Most importantly, the ostrich industry provides about 20 000 jobs (DAFF, 
2012). 
The ostrich industry produces three main products in the following ratios according to 
income: 45% ostrich meat, 45% leather and 10% feathers. Ostriches are slaughtered at 
14 months of age as this is the time when the bird presents the best meat, feathers and 
leather (Balog Ai and Paz, 2007). It is said that one slaughter ostrich produces as much 
as 27 kg of meat, 4.2 m2 of leather and 1 kg of feathers. Ostrich meat production only 
started to increase in the 1990’s and is strongly dependant on the high quality of the 
nutrition given to the ostriches (Majewska et al., 2009). The industry is a strongly export 
orientated industry. More than 8.3 million kg of ostrich meat, 90% of total production, is 
exported annually. The largest consumers of ostrich meat are European Union countries 
such as Belgium, Germany, the United Kingdom and the Netherlands, as the health 
benefits of the meat make it very popular. The rest is exported to the Far Eastern 
countries such as China (DAFF, 2012) 
To ensure that the high market demand is met, farmers have been forced to increase 
production that has resulted in an increase in the number of ostriches per stocking area. 
It is this increase in the stocking density of ostriches that results in the spread of pathogen 
related infections. These pathogens include mycoplasmas which take their toll as the 
ostriches are introduced into feedlot systems where they live in close proximity to each 
other. Mycoplasma infections lead to disease states associated with upper respiratory 
tract infections (Botes et al., 2005). A consequence of these infections is a reduction in 
the physical growth rate of the ostriches. Besides the influence these mycoplasma 




infections are having on the growth of ostriches, they can also make ostriches more 
susceptible to secondary infections which can place further constraints on optimal 
production and thereby the export of ostrich products. In order for South Africa to keep 
up as the world leader in ostrich production, it is important that such diseases be 
controlled. 
Botes et al. (2005) identified three Mycoplasma species that specifically infect ostriches 
in South Africa and these were provisionally named Ms01, Ms02 and Ms03. Langer 
(2009) described the Ms01 and Ms03 mycoplasmas isolated from ostriches in Namibia 
and proposed the names Mycoplasma struthionis sp. nov. str. 237IAT and Mycoplasma 
nasistruthionis sp. nov. str. 2F1AT, respectively. These descriptions have not been 
formally published and are yet to be accepted. In order to distinguish the South African 
isolated strains from those described by Langer, the mycoplasmas will be referred to as 
Mycoplasma struthionis sp. nov. str. Ms01, Mycoplasma sp. Ms02 and Mycoplasma 
nasistruthionis sp. nov. str. Ms03 in this thesis.  
To control mycoplasma infections it is important to separate sick from healthy ostriches 
and secondly, to treat existing infections with antibiotics. Antibiotics however are not 
always effective, as they do not eliminate mycoplasmas and some ostriches may appear 
healthy but act as carriers of the organism. Thus antibiotics have to be administered over 
a longer period of time, which is expensive and furthermore renders the meat unsuitable 
for export as it contains levels of antibiotics that are unexcitable. A different approach is 
thus needed to combat these infections in a cost effective manner. The era of molecular 
genetics has led to the development of DNA vaccines. The motivation to develop DNA 
vaccines against these ostrich-infecting mycoplasmas was that they do not require large-
scale cultivation of organisms, are inexpensive, easy to manufacture and safe to use.  
In 2009, Pretorius initiated the process of developing three DNA vaccines against Ms01. 
The oppA gene from the oligopeptide permease transport system was identified and 
cloned into the vaccine plasmids pCI-neo, VR1012 and VR1020. Attempts by Brandt 
(2012) and van Tonder (2013) to evaluate the ability of these vaccines to elicit an immune 
response were unsuccessful. Besides both trials being compromised by avian influenza 
outbreaks during the trial period, several other factors were given as possible reasons for 
the lack of an immune response. These included amongst others stress due to frequent 
handling during the course of a vaccination trial, a too low dose of vaccine and possibly 
insufficient expression of the oppA vaccine candidate gene.  




In an attempt to overcome previously encountered problems, the goal of the current study 
was to re-evaluate the DNA vaccines developed against Ms01 by evaluating the in vitro 
expression of the DNA vaccine plasmids as well as to determine the ability of different 
vaccine doses to elicit an anti-OppA immune response in ostriches. To this end the 
following objectives were set: 
 Objective 1: The expression and isolation of the Ms01 OppA protein for use in the 
production of rabbit anti-OppA antibodies and as coating antigen for ELISA 
analysis of immune responses. 
 Objective 2: The production of anti-OppA antibodies in rabbits using the OppA 
protein adsorbed to the naked bacteria for use in western blot analysis. 
 Objective 3: To determine in vitro transcription and translation of the Ms01 oppA 
gene in transfected COS-1 cells using reverse transcriptase polymerase chain 
reaction (RT-PCR) and SDS-PAGE followed by western blot analysis, 
respectively. 
 Objective 4: To perform a vaccination trial in ostriches using the pCI-neo_oppA 
and VR1020_oppA DNA vaccines at three different doses, together with a 
boosting dose. 
 Objective 5: To analyse the anti-OppA antibody responses using ELISA. 
A detailed literature review on the role of the immune system in reaction towards an 
infectious organism is given in Chapter 2 as well as background on vaccines, 
mycoplasmas and specifically ostrich-infecting mycoplasmas and their control. The 
experimental techniques used during this study are also presented. The expression and 
isolation of the Ms01 OppA protein and its use in the production of rabbit anti-OppA 
antibodies are described in Chapter 3. Both of these are used in downstream analyses. 
The in vitro expression of the Ms01 oppA gene within a mammalian cell culture system 
is examined in Chapter 4. The vaccination trial in ostriches and the evaluation of anti-
OppA antibody responses using an ELISA developed for this purpose are described in 
Chapter 5. Finally, a brief conclusion is provided in Chapter 6 together with future 
perspectives. An Addendum is given at the end of the thesis that contains the statistical 
analyses of the data accumulated in this thesis.  




 Literature Review 
 Introduction 
The focus of this thesis is the control of mycoplasma infections by means of DNA 
vaccination. To this end, this literature review gives a brief background of the immune 
system and how it responds to infectious organisms. This is followed by an overview of 
the different vaccine types and how they can elicit immune responses. Specific attention 
was given to DNA vaccines as this was the vaccine of choice for use against ostrich-
infecting mycoplasmas in this study. Furthermore, the characteristics, metabolism and 
pathogenicity of mycoplasmas are discussed. To evaluate the transcription and 
translation of DNA vaccines, an in vivo cell culture system was used, for which reason a 
brief introduction into mammalian cell culture is given. Background on the enzyme-linked 
immunosorbent assay (ELISA) technique for the evaluation of humoral responses elicited 
by vaccination is also provided.  
 The immune system  
 Introduction 
The immune system can be divided into innate immunity that provides initial protection 
against an infectious microbe and adaptive immunity or specific acquired immunity in 
which a more specific and longer acting response is induced against infecting microbe. 
Adaptive immunity can in turn be divided into the humoral immunity and cell mediated 
immunity. 
 Innate Immune system 
Innate immunity serves as the first line of defense that helps to fight off infectious 
microbes in the body. The innate immune system relies on pathogen-associated 
molecular patterns (PAMPs) in order to recognise microbes. These PAMPs are patterns 
that are only found on pathogens and not on any eukaryotic cells of the body and are 
thus identified as foreign. The innate immune system also recognises molecules that are 
released from damaged or necrotic cells termed damage-associated molecular pattern 
molecules (DAMPs). Innate immunity has certain receptors that recognise these PAMPs 
and DAMPs and are called pattern recognition receptors (PRR). The receptors are 
expressed on dendritic cells, phagocytes, epithelial and endothelial cells, lymphocytes 
and macrophages. The PRRs can be expressed intracellularly or extracellularly. 
Examples of these receptors include Toll-like receptors (TLRs) and NOD-like receptors 




(NLRs). The TLRs are specific for different components of the microbe. For instance TLR-
4 recognises bacterial lipopolysaccharides (LPS) and TLR-9 recognises unmethylated 
CpG oligonucleotides in microbial DNA. The NLRs are cytokine receptors for DAMPs and 
PAMPs in the cytoplasm. Examples are the NLRP-3 (NOD-like receptor family, pyrin 
domain containing 3) that sense microbial products that indicate cell damage and death, 
and NOD-2 that is specific for bacterial peptides that have entered the cytosol (Murphy 
et al., 2008; Abbas et al., 2012). 
 Adaptive immune system 
A brief overview of the adaptive immune system is shown in Figure 2.1. The activation of 
the adaptive immune system starts when a pathogen enters the body and is ingested by 
dendritic cells that are located in the epithelia of the body. The pathogen is then digested 
of which protein fragments are displayed on the surface of these dendritic cells via the 
major histocompatibility complex (MHC). The dendritic cells are also known as antigen 
presenting cells (APC). The APC’s can then either elicit a humoral immune response by 
the activation of the B-lymphocytes (B-cells) with subsequent antibody production, or it 
can lead to a cellular immune response by the activation of Cytotoxic T lymphocytes 
(CTL) and/or the T helper (Th) lymphocyte cells (Oshop et al., 2002; Browning et al., 
2011). B-lymphocytes can also ingest antigens and present them on MHC II molecules. 
The ability to raise antibody, Th and/or CTL responses determines the efficacy of a 
vaccine (Robinson and Torres, 1997; Liu, 2011).  
The Th cell receptors specifically recognise the antigens presented on the MHC II of the 
APC’s and the co-receptors (CD4+) specifically recognize the MHC II and are thereby 
activated. Th cell activation leads to cell proliferation followed by the release of certain 
cytokines and cell surface proteins that serve as an activation signal for the proliferation 
of B-cells and CTL. B-cells can also serve as APC that can then be activated by the Th 
cell. When B-cells are activated by Th cells, they start to differentiate into millions of either 
effector B-cells (plasma cells) or memory B-cells. The plasma cells produce antibodies 
that are secreted into the blood and can bind to the surface of the pathogen that allows 
recognition for destruction by macrophages and complement (Robinson and Torres, 
1997). Memory B-cells are also produced and can survive for a long period of time 
(Klinman et al., 1998; Abbas et al., 2012; Njongmeta et al., 2012).  
All normal nucleated cells in the body can express MHC I proteins. When normal cells in 
the body are infected by an intracellular pathogen, it digests them and parts of the 




pathogen are displayed on the cell surface via the MHC I. The cytokines released by the 
antigen activated Th cells and the fragments displayed on the surface of the MHC I 
activate the CTL (Gurunathan et al., 2000). The activation of CTL leads to the proliferation 
and differentiation into millions of specific CTL. CTL receptors recognise the pathogenic 
fragments on the MHC I and the co-receptor CD8+ recognises the MHC I of normal 
infected cells and bind to the cell. Thereafter the CTL releases certain chemicals that kill 
the infected cells subsequently killing the pathogen (Robinson and Torres, 1997; 
Gurunathan et al., 2000; Murphy et al., 2008; Abbas et al., 2012).  
The adaptive immune system is very specific and contains a highly diverse group of 
lymphocytes that can distinguish a specific antigen from millions of different antigens. 
The specificity of the adaptive immune system is obtained by recombination of the gene 
regions of the antibody and T-cell receptor genes. This means that lymphocytes consist 
of many different clones, where each clone expresses a receptor different from that 
expressed by other clones. Another important characteristic of the adaptive immune 
system is the fact that after the primary immune response, the immune system produces 
memory lymphocytes for future similar infections. This will ensure a rapid and longer 
secondary immune response that can eliminate the pathogen (Abbas and Lichtman, 
2011). 





Figure 2.1 A brief overview of the main cells involved in a humoral and cellular immune system 
(obtained from https://betournay.wikispaces.com/The+Immune+System). 
 Vaccines 
 Introduction 
The concept of vaccination was postulated by Edward Jenner in 1798 in his publication 
on how to prevent smallpox by means of inoculating with the pus from cowpox, which 
contained the Vaccinia virus. It was, however, only 100 years later in 1880 that the next 
vaccine was developed by Louis Pasteur, which was the killed attenuated Pasteurella 
multocida vaccine for use in poultry (as referenced by Makela, 2000; Plotkin, 2005). The 
development of vaccines has been fuelled not only by the need for prevention rather than 
treatment, but also by the technology itself and the continuous increase in knowledge of 
this field of study. 
The immune system has specifically evolved to defend the body against onslaughts of 
microbes. The adaptive immune system needs to be taught to recognise the different 
pathogens before it can protect the host when attacking the pathogen. It is on this basis 
that a vaccine functions. The vaccine contains an antigen derived from the pathogen that 
will stimulate the production of specific antibodies, Th cells and/or cytotoxic T-cells that 
serve as the front line of defence against the pathogen. Vaccination thus gives a high 




specificity to the induced immunity. Bacteria and viruses can circumvent this by antigenic 
variation, whereby even the slightest change in the target molecule can cause the 
immune system to not recognise it (Makela, 2000).  
This can include the following types of vaccines: live attenuated vaccines, inactivated 
(killed) vaccines, purified subunit vaccines (proteins or glycoproteins of the pathogen) 
and DNA vaccines (Evensen and Leong, 2013). 
 Live attenuated vaccines 
Attenuated vaccines are mutant forms of the microbe that are prepared in such a way 
that they do not have the ability to cause disease but are still immunogenic. The microbe 
is treated under conditions that differ in nutrition and surface to the host, making it 
unfavourable for its growth. Safety is regarded as a big disadvantage as the mutant can 
revert back to the disease causing state (Makela, 2000). An advantage of this type of 
vaccine is that it leads to both a cellular and humoral immune response, and also 
generally induces immunity with a prolonged memory immunity (Ferraro et al., 2011).   
 Killed or inactivated microbes as vaccines  
Killed or inactivated vaccines were developed for the first time in the 1890s where at the 
time it was the only means to prevent diseases. Killed vaccines work on the basis that 
the disease causing microbe is killed and used as an immunogenic vaccine target. The 
problems associated with these vaccine types are both their efficacy and safety. The 
efficacy of some of these vaccines (cholera and meningococcal vaccines) could never be 
proven (Makela, 2000). They also gave minimal protection to the host due to protein 
denaturation or disintegration of the microbe (Mora et al., 2003). Another disadvantage 
is the fact that they can revert back to the activated microbe (Makela, 2000; Mora et al., 
2003). 
 Subunit vaccines  
A difficulty that is associated with all of the abovementioned vaccines is the cultivation of 
the pathogen. There are many microbes that cannot be grown or are difficult to grow 
under in vitro conditions (Makela, 2000). These include some bacteria, most 
mycoplasmas and several viruses (Makela, 2000). A real breakthrough in the 
development of vaccines came with the introduction of genetic technology in which 
specific genes could be isolated and expressed as a recombinant product in an easily 
grown organism (Uzzau et al., 2005). 




Subunit vaccines were introduced in the 1920s and are a much more sophisticated 
product. These vaccines only use the immunogenic parts of the microbe as a vaccine 
target, rather than the whole microbe. This ensures that the reversion of the mutant 
microbe back to the disease causing state is no longer possible and therefore not a 
problem. The big advantage of this type of vaccines is their specificity. The immune 
response is directed towards the subunit itself, rather than the whole microbe. A problem 
that can be associated with these vaccines is that some pathogens undergo antigenic 
variation that changes the subunit to such an extent that it is not immunogenic any longer 
(Makela, 2000; Mora et al., 2003; Uzzau et al., 2005).  
 DNA vaccines 
The concept of transfecting mammalian cells with naked DNA was first reported in 1960 
and this formed the basis for DNA vaccines (Pardoll and Beckerleg, 1995). A DNA 
vaccine is a eukaryotic expression plasmid (circular ring of DNA) containing a specific 
gene of interest of the pathogen under the control of a eukaryotic promoter (Oshop et al., 
2002). When it is injected into a host, it can lead to the transcription as well as translation 
of the desired encoded protein and induce a specific immune response (Corr et al., 1996; 
Robinson and Torres, 1997; Dufour, 2001; Oshop et al., 2002). 
DNA vaccines, also known as third generation vaccines, have attracted much attention 
since the 1990s when Wolff et al. (1990) inoculated the skin of mice with a plasmid DNA 
containing the β–galactosidase gene and observed that it induced an antibody response 
(Wolff et al., 1990; Ferraro et al., 2011). Wolff et al. indicated for the first time that a 
recombinant plasmid when it was injected in vivo had the ability to directly enter 
mammalian cells to express the specific protein in the cell (Mir and Kamili, 2012). The 
application of DNA vaccines has been well studied. Up to 2011 there have been four DNA 
vaccines licenced for veterinary use: the West Nile virus in horses (Davis et al., 2001), 
the infectious haematopoietic necrosis virus in salmon (Alonso and Leong, 2013), 
melanoma in dogs (Bergman et al., 2003) and DNA vaccines for sows (Khan et al., 2010) 
that are aimed to increase litter survival (Liu, 2011). No further DNA vaccines have since 
been licenced. A variety of clinical trials are currently under way against a variety of 
different pathogens in humans as well as in animals (Dhama et al., 2008). 
 Construction of a DNA vaccine vector 
DNA vaccines elicit good levels of immune responses when plasmids are used that 
contain the following: a eukaryotic plasmid containing a desired target gene, an effective 




viral/eukaryotic promoter and a polyadenylation signal sequence (poly-A) (Dhama et al., 
2008; Dufour, 2001; Evensen & Leong, 2013; Faurez et al., 2010). The Cytomegalovirus 
(CMV) promoter is commonly used as a strong promoter to drive the in vivo transcription 
and translation of the target gene (Glenting & Wessels, 2005; Okuda et al., 2014). The 
plasmid also contains a bacterial origin of replication so that the plasmid can be multiplied 
within a bacterial mass production culture. It also contains an antibiotic resistance gene 
allowing for selection during the mass production of the plasmid in a bacterial culture 
(Dhama et al., 2008). Although some antibiotic resistance genes have been shown to be 
beneficial to humans, kanamycin which is predominantly used in this thesis does not 
influence humans (Bengtsson-Palme and Larsson, 2015). Figure 2.2 illustrates the 
different components that make up a DNA vaccine. 
Before a DNA vaccine can be developed, the genome of the pathogen has to be studied 
in order to identify an appropriate candidate gene. This candidate gene is then isolated 
and inserted into the plasmid in which the promoter and the poly–A signal will ensure 
stability as well as effective transcription and subsequent translation of the candidate 
gene (Gurunathan et al., 2000; Dhama et al., 2008). 
 
Figure 2.2 A diagram of a typical DNA vaccine plasmid containing a promoter, the immunogenic 
candidate gene, a poly-A signal, an antibiotic resistance gene and the ori of replication (Dhama 
et al., 2008). 
 
 Advantages of DNA vaccines 
Whole organism vaccine types rely on the development of immunity through the 
administering of live attenuated or killed inactivated pathogens. DNA vaccines on the 
other hand are much more specific due to the fact that the plasmid can be constructed to 




function with encoded safety features and still have the specificity of subunit vaccines. 
DNA vaccines are non-live which means that one does not have to work with a virulent 
pathogen during preparation or application of the vaccine. They are also non-replicating 
as well as non-spreading which contributes to the fact that there is little risk in the vaccine 
gene reverting back to the disease causing state or causing secondary infections. Most 
importantly, DNA vaccines lead to both humoral and cellular immunity inducing all three 
arms of adaptive immunity namely antibodies, helper T cells (Th) and cytotoxic T 
lymphocytes (CTL) (Robinson and Torres, 1997; Gurunathan et al., 2000; Ferraro et al., 
2011). DNA vaccines can be produced rapidly, a critical attribute for the production of 
DNA vaccines against emerging pandemic threats (Le et al., 2000; Liu, 2011). DNA 
vaccines are also easy to produce and are regarded as stable at room temperature in 
contrast to the live vaccines that require a cold chain. The vaccine candidate gene can 
code for proteins that have been modified to eliminate deleterious regions, thereby 
improving the safety and immunogenicity of the proteins delivered (Le et al., 2000; Oshop 
et al., 2002; Liu, 2011) 
 Potential safety concerns 
The initial concern associated with DNA vaccines was the potential for genomic 
integration, the development of anti-DNA immune responses, and activation of 
oncogenes or inactivation of tumour repressor genes (Dhama et al., 2008; Ferraro et al., 
2011). There is a large volume of research that has shown that the probability of naturally 
occurring mutations to be about three orders higher than the probability of mutations that 
might result from plasmid insertion (Schalk et al., 2006). This indicates that the integration 
of a DNA vaccine after injection is an extremely rare event and is not a safety concern 
(Gurunathan et al., 2000; van Drunen Littel-van den Hurk et al., 2001; Oshop et al., 2002; 
Zhang et al., 2005; Loots et al., 2006; Schalk et al., 2006). The vaccines that are currently 
in preclinical trials do not show any form of integration into the DNA of the host (Kutzler 
and Weiner, 2008). 
Although plasmid DNA has shown that it can induce the formation of anti-DNA antibodies, 
no evidence has been found that DNA vaccines induce systematic autoimmune disease 
in animals (van Drunen Littel-van den Hurk et al., 2001; Schalk et al., 2006). Other 
potential concerns regarding DNA vaccines may include the low levels of immunogenicity 
especially in larger animals and also tolerance against the DNA vaccine but this has not 
been observed to date (van Drunen Littel-van den Hurk et al., 2001; Oshop et al., 2002). 




 Environmental effects 
Very little attention has been given to the risk of plasmid DNA release into the 
environment. This may be due to the fact that the risk is so small and does not pose any 
significant threat (Schalk et al., 2006). The possible concerns that can be anticipated are 
the spread of the plasmid by shedding or the consumption of vaccinated food animals. If 
there is any shedding of plasmid DNA into the environment, the DNA will be degraded 
quickly and will cause no harm to any other animal or humans that come in contact with 
it (Blum et al., 1997; de Vries et al., 2003). The fact that DNA vaccines are non-live, non-
replicating and non-infectious also means that they hold little environmental risk. 
 Consumption of plasmid DNA vaccinated food 
Ingesting meat from animals that have been injected by plasmid DNA has long been a 
big safety concern and a regulatory hurdle to overcome, but research is proving that it 
does not have any effect on the consumer (Loots et al., 2006). The degradation rate of 
supercoiled plasmid DNA after injection was 86.8% after one day, indicating that most 
injected DNA was degraded (Zhang et al., 2005). Donnelly et al. (2003) indicated that the 
dose of DNA needed to obtain an immune response in humans is about 1 – 5 mg, thus 
the amount of plasmid consumed from vaccinated animals is orders of magnitude less 
than the dose given to humans. Schalk et al. (2006) also indicated that the consumption 
of vaccinated animals poses no greater risk to the consumer than the consumption of 
natural DNA. Furthermore, cooking the meat before it is consumed would further lead to 
the degradation of plasmid DNA making it safe to consume. Two of the licenced DNA 
vaccines, one aimed at increasing the litter survival in sows, and other to treat salmon, 
are used in animals that are a food source and there have been no effects shown when 
consuming these meats (Giese, 2012). 
 Different delivery systems of DNA vaccines 
DNA uptake by the vaccinated host’s cells in vivo is inefficient due to the fact that these 
vaccine formulations lack the structures utilized by viruses to infect cells. The 
concentration of DNA vaccines have to be high enough that it protect the plasmid from 
enzyme degradation and also to increase the ability of the vaccine to transfect the cells 
of the host (Liu, 2011).  
There are a variety of different methods used to get the vaccine antigen in contact with 
the immune system. These can include, amongst others injecting DNA vaccines directly 




using a carrier system, and electroporation as well as a gene gun (Okuda et al., 2014). 
Injecting DNA vaccines directly into the host, also termed “naked” DNA vaccines, is where 
the DNA is injected intramuscularly (i.m.) into the skeletal muscle which leads to both Th1 
and antibody responses (Robinson and Torres, 1997; Dufour, 2001). Another means is 
intradermal (i.d.) injection into the extracellular spaces or into the cells using a 
hypodermic needle, which also lead to Th1 responses (Faurez et al., 2010; Okuda et al., 
2014). The factors influencing the immune response after i.m. and i.d. injection may be 
affected by the needle type, muscle type, age of the animal and the speed of injection 
(Okuda et al., 2014). 
The DNA vaccines can also be delivered to the intestines of the host by transforming the 
DNA vaccine into bacterial vectors such as muted Salmonella (Salmonella enterica 
serovar typhimurium SL3261) and administrating them orally. The advantage gained by 
using bacterial carriers and administering them orally, is that this results in mucosal 
immunity (Liu, 2011).  
Electroporation involves the process whereby pores are temporarily induced in cells by 
an electric field, permitting the DNA to traverse membranes. This method was shown to 
increase the immune response in mice (Lei et al., 2011), rabbits (Medi et al., 2005), 
monkeys (Luckay et al., 2007), sheep (Scheerlinck et al., 2004) and pigs (Sardesai et al., 
2012). An increase in the amount of antigen that is produced due to more efficient 
penetration of cells by the plasmid was also found (Liu, 2011). The disadvantages that 
come with using this technique are that it is expensive and the apparatus required may 
limit its use (Liu, 2011; Ferraro et al., 2011). 
The gene gun method utilises gold particles coated with the DNA and introducing them, 
using compressed helium as an accelerant, to shoot them directly into the cells of the 
host (Okuda et al., 2014). When inside, the DNA dissociates from the beads and the gene 
it encodes is expressed. The advantage of this method is its effectiveness as it takes 
advantage of the molecular weight and the safety of gold. Using mice as model, naked 
needle injections require about 2-20 μg DNA per animal, whereas the gene gun only 
requires 1-3 μg DNA to evoke an effective immune response (Okuda et al., 2014). The 
disadvantages of using the gene gun method is that it is expensive and difficult to develop 
(Lin et al., 2000; Okuda et al., 2014). 




 Dose requirements of DNA vaccines 
Biodistribution studies showed that the number of plasmid DNA molecules surviving to 
transfect the target cells after i.m. injection was only a small fraction of the total DNA 
injected (Oshop et al., 2002). The amount of antigen produced from this was in the 
picogram to nanogram range. Despite this, an efficient antibody response was still 
induced (Oshop et al., 2002). It is believed that 90% of the DNA vaccine administered 
never reaches the cytoplasm and of the 10% that does reach it, less than 1% enters the 
nucleus in order to be expressed (Babiuk et al., 2003).  
The dose administered is dependent on the route of delivery, type and age of the animal. 
The dose typically administered to birds ranges from 0.5-1500 μg when injected 
intramuscularly (Kodihalli et al., 1997; Oshop et al., 2002). According to Dunham, (2002) 
the amount of DNA required for i.m. administration in mice is 10-100 μg, 100-300 μg in 
smaller animals and 500-2500 μg in larger animals. This is much higher when compared 
to the gene gun method where the concentration ranges from 0.1-1 μg of plasmid. 
Animals usually receive a booster vaccination after about 3 weeks (Dhama et al., 2008). 



















Table 2.1 DNA vaccine dose administered to different animals. 
Animal Dose (μg) Reference Boosting 
Pigs 4000 (Gorres et al., 2011) 3 weeks 
Pigs 400 (Borrego et al., 2011) 2 weeks 
Monkey 1250 (Raviprakash et al., 2006) Every 4 weeks 
Monkey 1500-5000 (Schadeck et al., 2006) (Every 4 weeks) x2 
Cattle 1000 (Skinner et al., 2003) 3 weeks 
Cattle 150 (Capozzo et al., 2011) 4 weeks 
Turkey 200-750 (Chen et al., 2013) 2 weeks 
Turkey 100 (Vanrompay et al., 1999) 3 weeks 
Duck 200 (Yao et al., 2010) 2 weeks 
Duck 250-750 (Triyatni et al., 1998) (Every 3 weeks) x2 
Mice 100 (Corr et al., 1996) (Every 2 weeks) 
Mice 25 (Muthumani et al., 2008) (Every 2 weeks) 
Chickens 100 (Fang Yan et al., 2013) 2 weeks 
Chickens 100 (Song et al., 2010) 1 week 
Chickens 200 (Gong et al., 2013) (Every 2 weeks ) x3 
Dogs 100-1500 (Bergman et al., 2003) (Every 2 weeks) x4 
Dogs 100 (Osorio et al., 1999) 7 weeks 
Horse 200 (Fischer et al., 2003) 4 weeks 
Horse 4000 (Ledgerwood et al., 2011) (Every 4 weeks) x2 
Cats 200 (Cupillard et al., 2005) - 
Cats 100-300 (Osorio et al., 1999) 7 weeks 
Sheep 100 
(Hiszczyńska-Sawicka et al., 
2011) 
4 weeks 
Sheep 100-500 (Kennedy et al., 2006) 4 weeks 




 The mechanism of action and immune responses elicited by DNA vaccines 
The exact mechanism by which DNA vaccines initiate an immune response is unknown, 
but there are several theories (Oshop et al., 2002). The responses elicited resemble 
those of live attenuated vaccines, but without the need for a replicating pathogen (Ferraro 
et al., 2011). The proposed mechanism of action of DNA vaccines is illustrated in Figure 
2.3. When the DNA vaccine is delivered into the muscle, the plasmid uses the host’s 
cellular machinery in order to reach the nucleus or to transfect local cells (Kutzler and 
Weiner, 2008). There are generally three obstacles to overcome before gene expression: 
firstly, to cross the plasma membrane; secondly, to cross the cytoplasm; and finally to 
cross the nuclear membrane. When the DNA vaccine has reached the nucleus, the 
immunogenic gene is transcribed into mRNA that is transported into the cytoplasm (Liu, 
2011). There the mRNA is translated into its encoded protein, which is the required signal 
needed to activate the immune system for an adaptive immune response (Faurez et al., 
2010). Along with the somatic cells, APC such as the dendritic cells are found to be the 
cell types that are efficiently transfected by the plasmids leading to the production of the 
encoded antigen (Dunham, 2002; Faurez et al., 2010; Liu, 2011).  
Once the APC’s are transfected the immune response can follow one of the following 
paths: it can either lead to a humoral immune response by the activation of the B-cells 
and subsequent antibody production; or it can lead to a cellular immune response by the 
activation of CTL as well as Th cells (Oshop et al., 2002; Browning et al., 2011). The 
ability to raise both antibody, Th and CTL responses is important for the efficacy of the 
vaccine and both also lead to memory against future infections as well (Robinson and 
Torres, 1997; Liu, 2011). 
 Fate of the plasmid DNA after intramuscular injection 
The biodistribution and persistence of DNA plasmids is dependent on several factors 
such as route of injection, number of injections, amount given, age and type of animal 
(Schalk et al., 2006; Loots et al., 2006). In a mouse model 90% of intramuscular injected 
plasmid was found in the muscle of the mice 5 min after injection, and no more than 10% 
of injected plasmid was present in observed organs at any given time (Levy et al., 1996). 
Zhang et al. (2005) indicated that the highest concentration of plasmid after injection was 
at the site of injection, but PCR analysis also revealed the presence of DNA in the thymus, 
spleen, lymph node, kidney, heart, liver and lungs. It has been reported that the 
concentration of DNA plasmid is at its maximum several minutes after administration and 




decreases within hours to trace amounts (Schalk et al., 2006). Faurez et al. (2010) 
indicated that more than 98% of the plasmid DNA is eliminated 9 hours after injection into 
mice. This was also indicated by Kim et al. (2003) where they found that 90 minutes after 
injection there was less than 1% plasmid left in mice.  
The remaining plasmid molecules that do not enter the nucleus for expression are free 
and have to be eliminated from the body. Endonucleases found in the muscle mediate 
the degradation of up to 98% of DNA plasmid within 90 min of injection (Faurez et al., 
2010). The percentage of plasmid that actually reaches the blood in pigs was found to be 
below 10% (Faurez et al., 2010). Zhang et al. (2005) indicated that the degradation of 
supercoiled plasmids in mice blood after intramuscular injection was 20.9% after 10 min, 
34% after 1 h, 86.8% after 1 day and 97.8% after 1 week. The persistence of the plasmid 
is also dependant on the age of the animal, Loots et al. (2006) showed 4 – 6 week old 
mice to have a higher expression level when compared to 10 week old mice. On the other 
hand, it was found that the plasmid can persist for 54 days in sheep, 10 weeks in turkeys 
and for more than 2 years in mice (Faurez et al., 2010). 





Figure 2.3 The proposed mechanism of action of a DNA vaccine. A candidate gene is identified 
from a pathogen, isolated and subsequently inserted into a eukaryotic DNA expression plasmid. 
This is then administered to the host and can lead to both a humoral immune response by the 
activation of the B-cells and subsequent antibody production or it can lead to a cellular immune 
response by the activation of T-helper and cytotoxic T-lymphocyte cells (CTL). Taken from 
Dufour, 2001). 
 
 The characteristics, metabolism and pathogenicity of mycoplasmas 
 Introduction 
The term mycoplasmas was first used in 1889 by Albert Bernhard Frank in his description 
of the structures in the root nodules of legumes due to their morphological similarities to 
fungi (mykes-fungus; plasma-formed) (Razin, 2010). It was then used in 1898 by Nowak 
to describe an organism causing bovine pleuropneumonia, which was later classified as 




Mycoplasma mycoides (Adamu et al., 2013). However the first mycoplasma was 
cultivated in vitro by E. Dujardin-Beaumetz in 1900 (Razin, 2010; Taylor-Robinson and 
Jensen, 2011). The first isolation of mycoplasmas only came in 1981 when Tully et al. 
successfully isolated a mycoplasma from two men with non-gonococcal urethritis which 
were analysed and termed M. genitalium.  
The on-going research on mycoplasmas is bringing us much closer to the goal of defining 
the minimal machinery of a self-replicating cell (Razin et al., 1998; Manhart et al., 2011). 
The fact that they lack a cell wall makes them ideal for studies on membrane structure 
and function. Unique characteristics that identify mycoplasmas are their small genome, 
low guanine + cytosine (G+C) content, cholesterol requirement for growth, optimum 
growth at 37°C as well as being very host specific (Kleven, 2008).  
 Origin and taxonomy 
Mycoplasmas are prokaryotic organisms that are classified as part of the family 
Mycoplasmataceae within the order Mycoplasmatales (Razin et al., 1998). The genus 
Mycoplasma is a member of the Class Mollicutes of which the name is derived from the 
latin ‘mollis’ meaning soft and ‘cutis’ meaning skin (Razin et al., 1998). Mycoplasmas are 
taxonomically distinguished from their closest relatives by their minute size and the lack 
of a conventional bacterial cell wall. They are therefore known as “naked bacteria” as 
they are only encapsulated by a single plasma membrane (Razin et al., 1998; Rottem, 
2003; Kleven, 2008; Taylor-Robinson & Jensen, 2011). It is only since the introduction of 
16S rRNA gene sequence data for phylogenetic inference, that mycoplasmas can today 
be defined as descendents of Gram-positive bacteria (Rottem, 2003; Razin & Hayflick, 
2010; Thompson et al., 2011). It was suggested that ancestral mycoplasmas arose from 
the genus Streptococcus about 600 million years ago (Razin, 2010; Taylor-Robinson and 
Jensen, 2011). Today more than 200 species of the genus Mycoplasma are recognised 
that are distributed over several taxonomic groups in the class Mollicutes and more are 
still being added (Bradbury, 2005; Le Roux & Hoosen, 2010; Razin & Hayflick, 2010; 
Adamu et al., 2013). Due to the specificity of the mycoplasmas they usually get their 
name from either their host, the site of infection or alternatively, symptoms associated 
with infections. 
 Cell size and morphology 
Mycoplasmas are the smallest self-replicating organisms known with sizes as small as 
0.2 – 0.7 μm (Le Roux and Hoosen, 2010). M. genitalium is the smallest with a size of 




0.6 – 0.7 μm in length and 0.3 – 0.4 μm wide. They were initially thought to be viruses 
due to the fact that they could pass through filters meant to trap bacteria, but were later 
accepted as bacteria when viruses were better defined in the 1930’s (Freundt, 1979; Le 
Roux and Hoosen, 2010; Taylor-Robinson and Jensen, 2011; Thompson et al., 2011).  
The absence of a cell wall is what gives Mycoplasma species unique properties such as 
formation of the peculiar fried-egg shaped colonies, sensitivity to osmotic shock as well 
as resistance to antibiotics that are targeting the cell wall for destruction (Morozumi et al., 
2010; Razin & Hayflick, 2010; Taylor-Robinson & Jensen, 2011). The absence of a cell-
wall allows for close proximity between the adherent mycoplasma cell and the 
cytoplasmic membrane of the host. 
 It is proposed that a mycoplasma has a simple cellular structure comprising of a nucleoid, 
ribosomes and a double stranded circular DNA molecule in a cytoplasm surrounded by 
a plasma membrane that is about 10 nm thick. The cytoplasmic membrane consists of 
lipids, cholesterol and a large number of proteins. The membrane and membrane 
associated proteins play an important role in the importation of nutrients that are used for 
the growth and function of the cell (Le Roux and Hoosen, 2010). The membrane 
associated lipoproteins that are found include the cytoadhesins that play a role in the 
motility of the mycoplasma as well as its virulence (Adamu et al., 2013). 
Mycoplasmas can have many different shapes with the most dominant shape being a 
sphere due to the fact that it is only surrounded by a cell membrane. Others include helical 
filaments, pear-shaped or flask-shaped cells with a terminal tip structure and filaments of 
varying length (Razin et al., 2010). The fact that these different cell shapes can be 
maintained without a cell wall indicates the presence of a cytoskeleton. Detergent 
treatment of a variety of mycoplasmas reveals the presence of filamentous threads and 
rods. The cytoskeleton is also important in cell division (Razin et al., 2010).  
 Genome  
Research done on mycoplasmas in the 1960s and 1970s regarding cell structure, 
genome size and metabolic pathways has led us to recognize that mycoplasmas are the 
smallest and simplest self-replicating organisms found today (Razin et al., 2010). The 
size of the mycoplasma genome can range from 0.58 – 2.20 Mb, compared to Escherichia 
coli with a size of 4.64 Mb (Rottem, 2003). M. genitalium was the organism with the 
smallest known genome size of 580 kb until M. parvum, a non-pathogenic mycoplasma 
was found in pigs. It was identified by Nascimento et al. in 2013 and has a genome size 




of 0.56 Mb. Due to their small genome, mycoplasmas were one of the first bacteria of 
which the genome was fully sequenced (Manhart et al., 2011). The genome sizes may 
vary not only within the genus, but also among strains of the same species. This may be 
due to the frequent occurrence of repetitive elements, consisting of segments of protein 
genes that differ in size and number. 
A small genome size gives mycoplasmas limited metabolic options for replication and 
survival that makes them dependent on their host for their required nutrients (Glass et 
al., 2006). Despite this small genome size, there are studies that suggest that the genome 
still carries double the number of genes that are required for minimal cellular function 
(Glass et al., 2006). The essential genes are described as the genes that are 
indispensable for the survival of an organism and are therefore the basis of life for a 
particular organism. Glass et al. (2006) identified 382 genes of the M. genitalium genome 
to be essential. These essential genes include coding regions for DNA replication, 
transcription, translation, DNA repair, cellular transport and energy metabolism (Le Roux 
and Hoosen, 2010).  
The genomes of mycoplasmas are also characterised by their low G+C content, 
possessing considerably less guanine and cytosine bases than adenine (A) and thymine 
(T). The G+C content of mycoplasma ranges between 24% and 33% (Razin et al., 1998; 
Le Roux & Hoosen, 2010). Another unique characteristic of mycoplasmas is their use of 
the UGA codon that codes for tryptophan instead of a stop codon as in the universal 
genetic code (Taylor-Robinson and Jensen, 2011). 
 Distribution 
Mycoplasmas in nature are widespread parasites living on reptiles, fish, mammals and 
humans and more hosts are being discovered regularly (Razin et al. 1998; Thompson et 
al. 2011). Mycoplasmas enter a specific host where they can multiply and survive for long 
periods of time (Rottem, 2003). The mucus surfaces of the urogenital and respiratory 
tract, the eyes, alimentary canal, joints and mammary glands are the primary 
environments for human and animal mycoplasmas. Christensen et al. (1994) found that 
mycoplasmas can survive on absorbent surfaces (wood, cotton) rather than smooth 
surfaces. The highest survival was on feathers followed by cotton, hair and feed. 
Mycoplasmas are said to be host specific and usually exhibit a strict tissue or host 
specificity, which is reflected in their exact nutritional requirements as well as parasitic 
mode of life (Kleven, 1998). However, several mycoplasmas are found in different hosts 




or tissues to hosts where they are known for to be. One example is of M. pneumonia 
which is known to cause respiratory disease in humans, but was also found to infect and 
cause similar symptoms in chimpanzees, albeit that chimpanzees are the closest 
relatives of humans (Razin et al., 1998). The specificity of mycoplasmas towards their 
host makes them very difficult to cultivate in a laboratory where their usual host supply of 
specific nutrients needs to be imitated.  
 Ostrich-infecting mycoplasmas 
In 2005, Botes et al. identified three unique Mycoplasma species infecting ostriches in 
the main ostrich producing areas in South Africa and these were provisionally named 
Ms01, Ms02 and Ms03. In 2009, Langer described two mycoplasmas which were isolated 
from ostriches in Namibia. The 16S rRNA sequences of these isolates matched those of 
Ms01 and Ms03 and the names Mycoplasma struthionis sp. nov. and Mycoplasma 
nasistruthionis sp. nov. respectively, were subsequently proposed for them.  
Langer (2009) determined that M. struthionis sp. nov. isolated from lungs and M. 
nasistruthionis sp. nov. isolated from the nostrils of ostriches appear to have typical fried 
egg-shape colonies that are non-helical and non-motile. They were both determined to 
have a requirement for serum and cholesterol for growth and were also filterable through 
a membrane with a pore size of 0.22 μm (Langer, 2009).  
From a phylogeny derived from 16S rRNA sequences (Figure 2.4) it appears that the 
three ostrich-infecting species fall into two different clades, but all three form part of the 
hominis group (Botes et al., 2005). In this phylogeny, Ms02 and Ms03 are more closely 
related to each other than to Ms01. The genomes were sequenced using 454 
pyrosequencing technology and a draft genome was obtained (estimated to have 99.7% 
accuracy). A summary of the genome information of the three ostrich specific 






























Figure 2.4 The phylogeny of different Mycoplasma species based on 16S rRNA sequences. The 
three ostrich-specific mycoplasma species fall within the hominis group (adapted from Wium et 
al., 2015).  
 





Genome sizes (kbp) 
G+C content 
Authors 
Ms01 700 27.0% (Pretorius, 2009) 
Ms02 900 32.0% (Steenmans, 2010) 
Ms03 900 28.7% (Wium et al., 2015) 




 Metabolism of mycoplasmas 
 Introduction 
Mycoplasmas have adopted a parasitic lifestyle within eukaryotic hosts from which they 
obtain their nutrient requirements (Hames et al., 2009). This has led to a degenerative 
genome evolution and resulted in a severe genome reduction with a loss of certain 
essential pathways for the production of macromolecules. The absence of essential 
pathways make them dependent on the host for the supply of cholesterol, amino acids, 
fatty acids, purines and pyrimidines (Henrich et al., 1999). Pathways specific to the 
pathogen and absent in the host are classified as unique pathways, and the essential 
proteins involved in these pathways can be considered as potential vaccine targets. Butt 
et al. (2012) identified 67 essential proteins in M. genitalium, of which six were mapped 
to unique pathways and 61 to common pathways.   
Mycoplasmas lack a complete tricarboxylic acid cycle as well as quinones and 
cytochromes and therefore do not use oxidative phosphorylation as an adenosine 
triphosphate (ATP)-generating mechanism. For this reason, the energy yielding 
pathways of mycoplasmas produce low ATP yields (Razin et al., 1998). Based on their 
carbohydrate metabolism they are divided into fermentative and non-fermentative 
organisms. Fermentative mycoplasmas gain energy by means of the pyruvate 
dehydrogenase pathway and they produce acids from carbohydrates. Non-fermentative 
mycoplasmas gain energy by the arginine di-hydrolyse pathway (Razin et al., 1998). It 
has been reported that M. struthionis sp. nov. uses arginine from its host as energy 
source, whereas M. nasistruthionis sp. nov. uses glucose as its energy source (Langer, 
2009).  
Mycoplasmas still contain a large number of genes that code for proteins that transport 
essential nutrients from the host into the organism. Three different types of transport 
systems were found in M. genitalium namely the ATP-Binding cassette (ABC-
transporters), the phosphoenolpyrovate-dependent sugar phosphotransferase (PTS) 
transport system and facilitated diffusion by transmembrane proteins (Razin et al., 1998). 
The genes that encode for many of the lipoproteins found in the membrane appear to be 
in operons encoding for ABC-transporters (Browning et al., 2011; Adamu et al., 2013). 
 ABC-transporters 
The ABC-transporters represent one of the largest superfamilies of active membrane 
transport proteins. They are found in all species, from the smallest microbe to man and 




are of special significance in mycoplasmas (Henrich et al., 1999; Higgins, 2001; Linton, 
2007). However, there are fundamental differences between prokaryotic and eukaryotic 
ABC-transporters and therefore major sequence differences in the genes that encode 
them. The presence of ABC-transporters in Mollicutes was first indicated by Dudler et al. 
(1998) when he was studying M. hyorhinus. He found a deduced amino acid sequence 
to have significant homology with ABC-transporter proteins. Nicolás et al. (2007) found 
that ATP-dependent transporters represent more than 50% of all the membrane transport 
systems and ABC-proteins represent up to 91.7% of all the ATP-dependent proteins 
found in mycoplasmas. The basic unit of an ABC-transporter consists of five core 
domains: two hydrophobic transmembrane domains (TMDs) facilitating the translocation 
of molecules, two highly conserved hydrophilic ATP-binding domains, which bind and 
hydrolyse ATP thus supplying energy for the translocation of molecules, and a peptide 
binding domain that is associated with surface-anchored lipoproteins (Higgins, 2001; 
Nicolás et al., 2007; Linton, 2007; Locher, 2009). The exact mechanism of this action 
remains unclear and various mechanistic models have been proposed.  
The ABC-transport system can be classified into two main classes: carbohydrate 
transporters and the di- and oligopeptide transporters (Gao et al., 2012). It was first 
discovered to be involved in the import of nutrients but is now known to import and export 
a variety of large and small substrates such as sugars, peptides, toxins, inorganic ions, 
complex polysaccharides, proteins and metabolic waste products (Razin et al., 1998; 
Higgins, 2001). ABC-transporters are very specific towards their substrates and there is 
an ABC-transporter for essentially every type of molecule that crosses the membrane. 
Although most have high substrate specificity, there are some that are multi-specific, such 
as the oligopeptide transporter which can handle all di- and tripeptides (Higgins, 2001). 
There is an increased interest in the ABC-transporters of mycoplasmas due to their 
potential as targets for the development of vaccines (Nicolás et al., 2007). 
 The opp operon of mycoplasmas – structure and function of OppA 
The oligopeptide permease (Opp) ABC-transporters are known for transporting 
oligopeptides not only for cell nutrition but also for signalling processes (Hopfe and 
Henrich, 2004; Nicolás et al., 2007). Figure 2.5 shows an illustration of the Opp 
transporter. The transport system is a multicomponent system which comprises of two 
homologous pore-forming TMDs (OppB and OppC), two homologous cytoplasmic ATP-
binding domains (OppD and OppF) that function in binding and hydrolysing ATP and an 




extracellular substrate binding domain (OppA). Henrich et al. (1999) found that OppB and 
OppC carry six transmembrane-spanning segments and a hydrophilic motif in their C-
terminals. Interestingly, OppF appears larger in size in mycoplasmas compared in other 
bacterial species. The cytoplasmic domains are considered to be the motors to transport 
substrates across the membrane for which purpose ATP is utilised (Hopfe and Henrich, 
2004; Hopfe and Henrich, 2008). The genes that encode for OppA, B, C, D and F domains 
are often found within a single polycistronic operon which is under the control of a single 
promoter (Henrich et al., 1999; Nepomuceno et al., 2007; Hopfe & Henrich, 2008). 
OppA is considered to be the surface-exposing domain and plays a role in substrate 
binding but also, in the case of M. hominis, cytoadherence (Henrich et al., 1999). The 
OppA proteins are unique within prokaryotes, differing in their amino acid sequence (Gao 
et al., 2012). Hopfe et al. (2004) stated that the OppA of M. hominis acts as the main ATP 
hydrolase on the surface of the cell since it contains an ATP-binding P-loop in the C-
terminal region of OppA. A lysine residue within the P-loop structure was found to be 
involved in ATP hydrolysis as well as the binding of nucleotides. A tryptic digestion pattern 
reveals that the M. hominis OppA has a high affinity for ATP and ADP and less affinity 
for GTP and CTP, and only has a high ATPase activity and very low GTPase (8%) and 
CTPase (6%) activity (Henrich et al., 1999; Hopfe and Henrich, 2008). The opp operons 
have been identified within the respective genomes of ostrich infecting mycoplasmas: 









Figure 2.5 Schematic illustration of the different protein domains that make up the oligopeptide 
permease transport (Opp) system (http://www.uark.edu/campus-resources/mivey/ressum.html). 
 Mycoplasma pathogenicity 
A variety of Mycoplasma species have been shown to be pathogenic to humans, animals, 
plants, and insects and particularly intracellular pathogens in animals such as poultry and 
swine (Thompson et al., 2011). Interactions between the mycoplasma and its host, as 
well as the host and its environment, can lead to disease causing states within the host. 
Environmental factors that can influence the immunity of the host and therefore its 
susceptibility to respiratory infections caused by mycoplasmas include temperature, 
ventilation, humidity, atmospheric ammonia as well as dust (Kleven, 1998). 
Mycoplasmas have over the years developed numerous ways of interacting and attaching 
themselves to the host in order to breach the host’s defences to gain its nutrition. For this 
to occur mycoplasmas first have to enter the host (Rottem, 2003; Bradbury, 2005; 
Browning et al., 2011). Mycoplasmas are said to enter the host mainly through inhalation, 
but can spread from one generation to the next through the eggs. Cross-infection from 
the colonised air sac to the adjacent ovaries of the female poultry animals can infect the 
developing embryo, which leads to egg transmission. In M. meleagridis and M. iowae, 
which infects turkey, they can also spread through the venereal route (Bradbury, 2005).   
After the mycoplasma has entered the host it has to identify its target tissue. 
Mycoplasmas attach predominantly to the epithelial surfaces of the respiratory or 
urogenital tract. After attaching itself, the pathogen must multiply and acquire nutrients 
from the host whilst evading the host’s immune systems. With the limited number of 




genes in mycoplasmas as well as the limited survival time outside the host, this seems a 
daunting task (Rottem, 2003; Bradbury, 2005).  
Mycoplasmas possess a unique way of movement which has been termed ‘gliding 
motility’. It is this gliding motility of the mycoplasma that enables the organism to reach 
its target tissue as well as allowing the pathogen to breach the host’s defences and 
immune systems (Taylor-Robinson and Jensen, 2011). These defences include the 
mucin layer in the respiratory tract and ciliary activity. In vitro studies have also shown 
that the gliding ability of the mycoplasma is influenced by the age of the culture as well 
as the incubation medium and temperature thereof (Le Roux and Hoosen, 2010). 
Entering different non-phagocytic cells of the host can be advantageous to the pathogen, 
as it can escape many of the immune response mechanisms developed by the host 
against extracellular pathogens (Bradbury, 2005). The exact mechanism whereby 
mycoplasmas enter the cell is still unclear, some internalise by using a unique tip like 
structure, others internalise without them (Razin et al., 1998). 
 Adherence to the target tissue 
After the pathogen has reached the target tissue, the next step in successfully infecting 
the host is achieved by adhering to the tissue of the host. This step is considered to be 
the first in pathogenesis and a prerequisite for colonisation and infection (Rottem, 2003; 
Hopfe and Henrich, 2008; Le Roux and Hoosen, 2010). The adherence of mycoplasmas 
has been well documented. Due to the absence of cell wall associated structures that are 
involved in adhesion, this process is mediated through the cell membrane bound 
components termed the adhesins (Le Roux and Hoosen, 2010).  
Some Mycoplasma species have developed unique features called tip structures to 
adhere to the target tissue (Browning et al., 2011). In M. genitalium the expression and 
translation of both the MgPa and P32 proteins, which make up the terminal tip structure, 
are required to successfully adhere to the host (Rottem, 2003; Taylor-Robinson and 
Jensen, 2011). Some mycoplasmas have a flask-like shape that is formed by specialised 
terminal-tip structures which help them to not only adhere to the host but also functions 
as the leading end in M. pneumoniae gliding-type motility (Rottem, 2003; Bradbury, 
2005). The cytoskeleton is of significant importance in that it functions in localising 
adhesins, gliding motility as well as to adjust the shape of the mycoplasma cell (Razin et 
al., 1998). There are also unique adhesin-like proteins that have been developed by 
species that enable them to bind to the host. These proteins are not adhesins, but are 




required by the organism for cytoadherence (Rottem, 2003; Taylor-Robinson and Jensen, 
2011). 
Mycoplasmas can attach to a wide range of tissues, for example M. genitalium that has 
shown to attach to the following cell types: erythrocytes, fallopian tube cells, respiratory 
cells and spermatozoa (Le Roux and Hoosen, 2010). Specific enzymes have also been 
found to play a role in attachment of the organism. Alvarez et al. (2003) found that the 
glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) plays a role in 
the attachment of M. genitalium in human vaginal and cervical mucin diseases. Here the 
GAPDH acts as a ligand to the mucin and fibronectin receptors (Rottem, 2003; Le Roux 
& Hoosen, 2010). 
 Invasion of the host  
After respiratory specific mycoplasmas successfully adhere to the epithelial tissue of the 
respiratory tract, they have to invade the respiratory system of the host. They do this with 
the assistance of other respiratory proteins. After adhesion, these mycoplasmas can 
penetrate the epithelial cells of the host by causing the membrane of the target cell to 
invaginate into the target cell similar to the clathrin-coated pit mechanism of endocytosis. 
Once the organism reaches the inside of the cell, it appears to reside in membrane-bound 
vacuoles close to the target cell nucleus. This process can take up to 30 minutes in M. 
genitalium (Le Roux and Hoosen, 2010). The basis of mycoplasmal invasion is the ability 
to bind fibronectin or sulphated polysaccharides, forming a molecular bridge between the 
mycoplasma and host cell surface proteins (Rottem, 2003; Taylor-Robinson and Jensen, 
2011). Several invasive bacteria have shown that when they come into contact with the 
host cell surface they trigger cytoskeletal rearrangements which facilitate bacterial 
internalisation. The lack of a mycoplasma cell wall allows for direct contact between the 
mycoplasma membrane and the cytoplasmic membrane of the host, which can lead to 
invasion of the host cell (Rottem, 2003). 
 Evasion of the host immune system 
The pathogenesis of mycoplasmas is dependent on close contact between the organism 
and the host, the ability to evade the host immune system, adapt to the environment and 
change phenotypically (Le Roux and Hoosen, 2010). The ability of mycoplasmas to 
sustain and persevere in the presence of the host’s immune system can be achieved in 
a few unique ways. Some mycoplasmas enter the host to protect themselves from the 
innate immune system (Rottem, 2003). It is thought that the mycoplasma can undergo 




molecular mimicry and antigenic variation. The Mollicutes do this by generating 
intragenomic variation in nucleotide sequences or DNA arrangement at selected 
chromosomal loci of membrane proteins expressed on the cell surface. They can do this 
without compromising the function of the specific protein (Le Roux and Hoosen, 2010). 
There are unique multigene families encoding for proteins that are involved in generating 
antigenic variation, phase variation as well as antigenic switching, allowing for immune 
invasion during an infection. Examples of such proteins showing antigenic variation 
include the P140 and P110 cell surface protein and the PvpA surface antigen. 
Alternatively the organism can also mimic the host cell antigens as a survival mechanism 
(Bradbury, 2005; Le Roux and Hoosen, 2010).  
 Damage to the host 
When the mycoplasma has successfully attached itself to the host and therefore infected 
it, the mycoplasmas can cause injury and cytopathic effects (Rottem, 2003). This can 
involve the innate and acquired immune responses. Most of the Mycoplasma species 
attach themselves to the epithelial surfaces of the host which is then the main area of 
damage to the host. As mycoplasmas are dependent on the host for their nutrition, they 
compete for biosynthetic precursors that can disrupt the host cell integrity and alter host 
cell function (Rottem, 2003). Nonfermenting mycoplasmas utilise the arginine di-
hydrolyse pathway for their source of ATP, which depletes the host of arginine thereby 
affecting protein synthesis and host growth (Rottem, 2003). In mycoplasmas that use 
glycerol as their energy source, the metabolism of glycerol can lead to host damage 
through hydrogen peroxide production by glycerol-3-phosphate oxidase (Hames et al., 
2009).  
The attachment of these mycoplasmas to the host surface also affects various host cell 
processes such as membrane receptors, transport mechanisms and K+ channels. During 
the fusion process some toxic material and mycoplasma components such as various 
superoxide radicals, ammonia, hydrolytic enzymes and nucleases of the adhering 
mycoplasma cause the membrane to become vulnerable and therefore affect the normal 
function of the cell (Rottem, 2003; Bradbury, 2005)  
 Pathogenicity of the ostrich-infecting mycoplasmas  
In ostriches, mycoplasmas lead to disease states associated with respiratory tract 
infections causing inflammation of the trachea, nostrils and air sacs (Botes et al., 2005). 
Mycoplasma infections in ostriches also have indirect consequences such as a reduction 




in physical growth rate, downgrading of carcasses, increased veterinary costs and also 
increasing their susceptibility to secondary infections of pathogens such as E. coli and 
other Gram negative bacteria (Botes et al., 2005). These secondary infections can lead 
to an increased mortality rate. The clinical symptoms associated with these infections in 
ostriches include nasal exudates, swollen sinuses, foamy eyes and shaking of their 
heads. Factors such as the weather, stress and an underdeveloped biosecurity can 
enhance the occurrence of these infections. Infections are especially high during the 
months of the year with extreme temperature fluctuations and during the cold and windy 
winters (Botes et al., 2005).  
 Control of mycoplasma infections 
The financial impact poultry mycoplasmas have on poultry production has motivated the 
development of methods to control these infections. The control of mycoplasma 
infections, specifically in poultry, can be divided into three categories: control by 
prevention, medication and vaccination.  
 Control by means of prevention 
An important consideration in prevention is the creation of an effective biosecurity system 
whereby animals infected with mycoplasmas are separated from uninfected animals. The 
vast market demand for different poultry species has forced farmers to increase their 
flocks through increased farming densities (Dr. Adriaan Olivier, research veterinarian, 
Klein Karoo international, personal communication). The problem thus arises that these 
animals live in such close proximity to each other that it can increases the chance of 
mycoplasma spread. It is thus of importance to have a consistent monitoring system for 
early detection of mycoplasma infections. It is preferred to rather monitor fewer samples 
more frequently, than to measure more samples less frequently (Glatz et al., 2005). 
Studies were performed on the survival of mycoplasmas on different materials, and in 
1994 Christensen et al. found that mycoplasmas can survive for two days on rubber and 
cotton, indicating the importance of using disinfectant foot baths as well as changing of 
overalls when moving between different flocks. It was also found that the mycoplasmas 
could survive longer on the unwashed hair of workers.  
Mycoplasmas can spread horizontally, meaning mainly through the air from one animal 
to another and can quickly infect the entire flock if the infected animals are not removed. 
After these infected animals are separated from the flock it is important to house the 
remaining uninfected animals in a different cage. Some Mycoplasma species can survive 




in the environment for longer periods that can lead to an indirect infection. These 
mycoplasmas can also form biofilms in drinking water, increasing their environmental 
survival (Glatz et al., 2005). It is therefore important to clean the cage where these 
animals were housed before reintroducing any new animals (Glatz et al., 2005).  
Mycoplasmas can also be transmitted vertically, meaning from one generation to the next 
through the eggs (Kleven, 2008). A process called ‘egg dipping’ is where the eggs get 
dipped or can be injected with antibiotics in an attempt to destroy mycoplasmas. This is 
an essential step in preventing the spread of the disease to subsequent generations. In 
some cases if the genetic lines or grandparent flocks are infected, the entire flock will 
have to be eliminated. Although it can be a costly process, it is still more favourable than 
to treat the animals and have the risk that the mycoplasma infections will reoccur (Kleven, 
2008).  
 Control by means of medication 
Another manner of treating infected animals is by means of medication. The use of 
antibiotics started in the 1950’s to assist with the increasing demand for food (Allen et al., 
2013). The fact that mycoplasmas lack a cell wall makes them resistant to any β-lactamic 
antibiotics that target the cell wall, such as penicillin (inhibits Gram-positive and negative 
bacteria), cephalosporins and thallium acetate (Razin et al., 1998; Morozumi et al., 2010). 
Antibiotics are mainly used to treat eggs to minimise egg transmission of mycoplasmas 
(Kleven, 2008). They can, however, also be administered to the birds. Some antibiotics 
such as enrofloxaxin or tilmicosin are highly effective, but are not approved for use in 
infected breeding stock.  
Antibiotics such as Oxytetracycline, Doxycycline, Chlortetracycline, Tylosin and 
Lincomycin have been used with success in treating ostriches with mycoplasma 
infections, but at a cost. Once the bird is infected, secondary infections often worsen its 
condition and increase the combinations of medication needed. The different antibiotics 
also have limited periods in which they can be administered. Using antibiotics can 
potentially reduce the clinical signs of mycoplasmas as well as spreading to neighbouring 
flocks, but often do not completely eliminate infections. This should therefore not be 
considered as a long term solution to control mycoplasma infections. In addition to this, 
the continuous usage of antibiotics can result in antibiotic resistance of the Mycoplasma 
species (Kleven, 2008).  




 Control by means of vaccination 
The best way to control Mycoplasma infections in animals is by preventing infections 
through immunisation (Makela, 2000). To date there have been various attempts to 
generate vaccines against mycoplasmas especially in chickens. Commercially available 
live attenuated vaccines against Mycoplasma gallisepticum (MG) include the ts-11 
(ts11MG), 6/85 attenuated vaccines and F-strain (FMG) that are for use in chickens 
(Whithear, 1996; Nicholas et al., 2009; Jacob et al., 2014). A commercially available live 
vaccine against Mycoplasma synoviae (MS) includes the strain MS-H (Bayatzadeh et al., 
2014). The inactivated vaccines (Bacterins) used today include the MG-Bacterin (MG-
Bac) and MS-bacterin (MS-Bac) that consist of a concentrated suspension of the MG and 
MS that are emulsified in an oil adjuvant (Whithear, 1996). Various other adjuvants can 
also be used such as aluminium hydroxide, liposomes and iota carrageenan. A Bacterin 
for MG has been licensed in the United States (Nicholas et al., 2009). Subunit vaccines 
are less frequently used than live and attenuated vaccines. There are some subunit 
vaccine developed using the MGC1 and MGS2 proteins and were evaluated against MG 
in chickens (Moura et al., 2012).  
 Control of mycoplasma infections in ostriches 
Controlling mycoplasmas infections in ostriches has proven to be expensive. Monitoring 
these infections within a commercial ostrich farm starts with a biosecurity system whereby 
monitoring and early identification of the pathogen are of utmost importance. The 
biosecurity system further includes: decreasing any stress causing factors, to clean their 
enclosures and water troughs regularly, and to have an area that provides shelter for the 
birds against wind and rain. It is also important to monitor the weight of each bird 
regularly. When the symptoms are visible, sick birds have to be separated from the rest 
of the flock. This generally also determines the type and period of treatment given (Botes 
et al., 2005; Dr Adriaan Olivier, personal communication).  
The use of antibiotics further does not eliminate infections, but only contains them (Dr. 
Adriaan Olivier, research veterinarian, Klein Karoo international, personal 
communication). Thus animals that do not exhibit symptoms of infections are found but 
they act as carriers of mycoplasma thereby exacerbating the problem. 
The financial and environmental implications of antibiotic use have necessitated an 
investigation into alternative methods of controlling mycoplasma infections in ostriches 
by means of vaccination.  




Live attenuated and inactivated whole organism mycoplasma vaccines (MS-Bac and MG-
Bac) for use in chickens were found to be ineffective in treating mycoplasmosis in 
ostriches (Pretorius, 2009). The Bacterin vaccines that are suspended in oil emulsion 
further produces granulomas in ostriches. To date there is no vaccine registered for use 
against mycoplasma infections in ostriches. The production of traditional live or inactived 
whole organism vaccines is problematic given the difficulty and expense of cultivating the 
ostrich-infecting mycoplasmas in large quantities (Johan Gouws, Laboratory manager, 
Onderstepoort Veterinary Institute, personal communication). These problems can, 
however, potentially be overcome by the development of suitable DNA vaccines. 
 The progress of DNA vaccine development against ostrich-infecting 
mycoplasma Ms01 
The availability of genome information of an organism allows the identification of potential 
antigen genes. The genome of M. struthionis sp. nov. str. Ms01 was previously partially 
sequenced (Pretorius, 2009), and the oppA gene identified as an antigen gene. The oppA 
gene codes for the substrate binding domain (OppA) of the oligopeptide permease 
transport system, as previously described. The OppA protein serves as a good potential 
antigen as it is predicted to be highly antigenic and is also a surface protein making it 
easier for the immune system to recognize it. Binding of antibodies to the OppA protein 
could inhibit the function of the OppA and therefore the flow of oligopeptides into the 
organism. This could in turn lead to cell death. In M. hominis the OppA protein also 
functions as the cytoadherence domain of the organism. If this is also the case for the 
Ms01 OppA protein, antibodies could prevent cytoadherence and in turn infections. Thus 
it can be concluded that the Ms01 OppA protein has an excellent potential to serve as a 
vaccine candidate gene. 
The TGA codon encodes for tryptophan in mycoplasmas, whilst TGA is a termination 
codon in all other organisms (Yamao et al., 1985). This can therefore lead to early 
termination of the gene containing these TGA codons in E. coli as well as in the 
vaccinated animal leading to an ineffective vaccine. These TGA codons therefore need 
to be modified to TGG codons by means of site directed mutagenesis (SDM) in order for 
the correct translation as a tryptophan residue within mycoplasma (Simionatto et al., 
2009). The oppA gene of Ms01 was previously cloned by Pretorius (2009). Ten TGA 
codons were identified by sequencing and these were modified to TGG codons by SDM 
(Pretorius, 2009). 




 Vaccine vectors pCI-neo, VR1012 and VR1020 
Three DNA vaccines each containing the oppA gene of Ms01 were previously prepared 
by Pretorius (2009). The DNA vaccine vectors used were pCI-neo, VR1012 and VR1020 
(Figure 2.6). The pCI-neo (Promega) expression vector contains a cytomegalovirus 
(CMV) immediate-early enhancer/promoter region promoting constitutive expression of 
the antigen gene within mammalian cells. The antigen gene was inserted into the multiple 
cloning site (MCS) downstream of the enhancer/promoter. It also contains a T7 and T3 
RNA polymerase promoter, f1 ori of replication, SV40 polyadenylation signal, neomycin 
phosphotransferase gene and an ampicillin resistance gene. The SV40 late 
polyadenylation signal helps to increase the steady state of RNA. The neomycin 
phosphotransferase gene is a selectable marker for mammalian cells and is under the 
regulation of the SV40 enhancer and early promoter region (pCI-neo manual, Promega).  
VR1012 and VR1020 (Vical Incorporated) both contain a polyadenylation sequence 
downstream of the MCS, a prokaryotic origin of replication and a kanamycin resistance 
gene. Both also express genes using a strong eukaryotic CMV promoter (Hartikka et al., 
1996; Smooker et al., 1999). The VR1020 plasmid has a tissue plasminogen activator 
(tPa) signal sequence upstream of its cloning site. This assists with the secretion of newly 
expressed proteins (Lobo et al., 1999; Luke et al., 1997).  
The ability of these DNA vaccines to elicit an anti-OppA immune response has previously 
been tested in vaccination trials, but due to unforeseen avian influenza infections, 
possible inefficient dose and handling of ostriches, results were limited (Brandt, 2012; 
van Tonder, 2013).  
 




           
 
Figure 2.6 The vector maps of the three DNA vaccines pCI-neo, VR1012 and VR1020 used in 
the development of DNA vaccines. 
 In vitro expression of DNA vaccines 
 Animal cell culture 
The term cell culture is the removal of prokaryotic and eukaryotic cells from in vivo plants 
or animals and subsequently growing them in a favourable artificial environment in vitro. 
The process further involves these single cells to act as independent units. These cells 
are either removed from tissues directly or they can be derived from an already 
established cell line or cell strain (Butler, 2005; Gibco & Thermo Fisher Scientific 
Handbook, 2015). 
The first evidence of eukaryotic cell growth was when Wilhelm Roux maintained 
embryonic chick cells in saline solution (Butler, 2005). The beginning of cell cultivation in 
vitro began in 1907 when Ross Harrison, who many believe to be the father of cell culture, 
was first to indicate the maintenance and growth of frog nerve cells in a hanging drop for 




up to 30 days (Harrison, 1912). A big drawback until 1955 was the stringent sterility 
controls needed until Earle and Eagle developed a chemically defined medium namely 
Eagle’s minimum essential medium (EMEM) that could replace the biological fluids used 
(Butler, 2004). The first therapeutic protein from recombinant mammalian cells to be 
obtained for market approval was the human tissue plasminogen activator in 1966 
(Kretzmer, 2002). 
Today animal cell culture is an essential laboratory technique to study biochemical and 
physiological processes and up to 70% of all pharmaceutical recombinant proteins are 
produced in mammalian cells. One of the advantages of mammalian cell culture is the 
consistency and reproducibility of results obtained due to the fact that one can control the 
conditions of growth. In addition to this the culture normally contains one type of cell that 
may be genetically identical. Animal cells, however, are more vulnerable than bacterial 
cells and therefore require extreme sterile conditions as well as specific nutrients (Wurm, 
2004; Butler, 2005). 
 Cell choice  
For successful transfection, the choice of cell line is of significant importance to obtain 
efficient expression and should be highly susceptible to transfection. There are generally 
two types of cells available namely continuous cell lines and primary or finite cell lines. 
Normal cells can only divide a limited number of times before losing their ability to 
proliferate, known as senescence. A primary cell line refers to cells that only have a 
limited senescence. Some cell lines can become immortal through the process of 
transformation. Continuous cell lines are primary cell lines that undergo transformation 
where after they have the ability to divide indefinitely (Gibco & Thermo Fisher Scientific 
Handbook, 2015). 
Among the most widely used cell lines for small scale expression are the African green 
monkey kidney CV-1 and COS cell lines (Aruffo, 1998). The COS-1 and COS-7 cell lines 
developed by Yakov Gluzman in 1981 were derived from the African green monkey CV-
1 cell line that was integrated into the chromosomal DNA of COS cells. Before integration, 
the CV-1 cell line was transformed with an ultraviolet-irradiated, replication-defective 
SV40 virus (Strayer, 1996; Aruffo, 1998). Plasmids containing the SV40 ori and that 
express the SV40 large T antigen (TAg) can replicate to a high copy number in these cell 
lines (Pham et al., 2006). For large scale expression and industrial usage the Chinese 




hamster ovary (CHO) and human embryonic kidney 293 (HEK 293) cells are commonly 
used (Pham et al., 2006; Baldi et al., 2007).  
In this thesis the expression of the OppA protein of Ms01 by different vaccine vectors was 
evaluated in a COS-1 cell line. In mycoplasma the OppA is a membrane bound protein. 
COS-1 cells were used since they are generally easy to transfect and have been used in 
various studies expressing membrane bound proteins (Zhou et al., 1994; Harding et al., 
1999; Rios-Esteves & Resh, 2013).  
 Transfection 
Cell transfection is the process in which plasmid DNA is introduced into a growing cell 
culture, leading to the expression of the plasmid DNA by the cells. This is usually done 
using a specific transfection reagent (Wurm, 2004; Pham et al., 2006). The main aspects 
that influence transfection are the cell line, expression vector, DNA plasmid quality, 
transfection agent and medium (Pham et al., 2006). 
The expression of proteins usually follows a well-established scheme (Wurm, 2004). The 
gene of interest is inserted into a plasmid vector where after it can be multiplied within 
and DNA isolated from E. coli cells. A specific eukaryotic cell-line is cultured in media 
until it is growing at its optimal reproducibility. The plasmid is thereafter used to transfect 
the cell line together with a transfection agent where after the cells are grown kept in a 
controlled environment. After transfection the cells are lysed and the expressed proteins 
are detected in the cell lysate  (Wurm, 2004; Matasci et al., 2008). 
 Plasmid expression vectors 
The choice of plasmid plays an important role in the production of recombinant proteins. 
A strong promoter/enhancer is the biggest influence driving the transcription of the gene 
(Matasci et al., 2008). The CMV promoter is considered very powerful and highly active 
in most of the mammalian cell lines (Aruffo, 1998; Pham et al., 2006). The presence of 
introns between the promoter and the coding sequence can also improve the expression 
by increasing the mRNA stability and export from the nucleus. 
The quality of the plasmid DNA can also influence the transfection efficiency and 
therefore the expression of the inserted gene. Before transfecting it is important to verify 
whether the plasmid DNA is supercoiled as this conformation gives the highest 
transfection efficiency and therefore should produces the highest level of expression. 




Some of the plasmid DNA will be converted into linear DNA inside the nucleus by the 
active endo- and exonucleases (Wurm, 2004).  
 Cell culture medium  
The choice of medium can influence the efficiency of the transfection. The main function 
of the medium is to create the optimum artificial environment that will replicate the 
physicochemical environment for the cells so that they can grow and divide. The medium 
supplies the cells with the essential nutrients such as amino acids, vitamins, minerals, 
growth factors and hormones (Gibco & Thermo Fisher scientific Handbook, 2015). It also 
regulates the pH, temperature and osmotic pressure for optimum growth. Either serum 
free or medium containing serum can be used. Bovine serum is mostly used for the 
propagation of mammalian cells (Wurm, 2004; Matasci et al., 2008;). 
For optimal and rapid cell growth it is important to subcultivate (or passage) the cells 
whenever the cell confluency reaches 90%. Subcultivation involves transferring the cells 
to a new vessel with fresh growth medium. This will ensure that there is sufficient room 
for continued growth and also to remove the cell waste material (Gibco & Thermo Fisher 
scientific Handbook, 2015). The COS-1 cell line grows rapidly, therefore it requires a 
passage every 3-4 days (Aruffo, 1998).  
 Detection of expressed protein 
Western blotting involve the use of highly sensitivity-enhanced chemiluminescence 
substrates, a technique developed by Mattson & Bellehumeur in 1996. These 
chemiluminecent techniques can detect protein levels in the femtogram range with high 
signal to noise ratio, making them more sensitive than the common colorimetric detection 
methods (Alegria-Schaffer et al, 2009). Chemiluminescence involves a chemical reaction 
whereby energy is released in the form of light. For example, when luminol is oxidised in 
the presence of a horseradish peroxidase (HRP) conjugated secondary antibody and 
peroxide (Alegria-Schaffer et al., 2009).  
 ELISA 
The enzyme-linked immunosorbent assay (ELISA) was first described independently by 
Engvall and Perlmann in 1971 who first termed immunoassays employing labelled 
enzymes, ELISA (Engvall and Perlmann, 1971; Clark et al., 1986). Today there are 
various types of ELISA’s available, which include amongst others: direct, indirect and 
sandwich ELISA’s. For the purpose of this study, the focus will be on the indirect ELISA 




method, which provides quantitative results and has a high sensitivity and specificity for 
high molecular weight proteins (Voller et al., 1978). Figure 2.7 illustrates the indirect 
ELISA assay. 
An indirect ELISA works on the basis of a microtitre plate being coated with an antigen 
by passive adsorption and covalent linkage (Snyder et al., 2014). A microtitre plate is 
used as it contains 96-wells and therefore can accommodate 96 samples in a single 
analysis. There are two types of Nunc 96-well microtitre plates that are generally used 
for ELISA the Maxisorp and the Medisorp. Both plates are polystyrene surface treated, 
with Maxisorp having a high affinity for polar groups and Medisorp binding molecules of 
an intermediate hydrophobic/hydrophilic nature. The addition of a positive control at 
relevant antigen concentration levels is also recommended by the European Medicines 
Agency. 
After the antigen binding step, the wells are saturated with a blocking agent, which will 
bind to all the areas that are not bound by the antigen. This is to prevent any non-specific 
binding of the secondary antibodies. This is followed by washing away the entire unbound 
blocking agent, a step that is essential in minimizing background. The serum (primary 
antibody) being tested during the study is thereafter incubated with the adsorbed antigen. 
This will allow the antibodies, in the serum, to attach to the antigen. After an appropriate 
incubation time the unbound serum components are washed away. This is followed by 
the secondary antibody that will specifically detect the primary antibody. Different 
detection methods are available, and one such method is the biotin/avidin method. Biotin 
is conjugated to the secondary antibody by a hydroxysuccinimide ester. The secondary 
antibody conjugated to biotin is left to incubate with the antigen-primary antibody 
complex. This will result in the secondary antibody attaching to the primary antibody. 
Washing again will remove any unbound antibody. With the biotin/avidin detection 
method, avidin in now added. Biotin has a high affinity for avidin which is a tetrameric 
protein that contains four binding sites. This results in more than one biotin molecule 
being bound to the avidin thereby increasing the signal. Streptavidin, that is isolated from 
Streptomyces, has the same affinity for biotin as avidin and is preferred as it is not 
glycosylated, and thereby less non-specific binding occurs (Chaiet and Wolf, 1964; 
Berman and Basch, 1980; Nerurkar et al., 1984). The avidin can be conjugated to 
horseradish peroxidase (HRP), which will result in the subsequently added substrate 
being converted to a coloured product. This colour change can be measured using a 




spectrophotometer and is an indication of the amount of conjugate bound, which is 
proportional to the primary antibody level in the serum sample (Voller et al., 1978; Snyder 
et al., 2014).  
There are a wide variety of substrates that can be used for ELISA that include amongst 
others: tetramethylbenzidine (TMB) and p-Nitrophenyl Phosphate (pNPP), both yielding 
yellow products that absorbs light at 405 nm (Caponi and Migliorini, 1999). In the case of 
HRP, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) is an excellent 
substrate that gives a green product that absorbs light at 405 nm (Hay and Westwood, 
2003).  
For the determination of antibody responses elicited in a host, ELISA is an excellent 
assay due to its specificity, sensitivity, rapidity and cost effectiveness (Alegria-Schaffer 







Figure 2.7 A schematic illustration of an indirect ELISA assay. The antigen is firstly incubated on 
the plate to bind to the plate by passive adsorption. Secondly the primary antibody binds 
specifically to the antigen. This is followed by a secondary biotinylated antibody that attach to the 
primary antibody. The addition of the substrate would lead to a colour reaction that is emitted. 
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 Expression, isolation and the purification of the OppA protein of 
Mycoplasma struthionis sp. nov. str. Ms01 and antibody 
production in rabbits. 
3.1 Introduction 
The primary goal of this study was to re-evaluate the ability of previously developed DNA 
vaccines to elicit an immune response in ostriches. However, the in vitro expression of 
the oppA gene by these DNA vaccines was firstly determined using a cell culture system 
(Chapter 4). Assessing the in vitro expression of the oppA gene required a western blot 
analysis for which primary anti-OppA antibodies were needed. Furthermore, the ability of 
the DNA vaccines to elicit an immune response (Chapter 5) was assessed using 
an enzyme-linked immunosorbent assay (ELISA) whereby the humoral immune 
response of vaccinated ostriches was determined. For this ELISA, purified Ms01 OppA 
protein was required for coating purposes. Both the recombinant expression of OppA in 
E. coli using a pGEX plasmid containing the oppA gene, and the production of antibodies 
in rabbits against this recombinant OppA is described in this chapter. 
3.2 Materials and methods 
3.2.1 Expression of the Ms01 OppA-GST protein in E. coli cells 
The oppA gene was previously cloned into the prokaryotic pGEX-4T-1 (GE Healthcare, 
United Kingdom) expression vector and transformed into E. coli BL21(DE3)pLysS cells 
(Promega, USA), after which they were stored as freezer cultures at -80°C (van Tonder, 
2012). To ensure high levels of protein expression, freezer stocks were not stored for 
longer than 6 months. For E. coli BL21(DE3)pLysS cultivation, Luria-Bertani/ampicillin 
(LB/amp) Petri dishes were prepared by adding 3.15 g bacteriological agar to 250 ml LB-
medium (2.5 g Bacto-Tryptone, 1.25 g Yeast extract, and 1.25 g NaCl). After autoclaving, 
the mixture was allowed to cool before adding 100 μg/ml ampicillin. One hundred 
microliters of BL21(DE3)pLysS cells containing the pGEX_oppA were plated onto the 
LB/amp agar and incubated overnight (16-18 hours) at 37°C. BL21(DE3)pLysS cells 
containing the pGEX-4T-1 plasmid without the oppA gene were used as controls. 
Colony PCR was used to verify the presence of the plasmid in the cells. The specific 
primer pairs are listed in Table 3.1. They were used to amplify the multiple cloning site 
(MCS) of the plasmid. All PCR reactions were carried out in 10 μl volumes containing 1 
μl 10x Reaction Buffer, 0.4 μl dNTP (5 mM), 0.6 μl MgCl2 (25 mM), 0.5 μl Pgex_F forward 




primer (20 pmol/μl), 0.5 μl Pgex_R reverse primer (20 pmol/μl) (all primers/ sequences 
were obtained from the vector map and synthesised by Integrated DNA 
Technologies(IDT), United states) and 0.1 μl Supertherm Taq (JMR holdings, United 
States) (5 U/μl). As positive control 0.5 μl diluted (1/500) pGEX containing the Ms03 oppA 
gene was used. The thermal cycler was programmed to perform 25 cycles of each 94°C 
(30 sec), 55°C (30 sec), 72°C (30 sec) followed by an additional 7 min at 72°C. PCR 
products were separated on a 1% agarose gel. A 0.1 μl/ml GelredTM Nucleic Acid Gel 
Stain (Biotium, USA) was used for UV visualisation of PCR products. 
For protein expression a 14 ml Falcon® tube containing 5 ml Terrific broth-medium (Bacto-
tryptone 12 g/l, Bacto-yeast extract 24 g/l, 2 M glycerol 4 ml/l), supplemented with glucose 
(20% m/v), ampicillin (100 μg/ml), chloramphenicol (34 mg/ml) and 100 ml/l phosphate 
buffer (1 M, pH 7.8) was thereafter inoculated with two positive colonies identified by 
colony PCR to contain the pGEX_oppA plasmid. Two colonies without the pGEX_oppA 
plasmid were used as controls, containing the same medium in a separate Falcon® tube. 
Both where incubated overnight at 37°C on an orbital shaker (150 rpm). 
Expression cultures were made with 100 ml and 10 ml supplemented TB-medium for the 
pGEX_oppA plasmid and the pGEX without the oppA gene in Erlenmeyer flasks, 
respectively. The 100 ml flask was inoculated with 2 ml of the overnight culture and the 
10 ml with 200 μl overnight culture. Both were incubated at 37°C on a shaker (200 rpm) 
until an OD600 value of 0.6 was reached. Expression of the plasmid was subsequently 
induced by adding 400 μl and 40 μl of 0.1 M isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to the 100 ml and 10 ml volumes, respectively and left to incubate for 8 h. Samples 
were taken after induction at 2, 4, and 6 hours. The cells were harvested by centrifugation 
for 10 min at 10 000 x g (Beckman Coulter, Avanti® J-E). The bacterial pellet was 
resuspended in TEN 50 buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 50 mM NaCl, 
0.1% Triton X-100, 0.2 M Dithiothreitol (DTT) and 10% (v/v) glycerol).  
 
Table 3.1 pGEX specific primer pairs used for the amplification of the cloned insert and the 
respective band sizes produced from pGEX plasmids with and without the oppA insert. 
Product size (bp) 
With oppA 2979 











The resuspended pellet containing the harvested cells was analysed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to identify whether the OppA-
GST protein was expressed. Thirty microliters of resuspended sample was mixed with 30 
μl of reducing treatment buffer (125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol and 
10% (v/v) 2-mercaptoethanol, pH 6.8) and 12 μl bromophenol blue (0.1% (w/v) in 100 
mM NaOH). The sample mixture was boiled for 2 min and kept on ice until it was loaded 
on the gel. As molecular marker a PageRulerTM Unstained Protein Ladder (Thermo 
Scientific) was loaded containing 14 proteins spanning 10 to 200 kDa in size. 
The SDS-PAGE apparatus was set up and filled with electrode buffer (25 mM Tris, 192 
mM glycine and 0.1% (w/v) SDS, pH 8.3) before 20 μl of sample mixture was loaded. The 
expression products were separated on an acrylamide gel consisting of a 4.5% stacking 
gel containing 4.25 ml stacking buffer (125 mM Tris-HCl (pH 8.8), SDS (0.1% w/v), 0.75 
ml monomer (30% T, 2.7% C), 15 μl TEMED (N,N,N‟N‟-tetramethylene diamine) and 30 
μl ammonium persulphate (20% w/v)) followed by an 8% resolving gel, containing 8.8 ml 
resolving buffer (375 mM Tris-HCl (pH 8.8), SDS (0.1% w/v), 3.2 ml monomer (30% T, 
2.7% C), 30 μl TEMED and 36 μl of ammonium persulphate (20% w/v)). The gel was 
electrophoresed for 2 h 30 min at a constant current of 25 mA. Afterwards the stacking 
gel was removed from the resolving gel and the latter incubated in staining solution 
(0.125% (w/v) Coomassie Brilliant Blue R250, 50% (v/v) methanol and 10% (v/v) glacial 
acetic acid) for 1 h at 37°C while shaking. Subsequent to that the gel was incubated in 
destain 1 (50% (v/v) methanol and 10% (v/v) glacial acetic acid) for 1 h at 37°C while 
shaking before it was incubated overnight at room temperature in destain 2 (5% (v/v) 
methanol and 7% (v/v) glacial acetic acid).  
The theoretical size of the OppA protein was predicted using Compute pI/Mw (Expasy). 
3.2.2 Isolation of the expressed OppA-GST protein using a glutathione agarose 
column 
The OppA-GST protein was isolated using a glutathione agarose column (Sigma-Aldrich, 
United States). The expressed OppA protein contains a GST-tag which binds with a high 
affinity to the glutathione resin, and can then be eluted from the column with reduced 
glutathione. The glutathione agarose lyophilized powder was allowed to swell in Milli-Q® 
water at 200 ml/g for 30 min at room temperature and left overnight at 4°C for complete 
swelling to occur. The column (10.5 mm in height and 2.5 mm in width) was then packed 




with a bed volume of 10 ml and subsequently washed with 10 volumes of phosphate 
buffered saline (PBS) equilibrium buffer (10 mM phosphate, 150 mM NaCl, pH 7.4) to 
remove the lactose present in the lyophilized product and left overnight at 4°C.  
The OppA protein expressed from the pGEX_oppA construct was resuspended in TEN 
50 buffer and prepared for isolation by three cycles of freeze thawing (10 min at 37°C 
followed by 10 min at -80°C). Thereafter the sample was sonicated for 2 sec and kept on 
ice for 20 sec (repeated 5 times). The sample was then centrifuged at 10 000 x g for 10 
min at 4°C (Labnet, PrismR). Four milliliters of clear supernatant were loaded onto the 
column at 4°C, and allowed to flow through the resin by gravity. It was passed through 
the column five times and thereafter incubated for 1 h on the column. The column was 
then washed firstly with 5 volumes of PBS-T (PBS (pH 7.2) and 1% Triton X-100) and 
followed by 5 volumes of PBS (pH 7.2). The OppA protein that was bound to the 
glutathione via its GST-tag was eluted with 3 volumes of elution buffer (10 mM reduced 
glutathione and 50 mM Tris-HCl, pH 9.5) and collected in 1 ml fractions. A total of 20 
samples were collected. The resin was then rinsed with 5 volumes of cleaning buffer 1 
(0.1 M boric acid, 0.5 M NaCl) followed by 5 volumes of cleaning buffer 2 (0.1 M sodium 
acetate, 0.5 M NaCl) before it was stored in a storage buffer (2 M NaCl, 0.2% Thiomersal) 
at 4°C.  
A Bradford assay was used to determine the protein concentration of the eluted fractions. 
A standard curve of increasing protein concentrations 0, 0.25, 0.50, 0.75, 1, 1.25 and 1.5 
mg/ml was prepared using bovine serum albumin (BSA) protein and the elution buffer. 
Five microliters of each isolated sample as well as the standards were pipetted into a 96-
well microtitre plate (Greiner Bio-One, Germany) in triplicate. Two hundred and fifty micro 
litters of Bradford reagent (0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) 
ethanol and 8.5% (v/v) phosphoric acid) was added to each well and incubated for 2 min 
before the absorbance was measured at 620 nm. 
3.2.3 SDS-PAGE and western blot analysis of isolated OppA-GST protein 
The purity of the isolated OppA protein was tested by 10% SDS-PAGE where after its 
identity was confirmed using western blotting. The gel assembly and electrophoresis 
conditions for the SDS-PAGE were the same as described in section 3.2.1. After 
electrophoresis the gel was transferred to a 0.45 μm nitrocellulose membrane 
(Schleicher & Schuell, Sigma-Aldrich, United States) using a wet transfer system. The 
gel and membrane was packed for electrophoresis in the following order: perspex support 




plate, sponge, 3 mm chromatography paper (Whatman®, England), SDS-PAGE gel, 
membrane, 3 mm chromatography paper, sponge and perspex support plate. The 
western blot apparatus was then set up and filled with electrode buffer (0.05 M Tris-base, 
0.2 M glycine, 20% MeOH) and electrophoresis was performed at for 18 h at constant 
120 mA. The membrane was then blocked with casein buffer (10 mM Tris-HCl, 0.15 M 
NaCl, 0.5% casein, 0.02% (w/v) Thiomersal, pH 7.2) for 1 h at room temperature before 
it was washed with PBS containing 0.1% v/v Tween® 20 (PBS-Tween) 3 times for 5 min 
respectively at room temperature. A goat anti-GST antibody (GE Healthcare) was used 
as the primary antibody and diluted 1:10 000 in casein-Tween (casein buffer containing 
0.1% (v/v) Tween® 20) in a volume that was sufficient to cover the membrane. The 
membrane was incubated for 1 h at 37°C while shaking at 6 rpm. The membrane was 
again washed with PBS-Tween and secondary antibody added. Horse-radish peroxidase 
(HRP) conjugated rabbit anti-goat antibody (Sigma-Aldrich, United States) was diluted in 
casein-Tween buffer (1:5000) and incubated for 1 h at 37°C while shaking at 6 rpm. The 
membrane was then washed three times with PBS-Tween. The substrate used was 
0.05% (w/v) 4-chloro-1-naphtol, 16% methanol (cold), 1x PBS (cold) and 0.025% (v/v) 
H2O2 (cold). It was added to the membrane and left to develop while shaking. The 
development was stopped after 30 min by washing with Milli-Q® water. 
3.2.4 Antibody production against OppA in rabbits 
The isolated OppA-GST protein was adsorbed to acid treated, naked bacteria that were 
used as an immune carrier (Bellstedt et al., 1987). To this end 2 mg naked bacteria was 
suspended in 0.5 ml Milli-Q® water in a 2.0 ml Eppendorf tube before the solution was 
homogenised using a pestle. The bacterial suspension was transferred to a 20 ml glass 
vial before the Eppendorf tube was washed with additional 0.5 ml Milli-Q® water that was 
also transferred to the vial. Thereafter 330 μl of 0.2 mg/ml expressed OppA-GST protein 
was added to the vial. Subsequently the mixture was dried overnight on a SavantTM 
SpeedVacTM concentrator (AEC Amersham, RSA). The OppA-GST protein that was now 
adsorbed to the naked bacteria was resuspended in 2.5 ml PBS before immunisation. All 
immunizations were done at the Animal Facility, Stellenbosch University, which also 
includes the ethics. A rabbit was injected with 500 μl of suspension on day 0, 4, 7, 14, 
18, 21, 28, 32 and 35. Blood samples (2 ml) were collected before the immunisation 
started and again on day 14 and 28. On day 42 a final volume of 24 ml was collected. All 
blood samples were kept at 37°C for 30-45 min after collection and thereafter at 4°C 
overnight to improve clotting. The blood samples were then centrifuged for 20 min at 3000 




x g (Hettich Universal, D-7200 Tuttlingen) and the serum transferred to a clean Eppendorf 
tube for storage at -20°C. 
3.2.5 Determination of anti-OppA antibody levels in rabbit serum 
To determine whether anti-OppA antibodies were successfully produced in the rabbit an 
antigen specific ELISA was developed. To this end two Maxisorp (Nunc, Denmark) 96-
well microtitre plates were prepared by coating wells in columns 1-12 of plate one and 1-
11 of plate two with the purified OppA-GST protein that was diluted in carbonate buffer 
(50 mM NaHCO3, pH 9.6). Concentrations of 1, 2 and 5 μg/100 μl/well were used. Column 
12 of plate two was left uncoated to test the specificity of the ELISA and only received 
carbonate buffer (100 μl/well). The plates were then incubated overnight at 4°C. 
On the following day the protein solution was decanted and the plates tapped dry on a 
paper towel. All of the wells of the 96-well plates were then blocked with 200 μl/well casein 
buffer (154 mM NaCl, 10 mM Tris-HCl, 0.02% Thiomersal and 0.5% casein, pH 7.6) and 
incubated at 37°C for 1 h. The excess casein buffer was subsequently removed and the 
plates were tapped firmly on a paper towel before all the wells was washed 3 times with 
PBS-Tween. The rabbit serum from day 0 (negative control), 28 and 42 was used as 
primary antibody. One hundred microliters of casein buffer containing 0.1% Tween 
(casein-Tween buffer) was added to column 1 and 3-11 of plate one and 1-11 of plate 
two. Thereafter 200 μl of the serum appropriately diluted 1:20 in casein-Tween buffer, 
was added to column 2 of plate one. A dilution series was then made by taking 100 μl of 
column 2 (plate one) and adding it to column 3, after mixing 100 μl was transferred to 
column 4. This was continued up until column 12 of plate one and the last 100 μl volume 
was transferred to column 2 of plate two. The dilution was continued up to column 11 of 
plate two and the final 100 μl was discarded. Column 12 of plate two received 100 μl of 
1:20 diluted serum.  
The plates were incubated at 37°C for 1 h and then washed 3 times with PBS-Tween 
before the secondary antibody (goat anti-rabbit IgG, Sigma-Aldrich), which was diluted 
1:500 in casein-Tween, was added. Columns 1-12 of both plates received 100 μl of 
diluted antibody after which the plates were incubated for 1 h at 37°C. Plates were again 
washed 3 times with PBS-Tween. The tertiary antibody, a anti-goat HRP-conjugated 
antibody was subsequently diluted 1:1000 in casein-Tween, before 100 μl was added to 
each well. The plates were incubated for 1 h at 37°C and again washed 3 times with PBS-
Tween. Substrate solution (0.006 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 




(ABTS), 12 ml citrate buffer (100 mM citrate acid monohydrate and 0.1 M trisodium citrate 
dehydrate, pH 5) and 6 μl hydrogen peroxide (H2O2) was subsequently added (100 
μl/well). The plates were thereafter left to incubate at 37°C for 30 min before the 
absorbance was measured at 405 nm on a Labysystem multiscan MS microtitre plate 
reader.  
The anti-OppA antibodies were further analysed using western blotting to determine the 
ability of these antibodies to detect the OppA protein of Ms01 and the OppA-GST fusion 
protein. The OppA protein of Ms03 was used as control. The western blot was done 
similarly as in section 3.2.3 with the following differences. The rabbit anti-OppA-GST was 
diluted 1:2500, the Goat anti-rabbit secondary antibody (Sigma-Aldrich, United States) 
was diluted 1:1250 and the tertiary antibody, a anti-rabbit Peroxidase anti-peroxidase 
(Sigma-Aldrich, United States), was diluted 1:10000. All dilutions were done in casein 
buffer.    
3.3 Results 
3.3.1 Expression of the Ms01 OppA-GST protein in E. coli cells 
Freezer cultures containing the BL21(DE3)pLysS cells with the pGEX_oppA plasmid 
were successfully grown on the LB/amp plates and yielded colonies containing 
pGEX_oppA as identified by colony PCR. Positive and negative colonies were identified 
as can be seen on the agarose gel electrophoresis image in Figure 3.1. A positive colony 
PCR produced a band size at about 3000 bp which corresponds to the 2979 bp size of 
the oppA gene. The control colony PCR produced a band size of 150 bp representing the 
multiple cloning site of pGEX. Two of the positive colonies identified were further used 
for protein expression. 
SDS-PAGE analysis (Figure 3.2) of the samples of the expressed OppA-GST fusion 
protein produced a band at the appropriate size of 126 kDa (lane 3, 5 and 7) after 
induction of protein expression at 2, 4 and 6 hours respectively. This indicated that the 
OppA protein was being expressed since the same band was not visible at the 
corresponding position in the samples containing the plasmid without the oppA gene 
(lane 4 and 6). The size of the OppA protein was predicted with Compute pI/Mw (Expasy), 
to be 100 kDa. The OppA protein (100 kDa) is expressed as a fusion protein (126 kDa) 
with GST (26 kDa). 





Figure 3.1 An image of a 1% agarose gel depicting the results of a colony PCR using colonies of 
E. coli BL21(DE3)pLysS cells transformed with the pGEX plasmid with and without the Ms01 
oppA gene. Lane 1-8 shows 8 positive colonies identified that contain the oppA insert. Lane 9-15 
on the right is 8 negative colonies identified that do not display the oppA insert. Lane 16 is a 
positive control, Ms03-oppA in pGEX. Lane L on the left and right contains a GeneRulerTM 
(Fermentas) ladder containing size standards of 100-10 000 bp. GelredTM Nucleic Acid Gel Stain 
0.1 μl/ml, was used for staining. 
 
 
Figure 3.2 An image of a 10% SDS-PAGE gel showing expression of the OppA-GST protein 0, 
2, 4 and 6 h after inducing with IPTG. Lane L: PageRulerTM Unstained Protein Ladder (Thermo 
Scientific). Lane 1: pGEX_oppA at 0 h expression. Lane 2: pGEX at 0 h expression. Lane 3: 
pGEX_oppA at 2 h expression. Lane 4: pGEX at 2 h expression. Lane 5: pGEX_oppA at 4 h 
expression. Lane 6: pGEX at 4 h expression. Lane 7: pGEX_oppA at 6 h expression. 
3.3.2 Isolation of the expressed OppA-GST protein using a glutathione agarose 
column and the subsequent SDS-PAGE and western blot analysis 




The solution containing the expressed Ms01 OppA protein fused to GST was 
subsequently harvested and loaded on a glutathione agarose column and eluted by the 
introduction of reduced glutathione. Figure 3.3 shows the elution profile of the 20 fractions 
collected as analysed using the Bradford assay. From the profile it can be seen that the 
protein starts to elute from sample 5 and that sample 7, 8 and 9 contained the highest 
protein concentration; determined as 0.455 mg/ml, 0.436 mg/ml and 0.342 mg/ml 
respectively. The majority of the bound protein was eluted by the time sample 12 was 
collected. An SDS-PAGE analysis of elution samples 7, 8, 9 and 10, showed protein 
bands with sizes of about 126 kDa, corresponding to the size of the OppA protein of 100 
kDa attached to the GST of 26 kDa (Figure 3.4). The same band size was present in the 
sample before chromatography but not after addition to the column, indicating that the 
OppA-GST fusion protein successfully attached to the glutathione via the GST. 
 
Figure 3.3 Graph illustrating the protein concentrations (mg/ml) as determined by the Bradford 
assay of the fractions that eluted from the glutathione agarose column onto which the expressed 
protein solution was loaded. The elution profile indicates that sample 7, 8 and 9 contains the 










































Figure 3.4 An image of an 8% SDS-PAGE gel of OppA-GST protein fractions eluted from the 
glutathione agarose column. Samples revealed a band at the appropriate size of 126 kDa. Lane 
L: PageRulerTM Unstained Protein Ladder (Thermo Scientific). Lanes 2-5 are the eluted samples 
7, 8, 9, and 10 respectively. Lane 6 was a supernatant sample before it was loaded onto the 
column and lane 7 a sample taken from the flow through after it was loaded onto the column. 
 
Four elution samples (7, 8, 9 and 10) were subsequently analysed with western blot 
(Figure 3.5) using an anti-GST antibody and a band at 126 kDa could be seen in all four 
elution samples (lane 2-5) as well as before addition to the column (lane 6) but not after 
addition (lane 7). The band size corresponds to the size of the OppA-GST protein. 
 
 
Figure 3.5 Image of a western blot analysis of four OppA-GST samples eluted from a glutathione 
agarose column. The samples were separated on an 8% SDS-PAGE gel and transferred to a 
0.45 μm nitrocellulose membrane. Lane 1: Full range rainbow marker (Amersham), not visible on 
the figure due to inadequate transfer. Lane 2-5: eluted samples 7-10, respectively. Lane 6: after 
wash buffer 1. Lane 7: after wash buffer 2. Lane 8: before wash. Lane 9: before binding to the 
column. 
 
 Development and validation of rabbit anti-OppA antibodies 
The OppA protein was adsorbed to the naked bacteria and used to immunise rabbits over 
a period of 6 weeks. Blood samples collected during this period were analysed by ELISA 
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to confirm the presence of anti-OppA antibodies (Figure 3.6). Column one which did not 
receive any serum was used as a blank and was colourless. Rabbit serum from day 0 
resulted in no colour reaction, which indicated the absence of any OppA antibodies. Using 
a cut off titre value of 0.1 a colour reaction could be observed for day 28 and 42 serum 
up to a dilution of 1/327680 on plate two, indicating the presence of rabbit anti-OppA 
antibodies.  
The ELISA results were used to generate a graph (Figure 3.7) as an illustration of the 
immune response generated by the rabbit in response to vaccination with the OppA-GST 
protein adsorbed to the naked bacteria. From the graph there is a consistent increase in 
titre values up to day 28 after which no increase in titre values was observed up to day 
42.  
The rabbit anti-OppA-GST antibodies were able to detect the Ms01 expressed OppA-
GST protein with western blot analysis (Figure 3.8), but not the GST protein on its own 
nor the OppA-GST protein of Ms03. This indicates the specificity of the antibody towards 




Figure 3.6 A 96 well Maxisorp plate showing ELISA results of rabbit serum immunised with the 
OppA-GST protein adsorbed to naked bacteria. Serum collected at days 0, 28 and 42 was 
compared using three concentrations 1 μg/100μl, 5 μg/100μl and 10 μg/100μl purified OppA-GST 
protein. This was followed by a serial dilution from column 3 up to column 12. Only results for the 
















Figure 3.7 A graph that illustrates the rabbit anti-OppA-GST antibody response against the 
purified OppA-GST protein. Serum collected during days 0, 28 and 42 was compared at a protein 
concentration of 5 μg/100 μl. The graph illustrates day 0, 28 and 42 when an absorbance (OD405) 














Several studies have used the pGEX expression system for successful expression of 
mycoplasma genes (Okamba et al., 2007; Rosati et al., 2000; Shil et al., 2011). The pGEX 




















Immune response of rabbit
Figure 3.8 The corresponding SDS-PAGE (A) and western blot (B) analysis of the respective 
Ms01 and Ms03 OppA proteins. Lane 1: Full range rainbow marker (Amersham). Lane 2: Ms01 
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of proteins that are soluble, correctly folded and covalently bound to a GST moiety on 
their amino terminus (GST Gene Fusion System Handbook, 2002). The presence of a 
lacIq gene in the plasmid prevents expression of the fusion protein until the introduction 
of IPTG. This results in an increase of expressed fusion protein within the bacterial 
cytoplasm(GST Gene Fusion System Handbook, 2002). By employing the pGEX 
expression system in this study, successful expression of the OppA protein from Ms01 
could be achieved as an OppA-GST fusion protein. A 126 kDa protein product was visible 
after SDS-PAGE that corresponds to the theoretical size calculated for the OppA-GST 
fusion protein.  
The GST tag allows for the purification of the fusion protein by affinity chromatography, 
resulting in a GST fusion protein that contains preserved antigenicity as well as function 
(GST Gene Fusion System Handbook, 2002; Harper and Speicher, 2011). Using anti-
GST antibodies, western blot analysis of the purified OppA-GST fusion protein confirmed 
the presence of the GST moiety as part of the 126 kDa protein and thereby confirming 
successful purification. The GST moiety was found to separate from the recombinant 
protein after storage at 4°C for about 3 weeks. This could be shown on an SDS-PAGE 
where the 126 kDa band will became less intense and the 100 and 26 kDa bands 
increased in intensity which corresponds to the sizes of the OppA and GST proteins 
respectively. The separation of the GST moiety can be explained by the  natural protease 
enzymes found within the E. coli cells. The polylinker between GST and the recombinant 
protein is said to contain a specific protease cleavage site (Harper and Speicher, 2011). 
It might also be due to natural degradation of the linker between the protein and GST. 
Intact fusion protein was, however, always used for downstream applications since GST 
is a homodimeric protein that ensures solubility and the correct folding of the protein as 
well as avoiding denaturation of the protein (Harper and Speicher, 2011). The addition of 
a protease inhibitor could help prevent the GST from separating. 
Successful production of rabbit anti-OppA-GST antibodies was achieved using the OppA-
GST protein adsorbed to naked bacteria. The GST moiety was not removed from the 
fusion protein before immunisation of rabbits, since the GST protein is much smaller than 
the Ms01 OppA and is not likely to result in antibody production against the GST protein. 
This was confirmed by western blot analysis where the rabbit anti-OppA-GST antibodies 
were able to detect the OppA-GST and OppA protein but not the GST on its own in 
expressed samples that were not isolated using affinity chromatography. This indicates 
that the developed antibodies can be used in a western blot system to detect OppA 




production. The ELISA assay further indicated the specificity of the rabbit anti-OppA 
antibodies as the antibody did not bind to any of the expressed lysate proteins in the 
absence of the Ms01 OppA protein. 
Successful expression and purification of the OppA protein was achieved and this may 
therefore be used for ELISA analysis of anti-OppA antibody responses in DNA-vaccine 
trials in ostriches (Chapter 5). The anti-OppA-GST antibodies produced in rabbits was 
next used in western blot analysis to confirm the in vitro expression of OppA protein by 
the DNA vaccine vectors in a mammalian cell culture based study (Chapter 4).  




 Evaluation of the expression of the oppA gene using a mammalian 
cell culture based system.  
 Introduction  
The ability of any DNA vaccine to elicit an immune response is evaluated through 
vaccination trials during which the vaccine is administered to live animals and the 
resulting immune response determined. The lack of an immune response can on the one 
hand be due to the inability of the vaccine to trigger the immune system. On the other 
hand, it may be due to the lack of expression of the antigen gene. The possible lack of 
expression of the oppA gene by the DNA vaccine vectors was given as a reason for the 
lack of success of previous Ms01 vaccination trials (van Tonder, 2013).  
The ability of the DNA vaccine plasmid to express the vaccine antigen can be evaluated 
before an expensive DNA vaccination trial is undertaken by means of mammalian cell 
culture. The process of recombinant protein expression in the vaccinated animal can be 
mimicked by transfecting a mammalian cell with the DNA vaccine. During this process, 
the transfected cell culture may express the gene of interest over a period of time. This 
would confirm that the DNA vaccine is able to express the antigen gene and translate it 
to a protein. 
In order to evaluate the in vitro expression of the previously developed DNA vaccines 
against Ms01 (Pretorius, 2009), the three DNA vaccine plasmids were prepared in large 
amounts and isolated for transfection. As a supercoiled configuration is preferred for 
transfection, the configuration of the isolated plasmids was evaluated using restriction 
enzyme digestion. The isolated plasmids were thereafter used for transfection of a COS-
1 cell culture in 6 and 12 well plates. In order to determine if transcription resulted from 
the transfected plasmids, RNA was isolated and analysed using the reverse 
transcription polymerase chain reaction (RT-PCR). After cell lysis of the transfected cells 
using two different lysis buffers, the translation of the transcribed product was analysed 
using SDS-PAGE and western blot using chemiluminescence for sensitive detection. 
 Materials and methods 
  Preparation of three DNA vaccine plasmids for transfection 
Frozen stocks of three DNA vaccine plasmids pCI-neo, VR1012 and VR1020 containing 
the oppA gene of Ms01 were previously prepared by van Tonder (2012). The plasmids 
were, however, transformed into Salmonella enterica serovar Typhimurium SL3261 cells. 




In order to isolate the plasmids using a Nucleobond® Xtra Midi kit (Macherey-Nagel, 
Germany), the plasmids had to be transformed into Escherichia coli cells. One liter of 
Tryptic soy broth (TSB) (Merck, USA) was prepared by adding 38 g TSB medium to 1000 
ml of Milli-Q® water and the solution autoclaved. In a 14 ml Falcon® tube, 5 μl ampicillin 
(100 μg/ml, Sigma-Aldrich, USA) was added to 5 ml TSB and inoculated with 4 μl of the 
S. enterica serovar Typhimurium SL3261 cells containing the pCI-neo_oppA. Twenty 
microliters of kanamycin (100 μg/ml, Biochemica, Fluka) was added to 5 ml TSB-medium 
in a 14 ml Falcon® tube for VR1012_oppA and VR1020_oppA, respectively. Thereafter 
these tubes were incubated for 16-18 h at 37°C while shaking at 200 rpm. Each of the 
plasmids were isolated from the S. enterica serovar Typhimurium SL3261 cells using an 
Invisorb® spin Plasmid mini two kit (Invitek, Germany) by following the manufacture’s 
protocol. Briefly, the cells were first separated from the medium by centrifugation and the 
pellet resuspended, cells lysed and lysis buffer neutralized using the supplied Solution A, 
B and C respectively. Thereafter the cell suspension was loaded onto a column and the 
column cleaned using various washing buffers supplied as part of the kit. The plasmids 
were finally eluted from the column in 60 μl Milli-Q® water and their concentration 
determined as 25 ng/μl for pCI-neo_oppA, 51.2 ng/μl for VR1012_oppA and 55.1 ng/μl 
for VR1020_oppA using a Nanodrop® ND 1000 spectrophotometer (Novell®, USA). 
Transformation into E. coli cells was achieved by adding 2 μl of each plasmid, pCI-
neo_oppA, VR1012_oppA or VR1020_oppA, to 50 μl BL21 (DE3)pLysS E. coli 
competent cells in a 14 ml Falcon® tube and leaving the tubes to incubate on ice for 20 
min. Thereafter the cells were treated with a heat shock for 45 sec at 42°C in a water 
bath and immediately returned to ice for 2 min. Nine hundred and fifty microliters of LB 
medium (10 g/l Bacto-tryptone, 5 g/l Bacto-yeast extract, 5 g/l NaCl) medium was 
subsequently added to the cells and left to incubate for 90 min at 37°C with shaking at 
150 rpm. 
LB Petri dishes were subsequently prepared by adding 15 g/l agar to LB-medium. The 
solution was autoclaved and allowed to cool before the addition of either ampicillin (100 
μg/ml) for pCI-neo_oppA or kanamycin (100 μg/ml) for VR1012_oppA and 
VR1020_oppA, respectively. Fifty microliters of the LB-medium containing the E. coli cells 
with plasmid was plated out onto the LB-agar and incubated for 18 h at 37°C.  
Ten colonies for each plasmid culture were chosen for further analysis by colony PCR. 
Primer pairs used during the PCR reaction was synthesised by IDT and is shown in Table 




4.1. All primer pairs consisted of one plasmid specific primer and one primer specific for 
the oppA gene. All PCR reactions as well as the thermal cycler programming were done 
as described in section 3.2.1. All the PCR products were electrophoresed on a 1% (w/v) 
agarose gel. The staining of the gel was done by adding 0.1 μl/ml GelredTM Nucleic Acid 
Gel Stain to the gel before casting for visualisation of the PCR products under a UV-light.  
To ensure that the plasmid to be used for transfection was supercoiled, each plasmid 
was digested with specific restriction enzymes of which the restriction sites are situated 
in the multiple cloning site. The pCI-neo_oppA plasmid was digested with Acc1 
(Promega, USA) and VR1020_oppA with BamH1 fast-digest (Fermentas, USA). 
VR1012_oppA was digested with Sal1 and Not1 fast-digest enzymes (Fermentas, USA). 
This was the two restriction enzymes that are situated at the opposite ends of the oppA 
gene. For the Promega enzyme (Acc1) a master mix of 16.3 μl Milli-Q® water, 2 μl 10x 
buffer, 0.2 μl BSA (10 mg/ml), 1 μl pCI-neo_oppA plasmid (1 μg/μl) and 0.5 μl of restriction 
enzyme was prepared and incubated for 2 h at 37°C, followed by a deactivation step of 
5 min at 80°C. For the Fermentas enzymes (BamH1, Not1 and Sal1) 14 μl Milli-Q® water, 
2 μl 10x fast-digest buffer and 1 μl of each restriction enzyme was mixed with 2 μl of the 
VR1012_oppA and VR1020_oppA plasmids (1 μg/μl) and left to incubate for 5 min at 
37°C followed by an enzyme deactivation step of 5 min at 80°C. All the enzyme digested 
products were electrophoresed on a 1% (w/v) agarose gel. The staining of the gel was 
done as above.  
Overnight cultures of positive colonies were prepared by inoculating a 14 ml Falcon® tube 
containing 5 ml LB-medium and 1 μl/ml ampicillin (100 μg/ml) for pCI-neo_oppA or 4 μl/ml 
kanamycin (100 μg/ml) for VR1012_oppA and VR1020_oppA, with the positive colony 
and incubating it for 16 h at 37°C on an orbital shaker (150 rpm). Thereafter a starter 
culture was prepared for pCI-neo_oppA in a 50 ml Erlenmeyer flask containing 10 ml LB 
medium and 10 μl of ampicillin (100 μg/ml) with 1 ml pCI-neo_oppA overnight culture. For 
VR1012_oppA and VR1020_oppA the starter culture contained 40 μl of kanamycin (100 
μg/ml) together with the 10 ml LB medium and 1 ml of the respective plasmids overnight 
culture. These cultures were left to incubate at 37°C while shaking at 200 rpm until an 
OD600 of 0.6 was reached after 8 h. The respective starter culture mixtures were next 
added to a 1 L Erlenmeyer flask containing 200 ml LB-medium and 1 μl/ml ampicillin (pCI-
neo_oppA) or 4 μl/ml kanamycin (VR1012_oppA and VR1020_oppA) and left to incubate 
for 16 h at 37°C while shaking at 200 rpm.  




Plasmids were isolated with the Nucleobond® Xtra Midi kit, Macherey-Nagel following the 
manufacturers protocol. Plasmids were finally eluted in 800 μl Milli-Q® water and stored 
at 4°C until use. Frozen stocks of all three plasmids were also prepared for future plasmid 
isolations by adding 500 μl of overnight culture to 500 μl of an 80% glycerol solution in a 
1.5 ml Eppendorf tube which was then stored at -80°C. 
 



























 Transfection of COS-1 cells 
 Preparation of cell culture medium 
Dulbecco’s Modified Eagle’s Medium (DMEM) was prepared by adding DMEM powder 
(Sigma-Aldrich), 700 ml sterilized Milli-Q® water, 0.1 g sodium pyruvate (0.1 g/l) (Sigma 
Aldrich) and 3.7 g sodium bicarbonate (3.7 g/l) (Sigma Aldrich) to a 1 liter Schott Bottle. 
The pH was adjusted to 7.2, volume adjusted to 1 L. Thereafter the medium was filter 
sterilized by passing the medium through a glass fibre pre-filter (Merck) followed by a 
second 0.22 μm filter (Millipore) before it was passed through a Sterivex bell filter 
(Millipore) using a Millipore easy-load® Masterflex® L/S® pump (Millipore). A sample of 
the medium was kept at 37°C overnight to test for any contamination of the medium. 
Subsequent to that the medium was supplemented with 10% heat inactivated fetal calf 
serum (PAA the Cell Culture Company) as well as 1% Penicillin-Streptomycin (100 μg/ml) 
(Sigma-Aldrich) and kept at 4°C for no more than one month. 




 Maintenance of COS-1 cells for transfection 
African green monkey kidney cells (COS-1 cells), were purchased from ATCC and 
obtained from a stock cultivated at the Department of Biochemistry, University of 
Stellenbosch. In a laminar flow cabinet, 4 ml supplemented DMEM medium (preheated, 
20 min, 37°C) was added to a 1 ml COS-1 (3 passages) frozen stock in a 50 ml Falcon® 
tube and centrifuged for 5 min at 3500 x g using an Eppendorf 5702 centrifuge. The 
supernatant was removed and the pellet resuspended in 5 ml supplemented DMEM 
medium. Thereafter the DMEM-cell mixture was added to a T75 cell culture flask (Nest 
Biotech, China) and incubated at 37°C (5.0% CO2) and 90 % humidity, until the cells 
reached a confluency of 90%. The cells were transfected after three passages. A 
passage firstly involved removing the medium from the growing culture in the T75 flask. 
Thereafter 2 ml 0.05%/0.02% Trypsin/EDTA (Biochrom, UK) was added to the cell culture 
flask and left to incubate at 37°C (5.0% CO2) for 3 min to loosen the cells from the base 
of the flask. Next 5 ml supplemented DMEM medium was added to the trypsin/cell 
solution to neutralize the trypsin, before it was transferred to a 50 ml Falcon® tube and 
centrifuged for 5 min at 3500 x g. The supernatant was removed and the pellet 
resuspended in 5 ml supplemented DMEM medium after which 1 ml was added to 19 ml 
supplemented DMEM medium in a new T75 cell culture flask. This was left to incubate at 
37°C (5.0% CO2) and 90 % humidity, until a confluency of 90% had been reached after 
which the process was repeated. 
 Transfection conditions 
When 90% confluency was reached after the third passage, the medium was removed 
and the COS-1 cells detached from the T75 flask by adding 2 ml 0.05%/0.02% 
Trypsin/EDTA in PBS (Biochrom, UK) and incubated for 3 min at 37°C (5.0% CO2). 
Thereafter 10 ml supplemented DMEM medium was added to the COS-1 cells to 
neutralise the trypsin and centrifuged for 5 min at 3500 x g. The pellet was subsequently 
resuspended in 10 ml supplemented DMEM.  
COS-1 cells were counted and cell viability calculated using a Countess® automated cell 
counter (Life Technologies, USA). For this purpose a 10 μl resuspended cell sample was 
mixed with 10 μl, 0.4% Trypan Blue solution (Life Technologies, USA) and pipetted onto 
a Countess® cell counting chamber slide (Life Technologies, USA). The slide was then 
inserted into the cell counter to count the number of cells in the sample, as well as to 




determine the viability. The COS-1 cells were seeded into 12 well cell culture plates at 
1X105 cells per well and incubated for 24 h at 37°C (5.0% CO2) in 90 % humidity.  
For transfection the X-tremeGENE HP DNA (Roche, USA) transfection reagent was 
used. Three different plasmid (pCI-neo_oppA) concentrations of 0.005 μg/μl, 0.01 μg/μl 
and 0.02 μg/μl were tested for transfecting COS-1 cells at three different transfection 
reagent to DNA ratios of 1:1, 3:1 and 4:1. A un transfected COS-1 cell sample, which did 
not receive any plasmid, was also included at each time point. For transfection, the 
plasmid was diluted to the appropriate concentration using unsupplemented DMEM (final 
volume of 100 μl). The appropriate amount of transfection agent was added to the solution 
and mixed by swirling. The plasmid-DMEM mixture was left to incubate for 15 min. 
Thereafter 100 μl of the mixture was added dropwise to each well and left to incubate at 
37°C (5.0% CO2) for 24 h, 48 h and 72 h.  
The transfection was repeated and transfections with VR1012_oppA and VR1020_oppA 
using 0.01 μg/μl plasmid at a transfection reagent to DNA ratio of 3:1 were prepared. 
Controls in which pCI-neo, VR1012 and VR1020 without the oppA insert and an 
untransfected sample, were included.  
 Transfection using 6 well culture plates 
In order to increase the total amount of expressed protein in the COS-1 cells the 
transfection was repeated using 6 well cell culture plates. Cell culture plates were 
prepared for three time periods: 24, 48 and 72 hours. COS-1 cells were again prepared 
as in section 4.2.2.2 and after three passages, and at a confluency of 90%, a final volume 
of 40 ml was prepared with 2X105 cells in supplemented DMEM. Thereafter 2 ml of the 
cell suspension was added to each well of a 6 well cell culture plate (Greiner, Bio-One) 
and incubated for 24 h at 37°C (5.0% CO2) before it was transfected. The transfections 
were performed in a similar way as in section 4.2.2.3 and included pCI-neo_oppA, 
VR1012_oppA and VR1020_oppA (all at 0.01 μg/μl) and a un-transfected control at a 
transfection reagent to DNA ratio of 3:1. A total volume of 200 μl DNA/transfection 
reagent was added dropwise to each well and left to incubate at 37°C (5.0% CO2) for the 
time periods specified above.  




 Lysis of cells after transfection 
 Reducing treatment buffer 
After each of the 24, 48 and 72 h time periods in the 6 and 12-well plates, the adherent 
cells were lysed. This was achieved by adding 100 μl reducing treatment buffer (RTB: 
0.125 M Tris-HCl, 4% (m/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol, pH 
6.8) in each well of a 12-well plate and mixed with the cells using the pipette tip. The 
lysate was transferred into a 1.5 ml Eppendorf tube and were either boiled and analysed 
immediately using SDS-PAGE or stored at -20°C for analysis at a later stage. For 6-well 
plates the procedure was repeated as outlined above but 200 μl RTB was used. 
 RIPA buffer and protease inhibitor 
Radioimmunoprecipitation assay (RIPA) buffer (Sigma, USA) was used as alternative to 
RTB due to concerns that the OppA protein was not being extracted from the insoluble 
cell lysis material by means of RTB. One protease inhibitor tablet (Complete ULTRA 
Tablets, Mini, Easypack, Roche) was added per 10 ml RIPA buffer to protect proteins 
against degradation. The medium was firstly removed from the wells and the attached 
cells were washed with 800 μl sterilised PBS buffer (pH 7.2) as the medium can influence 
the RIPA buffer. The PBS was removed and 125 μl of the RIPA buffer, containing the 
protease inhibitor, was added to each well of a 12-well plate. The buffer was left to 
incubate for 5 min on ice before the plates were swirled to loosen the cells. The cell 
mixture of each well was then transferred into a 1.5 ml Eppendorf tube and were either 
boiled and analysed immediately using SDS-PAGE or stored at -20°C for analysis at a 
later stage. For a 6-well plate the procedure was repeated as outlined above but 250 μl 
RIPA buffer was used. 
 Procedure for increasing the concentration of expressed protein in 
transfected cell cultures 
In an attempt to increase the overall protein concentration of expressed OppA protein the 
cell contents of different wells within a cell culture plate were combined. This was done 
only for transfections using the VR1020 plasmid. Only 6-well plates were used for this 
purpose and the harvested cells from 3 wells were combined resulting in a volume of 750 
μl. This was repeated using both RTB and RIPA buffer for cell lysis on the same plate. 
This combined volume was thereafter concentrated to a final volume of 250 μl using a 
SavantTM SpeedVacTM concentrator. This was done for transfected and untransfected 
samples. Protease inhibitor was again added to the RIPA buffer to limit protein 




degradation during storage. In an attempt to further increase the concentration of the 
expressed OppA protein, transfected COS-1 cells were incubated for longer incubation 
periods up to 96 h. Expression levels of OppA were analysed using SDS-PAGE as 
described in section 4.2.5.1. Analysis was done both directly after lysis and after storage 
at -20°C. 
 Analysis of gene transcription 
 RNA isolation with the Nucleospin RNA midi kit 
Reverse transcriptase-PCR (RT-PCR) was used to assess oppA gene transcription in 
cell culture lysates. As this involved a different cell harvesting method, transfection was 
repeated as described for the 12-well plates using the different plasmids. COS-1 cells 
were maintained as in section 4.2.2.2, and transfected as described in section 4.2.2.3. 
The medium was removed and the harvesting of the cells for RT-PCR was done by firstly 
washing the cells with PBS buffer before 0.3% trypsin/EDTA, diluted in PBS, was added 
to each well and incubated in a CO2 (5.0%) oven at 37°C for 3 min to loosen the cells. 
Afterwards supplemented DMEM medium was added to each well, mixed and pipetted 
into a 1,5 ml Eppendorf tube. RNA was isolated using a RNA-Isolation Nucleospin RNA 
midi kit (Macherey-Nagel) according to the manufacturer’s protocol. The RNA was finally 
eluted in 60 μl RNase-free water. 
 RNA isolation with Trizol® 
An alternative to the RNA-Isolation Nucleospin RNA midi kit was also used to isolate RNA 
from the cultured cells. After the appropriate incubation period, the medium was removed 
before the cells were washed with 100 μl of sterilised PBS buffer (pH 7.2) to remove the 
excess medium. The PBS was subsequently removed and 400 μl Trizol® (Sigma, USA) 
added to each well of the 12-well plate and 800 μl to each well of a 6-well plate. The cells 
were lysed by pipetting up and down and subsequently pipetted into Eppendorf tubes. 
The Trizol-cell solution was left to incubate at room temperature for 5 min before 80 μl 
chloroform was added to each sample collected from a 12 well plate and 160 μl to each 
sample collected from a 6 well plate and mixed by inverting the tube. The mixture was 
subsequently centrifuged at 14 000 x g using a Labnet Prism R centrifuge for 15 min at 
4°C. The clear aqueous phase was thereafter transferred to a clean Eppendorf tube 
before equal volumes of isopropanol were added to the Eppendorf tubes and mixed by 
inverting the tube. The solution was again centrifuged at 14 000 x g for 10 min at 4°C. 
The supernatant was removed whereafter the remaining pellet was washed with 500 μl 




of 75% EtOH containing Diethylpyrocarbonate (DEPC) treated water. The solution was 
mixed using a vortex mixer for 1 min before it was again centrifuged at 8000 x g for 5 min 
at 4°C. The pellet was subsequently air dried for 10 min. The pellet containing the RNA 
was dissolved in 15 μl of DEPC-treated water and stored at -20°C until analysed. 
 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
The specific primer pairs listed in Table 4.2 were used to amplify a 541 bp gene-product 
of the oppA gene by RT-PCR in order to assess oppA gene expression. All PCR reactions 
were carried out in 25 μl volumes containing 15.12 μl Milli-Q® water, 2.5 μl 10x Buffer, 
1.25 μl Dithiothreitol (DTT) (0.1 M), 1.0 μl dNTP (5 mM), 1.5 μl MgCl2 (25 mM), 0.625 μl 
P2F forward primer (20 pmol/μl), 0.625 μl P3R reverse primer (20 pmol/μl), 0.25 μl 
Supertherm Taq (5 U/μl), 0.125 μl Superscript (200 U/μl, Invitrogen, USA) and 2 μl RNA 
sample. The thermal cycler was programmed as follows: 48°C (30 min) 35 cycles of each 
94°C (30 sec), 55°C (30 sec), 72°C (30 sec) and an additional 7 min at 72°C. The PCR 
results were verified on a 1% agarose gel containing 0.1 μl/ml GelredTM Nucleic Acid Gel 
Stain for UV visualisation.  
 




Base-pair sequence (5’ - 3’) 
Product 
size (bp) 






 Analysis of gene translation 
 SDS-PAGE 
The expression of OppA protein in transfected cell cultures was analysed by SDS-PAGE. 
The gel was cast as described in section 3.2.1 and an 8% resolving gel was used to 
separate the proteins. The positive control used was the previously expressed and 
purified OppA protein (Chapter 3). Thirty microliters of the control was mixed with 12 μl 
of 0.1% (v/v) bromophenol blue and 30 μl RTB before it was boiled for 10 min in water 
over a Bunsen burner. For samples collected from cell culture plates using RTB, 0.1% 
(v/v) bromophenol blue was added to 30 μl of the sample followed by boiling for 10 min. 




For samples collected from cell culture plates using RIPA buffer, 0.1% (v/v) bromophenol 
blue was added to 30 μl of the RIPA buffer-sample and 30 μl RTB followed by boiling for 
10 min. Each sample mixture (30 μl) was loaded onto the 8% SDS-PAGE gel. Coomassie 
staining of the gel was performed as described in section 3.2.1.  
 Western blot analysis 
Western blot using colorimetric detection  
The proteins on the SDS-PAGE gel were transferred to a 0.45 μm nitrocellulose 
membrane and western blotting analysis performed as described in section 3.2.3. Briefly, 
the membrane was blocked using casein buffer. Next, rabbit anti-OppA serum (as 
prepared in Chapter 3, diluted 1:2 000 in casein-Tween buffer) was added to the 
membrane and incubated for 90 min at 37°C on a shaker (6 rpm). The membrane was 
washed twice for 10 min at 37°C with 0.1% PBS-Tween followed by the addition of the 
goat anti-rabbit (Sigma-Aldrich, USA) antibody (diluted 1:2500 in casein-Tween). The 
membrane was again incubated for 90 min at 37°C followed by a PBS-Tween wash. 
Rabbit peroxidase anti-peroxidase (PAP, Sigma-Aldrich, USA), diluted 1:5 000 in casein-
Tween was then added and the membrane incubated for 1:30 h at 37°C on a shaker (6 
rpm) followed by a PBS-Tween wash. Substrate (50% 4-chloro-1-naphtol, 16% MeOH 30 
ml PBS and 9 μl H2O2) was finally added to the membrane which was allowed to incubate 
until a band could be detected.  
Western blot using chemiluminescence detection 
A chemiluminescence detection system was used as an alternative to detect expressed 
oppA. Chemiluminescence as detection method was chosen over the colorimetric 
method as it is much more sensitive. The oxidation of luminol by peroxide results in 
creation of an excited state product called 3-aminophthalate. This product decays to a 
lower energy state by releasing photons of light to which an X-ray film can be exposed 
(Odyssey imaging system, 2011). The different cell samples were firstly separated on an 
8% SDS-PAGE gel before they were transferred to a 0.45 μm nitrocellulose membrane. 
Thereafter the membrane was blocked with blocking buffer (10 mM Tris-HCl, 0.15 M 
NaCl, 5% fat free milk powder (Elite, RSA), 0.02% Thiomersal) for 1 h at 37°C on a shaker 
(6 rpm) before it was washed three times for 5 min with 20 ml PBS that contained 0.05% 
(v/v) Tween® 20. The primary antibody used was rabbit anti-OppA anti-serum which was 
diluted (1:2000) in blocking buffer containing 0.05% (v/v) Tween® 20. The membrane was 
incubated for 18 h at 4°C on a shaker (6 rpm) followed by a PBS-Tween wash as before. 




A goat anti-rabbit HRP conjugate (Santa Cruz, USA) was used as a secondary antibody 
and was diluted 1:20 000 in blocking buffer containing Tween. The membrane was 
incubated for 90 min at 37°C on a shaker (6 rpm) and again washed three times with 
PBS-Tween.  
The development of the blot was done in a dark room that was fitted with a red dark room 
photo lamp (Dr Fischer, Germany) that does not emit UV-light. Within the dark room the 
substrate, 2 ml of luminol reagent mixed with 2 ml hydrogen peroxide solution (Thermo 
Scientific, USA), was added, whereafter the membrane was incubated for 1 min. After 
incubation the membrane was placed in a 18 x 24 cm Cronex® Blot developer (Du Pont, 
USA) and exposed to X-ray film (Fuji-film) for different time periods ranging from 10 sec 
to 30 min at room temperature. After exposure, the film was first incubated in a X-ray 
Developer (Axim, RSA) for 1 min, washed with water and thereafter incubated in a X-ray 
Fixer (Axim, RSA) for 1 min. This ensured that the film would be unaffected by UV-light 
afterwards. 
Optimisation was done by varying the concentrations and incubation times, as described 
above, of the primary and secondary antibodies as well as the subsequent X-ray film 
exposure time.  
 Results 
 Preparation of three DNA vaccine plasmids for transfection 
The three plasmids pCI-neo_oppA, VR1012_oppA and VR1020_oppA were successfully 
isolated from the Salmonella cells whereafter a Nanodrop® reading revealed the 
concentration to be 95.5 ng/μl, 51.2 ng/μl and 55.1 ng/μl, respectively. The plasmids were 
subsequently transformed into BL21(DE)pLysS E. coli cells and successful 
transformation confirmed using colony PCR. Figure 4.1 shows the results obtained from 
the colony PCR. For VR1020 colony 1, 2, 3, 6, 7 and 9 were positive. For Vr1012 all the 
colonies tested were positive and for pCI-neo only colonies 1, 2, 3, 7 and 9 were positive. 
Although not all the colonies containing the VR1020_oppA and pCI-neo_oppA plasmids 
tested positive, the transformation efficiency was sufficient to allow for the identification 
of positive colonies for further use. 
 





Figure 4.1 A 1% agarose gel electrophoresis image of a colony PCR done with the respective 
plasmids, pCI-neo_oppA, VR1012_oppA and VR1020_oppA within E. coli cells. In image (A) lane 
L: GeneRulerTM (Fermentas), lane 1-9 the different colonies tested. In image (B) lane L represents 
a Fermentas gene ruler ladder, lane 1-9 the different colonies tested. In image (C) lane L 
represents a Fermentas gene ruler ladder, lane 1-9 the different colonies tested. 
 
After positive colonies were identified, they were grown to a high density overnight for 
large scale plasmid isolation. The plasmid DNA were successfully isolated from the 
cultures and Nanodrop® readings gave concentrations of 816.0 ng/μl, 867.4 ng/μl and 
1077 ng/μl for VR1012_oppA, VR1020_oppA and pCI-neo_oppA respectively. 
Although in figure 4.2 some of the band sizes appear more intense that others, most of 
the plasmids were shown to be supercoiled, which is needed for transfection as it is the 
smallest configuration that will allow for better internalisation.  Restriction digestion of the 
isolated plasmids revealed that the Acc1 cuts the pCI-neo_oppA plasmid once, producing 
a linear band of about 8000 bp. VR1012_oppA was digested with Sal1 and Not1 and 
produced 2 bands, one corresponding to the size of the oppA gene of 2828 bp and 
another that corresponded to the size of the plasmid of 4900 bp. VR1020_oppA was 
digested with BamH1 and resulted in the plasmid being cut twice, producing 2 bands, 
one representing the size of the gene and the other the size of the VR1020 plasmid (5000 


















 Transfection and lysis of COS-1 cells  
COS-1 cells prepared for all transfections had a viability rate of about 90% and live cell 
counts of 6.5 x105, although the final transfection was only done on cells with a 72% 
viability that contained 2.0 x105 live cells. According to the manufacturer, the optimum 
transfection ratio for using the X-tremeGENE HP DNA transfection reagent is 3 μl 
transfection reagent to 1 ng DNA. Different plasmid concentrations in combination with 
different ratios were tested using the pCI-neo plasmid, but no distinct difference could be 
observed during SDS-PAGE and western blot analysis. A final plasmid concentration of 
0.01 μg/μl with a plasmid to transfection reagent ratio of 3:1, as suggested by the 
manufacturer, was therefore used for all plasmids and subsequent transfections.   
After COS-1 cells were transfected with the respective plasmids the cells were harvested 
successfully from the wells using both RTB and RIPA buffer. Harvesting with RTB, 
however, resulted in a very viscous solution that was probably due to the release of 
genomic DNA (gDNA) during lysis. This caused difficulty in pipetting the sample into the 
well of the SDS-PAGE gel. Although RIPA buffer also results in the release of gDNA, the 
gDNA forms a pellet in the solution and thereby reduces the viscosity of the lysis solution. 
 Analysis of gene transcription 
After harvesting the cell samples from the plate, the newly transcribed mRNA was 
isolated from the cell solution using both the Trizol® reagent and a Nucleospin RNA midi 
kit. A Nanodrop reading for Trizol® isolated RNA revealed concentrations for the 
transcription product (total RNA) of pCI-neo_oppA, VR1012_oppA and VR1020_oppA to 
Figure 4.2 A 1% agarose gel electrophoresis image of the enzyme digestion of the respective 
plasmids. (A) Lane L: GeneRulerTM (Fermentas). Lane 1: Undigested supercoiled VR1020_oppA. 
Lane 2: VR1020_oppA digested with BamH1. (B) Lane L: Fermentas gene ruler ladder. Lane 1: 
Undigested supercoiled pCI-neo_oppA Lane 2: pCI-neo_oppA digested with Acc1. (C) Lane L: 
Fermentas gene ruler ladder. Lane 1: Undigested supercoiled VR1012_oppA. Lane 2: 









be 57.2 ng/μl, 49.2 ng/μl and 47.7 ng/μl respectively. RNA isolation from 60 μl VR1020 
using the RNA-Isolation Nucleospin RNA midi kit, yielded 42.3 ng/μl, which was 
comparable to that of Trizol®. 
The oppA gene expression results as detected by RT-PCR are shown in Figure 4.3. From 
the figure a band at approximately 531 bp could be identified for all the samples of the 
cell cultures that were transfected with oppA gene containing plasmids (lane 1-3). The 
RT-PCR product was already visible at 24 h and continued up to 72 h after   transfection 
with a slight increase in band intensity over time. The samples that were transfected with 
plasmid without the oppA insert as well as un transfected samples did not contain any 







Figure 4.3 An 1% agarose gel electrophoresis image displaying the RT-PCR results of the three 
different plasmids pCI-neo_oppA, VR1012_oppA and VR1020_oppA at three different time points 
24 h, 48 h and 72 h. Lane L: GeneRulerTM (Fermentas). Lane 1: pCI-neo with the oppA insert. 
Lane 2: VR1012 with oppA insert. Lane 3: VR1020 with oppA insert. Lane 4: pCI-neo without 
oppA insert. Lane 5: VR1012 without oppA insert. Lane 6: VR1020 without oppA insert. Lane 7-
8: un-transfected COS-1 cells. 
 
 Analysis of protein translation  
SDS-PAGE analysis was performed to determine if the OppA protein was expressed after 
transfection with each of the different oppA gene containing plasmids. From Figure 4.4 
(A) it can be seen that the 12-well cell samples, lysed with RTB, contained a large amount 
of other cell proteins making it difficult to identify the 100 kDa OppA protein as being 
present in the transfected samples, but not the untransfected samples. The positive 
control contained the OppA-GST protein expressed by the prokaryotic pGEX-4T (Chapter 
3), which resulted in a fusion protein, of 126 kDa. The GST dissociates during storage 
causing visible bands at 126 kDa (OppA + GST), 100 kDa (OppA without tag) and 26 
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kDa (dissociated tag). Results were not influenced by performing the analysis directly 
after lysis or only after storage at -20°C. 
When RIPA buffer was used for lysis of 12-well samples transfected with the 
VR1020_oppA, cell proteins were also observed upon SDS-PAGE analysis with no 
distinct band at 100 kDa for the transfected samples. Results did not improve upon 
analysis directly after lysis. The SDS-PAGE gels from cells harvested with RIPA resulted 
in a smear on the gel (results not shown). This could be due to protein degradation 
despite the addition of a protease inhibitor.  
Six-well culture plates were subsequently used for transfection of all of the plasmids as 
this would result in more cells being transfected thereby increasing the concentration of 
expressed protein and possible detection by SDS-PAGE. RTB and RIPA buffers were 
used for these samples. Due to the increased transfected cell volume and therefore 
increased viscosity the RIPA buffer used for lysis was easier to pipette during 
downstream analysis. The increased transfected cell volume (6-well) had no noticeable 
effect on the concentration of expressed OppA protein during SDS-PAGE analysis as a 
band was still not visible at the appropriate size.   
However, after combining and concentrating the content of a 6-well plate (lysed with 
RIPA) a band was identified at the appropriate size of 100 kDa in the VR1020_oppA 
transfected sample after 48 h which was absent in the untransfected sample (Figure 4.4 
B, lane 3, indicated by arrow). The same band could also be seen when transfecting cells 
for 72 h. Since the 48 h and 72 h samples were analysed on a single gel, the 48 h sample 
was stored at -20°C for 24 h before analysis, but the 72 h sample analysed directly after 
lysis. This result, however, proved difficult to reproduce even when using the same 
sample, indicating that the protein was degraded when stored at -20°C, despite the use 
of RIPA buffer and the addition of a protease inhibitor. In an attempt to repeat protein 
expression, longer transfection times were used up to 96 h, but did not results in any 
positive band for the cells transfected with plasmid that was absent in un transfected 
cells. Analysis was repeated using RTB for lysis, but no positive band was identified for 
the cells transfected with plasmid that was absent in un transfected cells. The reason for 
this was probably due to the fact that the COS-1 cells used for transfection only had a 
confluency of 72 % compared to the previous attempt using RIPA buffer where the 
confluency was calculated as 94 %. The lower viability was a result of the slower growth 
rate of the COS-1 cells during the different passage steps in preparation for transfection.  





Figure 4.4 An image of two SDS-PAGE gels of harvested COS-1 cells transfected with the 
VR1020_oppA DNA vaccine.  
Gel A represents COS-1 cells from 12-well plates lysed with reducing treatment buffer. Lane L: 
PagerulerTM unstained protein ladder (Thermo Scientific). Lane +: positive control, expressed 
OppA-GST protein (126 kDa). Lane 1-3: transfected 48 h. Lane 4: untransfected 48 h. Lane 5-8: 
transfected 72 h.  
Gel B represents COS-1 cells from 6-well plates of which the content of three wells were 
combined and lysed using RIPA. Lane 1: transfected 72 h. Lane 2: untransfected 48 h. lane 3: 
transfected 48 h indicating 100 kDa band (arrow). Lane +: positive control, expressed OppA-GST 
protein (126 kDa). Lane L: Pageruler unstained protein ladder. 
 
To confirm the presence of OppA, the proteins on the SDS gel (Figure 4.4 B) were 
transferred to a nitrocellulose membrane for western blot analysis using the rabbit anti-
OppA-GST antibody and a colorimetric detection method. The results of samples 
harvested from 12-well plates using RTB are shown in Figure 4.5. Two bands were visible 
for the positive control at 126 and 100 kDa. No bands were visible on the membrane at 
the appropriate size for either transfected or un transfected samples. The colorimetric 
western blot was therefore unsuccessful.  





Figure 4.5 The image of a 0.45 μm nitrocellulose membrane displaying the results from a western 
blot analysis using a colorimetric detection method. Samples were from transfected cells in 12-
well plates harvested using RTB and separated on an 8% SDS-PAGE gel. Lane L: Full range 
rainbow marker (Amersham). Lane +: expressed OppA-GST positive control (OppA + GST at 126 
kDa as well as OppA at 100 kDa can be seen). Lane 1-8: different concentrations of pCI-
neo_oppA plasmid used to transfect COS-1 cells after 24 h, 48 h and 72 h.  
 
The western blot was repeated using chemiluminescence as detection method. Figure 
4.6 shows the X-ray film exposed at 30 sec and 1 min to the light emitting membrane. 
Lane 2 (pCI-neo_oppA), 3 (VR1020_oppA) and 5 (VR1012_oppA) where all lysed with 
RTB from a 12-well plate. The positive control reveals a band at approximately 100 kDa. 
A band was visible at 100 kDa across all the samples, but this band was more intense 
for VR1020_oppA than the others. A 100 kDa band was not visible in the un transfected 
samples after 48 h (lane 1), indicating that the darker, more intense band produced by 
VR1020_oppA (lane 3) represents the expressed OppA protein. Results could not be 
reproduced with success using a larger culture volume (6-well plates), analysing results 
directly after lysis, longer incubation periods, RIPA buffer or additional attempts to 









Figure 4.6 The X-ray film image of a western blot using chemiluminescence as detection method. 
COS-1 cells were transfected with either pCI-neo_oppA, VR1012_oppA or VR1020_oppA. 
Samples were harvested from a 12-well plate, using RTB and separated on an 8% SDS-PAGE 
gel and transferred to a 0.45 μm nitrocellulose membrane which was illuminated onto Fujifilm X-
ray film for 30 sec (A) and 1 min (B). Lane +: positive control, expressed OppA protein without 
attached GST (100 kDa). Lane 1: untransfected COS-1 cells after 48h. Lane 2: pCI-neo_oppA 
after 24h, Lane 3: VR1020_oppA after 48h. Lane 4: medium sample taken from VR1020_oppA 
cells after 48h. Lane 5: VR1012_oppA after 24h. 
 
 Discussion 
During this study the three DNA vaccines pCI-neo_oppA, VR1012_oppA and 
VR1020_oppA were used to transfect a COS-1 mammalian cell line in order to determine 
transcription and subsequent translation of the OppA protein in vitro. The topology of the 
plasmid DNA (pDNA) is found to be critical in gene expression in mammalian cells and 
thus influences the transfection efficiency (Maucksch et al., 2009). Supercoiled DNA has 
shown to have up to 100 fold higher transfection rates when compared to other pDNA 
topologies such as linearized or open circular pDNA (Weintraub et al., 1986; Maucksch 
et al., 2009). The plasmids used in this study were shown to be predominantly 
supercoiled, which increased the chance of plasmids entering the COS-1 cells during 
transfection. 
Transcription of the oppA gene after transfection was determined using RT-PCR analysis. 
RNA was isolated from transfected and control cells using both a RNA isolation kit from 
Macherey-Nagel and the Trizol® reagent from Sigma. Both RNA isolation methods were 
successful in isolating RNA, but the Trizol® method proved to be more efficient compared 
to the RNA isolation kit, due to the fact that it was more cost effective. RT-PCR showed 
that transfection with all three DNA vaccine vectors leads to expression of the oppA gene 
at 24 h after transfection which increases slightly by 72 h after transfection. All three 




plasmids were therefore entering the cells and the oppA gene was being transcribed into 
mRNA.  
Translation of the oppA mRNA into the OppA protein could not be confirmed by SDS-
PAGE analysis when using cells harvested from 12-well plates and lysed with RTB or 
RIPA. Results could not be improved by using a larger number of cells. This indicated 
that the concentration of translated protein was not sufficient for detection during SDS-
PAGE analysis. Expressed protein could however, be detected when combining and 
concentrating the content of 6-well plates lysed with RIPA buffer. Analysis of these 
samples after storage for longer than 24 h at -20°C indicated that the OppA protein was 
being degraded despite the use of RIPA buffer for lysis and the addition of a protease 
inhibitor. RIPA buffer is known for its stability and reduces non-specific protein-binding. 
Only VR1020_oppA was however analysed using this method, due to the fact that this 
plasmid produced the most promising results after western blot analysis. 
Western blot analysis using a colorimetric method of detection was unable to detect 
expressed protein. From this it could be concluded that the protein, if being translated, 
was expressed at a too low concentration to be detected or that the method was not 
sensitive enough. Chemiluminescence was subsequently used as a more sensitive 
detection method for western blot analysis as it provides greater sensitivity as well as 
convenience for the detection of proteins on a film (Alegria-Schaffer et al., 2009). When 
a 12-well plate, lysed with RTB was used for western blot analysis with 
chemiluminescence, a band was identified in the VR1020_oppA transfected cells that 
appeared to be more intense when compared to that of pCI-neo_oppA and 
VR1012_oppA transfected cells. Although pCI-neo was after 24 h, this was due to 
insufficient sample, the 24 h time point was included to provide a relative comparison to 
the others. This was after the sample had been stored at -20°C for about 1 month 
indicating that the RTB was probably a better alternative for storage of samples at -20°C 
compared to RIPA buffer. This might be due to the fact that RTB contains β-
mercaptoethanol that can act as a biological antioxidant. No results were obtained using 
samples from a 6-well plate or by combining and concentrating the content of a 6 well 
plate. The latter was probably due to the use of COS-1 cells with viability below 90% for 
transfection. This highlights the importance of cell viability in the outcome of transfection 
results. 




There are many contributing factors that influence expression levels of plasmids such as 
the promoter, presence of enhancing elements, presence of introns and polyadenylation 
sites. All of the plasmids used in this study, contain a polyadenylation signal that 
increases mRNA stability with that of VR1012 and VR1020 being from bovine growth 
hormone (BGH) and that of pCI-neo containing a SV40 late polyadenylation signal. A 
study by Pfarr et al. (1986) revealed that the use of a BGH poly(A) region produced three 
times higher protein expression when compared to the SV40 late polyadenylation region. 
Although the study was performed using R1610 hamster mammalian cells, this might 
also apply to COS-1 cells, resulting in a protein product being detected when the 
VR1020_oppA was used for transfection and not when the pCI-neo_oppA was used.  
Despite having the BGH polyadenylation signal, a protein product was not detected when 
VR1012_oppA was used for transfection. As with the other plasmids VR1012 also 
contains a strong CMV promoter, but the VR1012 promoter is optimised for the use in 
mice (Suarez et al., 2015). This can influence transcription levels and therefore 
translation of protein expressed by the VR1012 plasmid demonstrating the importance of 
all elements of the plasmid functioning together to increase expression of a gene. 
Although the production of oppA mRNA was shown, it is possible that the mRNA is not 
translated into protein at levels high enough for detection using SDS-PAGE and western 
blot analysis (Struhl, 1999; Elbashir et al., 2001). A band representing the OppA protein 
was, however, visible in the VR1020_oppA transfected cells on SDS-PAGE and upon 
western blot analysis using chemiluminescence as detection method.  
All of the COS-1 cell cultures transfected with the oppA containing DNA vaccine plasmids 
showed transcription of the oppA gene, but translation could possibly only be indicated 
in COS-1 cell cultures transfected with the VR1020_oppA DNA vaccine plasmid. This 
therefore indicates that the VR1020_oppA DNA vaccine plasmid might have the potential 
of acting as a DNA vaccine and the ability of this vaccine to elicit an immune response 
was next evaluated in a field trial in ostriches.  
  




 Vaccination trial 
 Introduction 
DNA vaccines were used in preliminary vaccination trials in ostriches in which the Ms03 
oppA gene cloned into the VR1012, VR1020 and pCI-neo plasmids were used to 
determine their ability to elicit an anti-OppA immune response in ostriches (Wium, 2015). 
This resulted in an immune response against Ms03 VR1020_oppA and Ms03 pCI-
neo_oppA but no response was observed after vaccination with the Ms03 VR1012_oppA 
plasmid. In this study the cell culture analysis indicated that the Ms01 pCI-neo_oppA and 
Ms01 VR1012_oppA did not lead to protein expression but the Ms01 VR1020_oppA did 
lead to OppA protein production. It was therefore concluded that the Ms01 VR1020_oppA 
warrants further consideration as a DNA vaccine in ostriches. However, it was decided 
to include the Ms01 pCI-neo_oppA vaccine in this trial because of the plasmid differences 
between Ms01 pCI-neo_oppA and Ms03 pCI-neo_oppA. 
For administration, DNA vaccines are routinely dissolved in a saline solution and 
administered at specific plasmid doses. According to Dunham (2002) mice can receive 
an intramuscular (i.m.) DNA vaccine dose in the range of 10-100 μg, small animals 100-
300 μg and large animals 500-2500 μg. The dose typically administered to birds ranges 
from 0.5-1500 μg when injected i.m. (Kodihalli et al., 1997) and they also typically receive 
a boosting dose after about 2-3 weeks (Vanrompay et al., 1999; Fang Yan et al., 2013; 
Chen et al., 2013). In previous trials vaccination with the Ms01 VR1020_oppA, Ms01 pCI-
neo_oppA and Ms01 VR1012_oppA plasmids, a single dose (100 μg/ml) was used for 
vaccination, but these trials were jeopardised by avian influenza outbreaks and the birds 
were exposed to stress due to weekly sampling (Brandt, 2012, van Tonder, 2013).  
The objectives for this part of the study were therefore to determine the ability of different 
doses of the Ms01 oppA containing DNA vaccines (pCI-neo and VR1020), in combination 
with a booster immunisation, to elicit an anti-OppA immune response in ostriches. As the 
detection and quantification of the ostrich cellular immune response elicited by these 
vaccines is technically complex, only the humoral immune response was evaluated by 
measuring antibody production. 
The two DNA vaccines were firstly produced in different amounts for vaccination 
purposes. In order to determine if the isolated plasmids were in the supercoiled 
configuration the plasmids were digested with restriction enzymes and analysed by gel 
electrophoresis. These plasmids were injected into the ostriches at three different doses 




followed by a booster vaccination. To assess mycoplasma infections of the ostriches 
during the trial, trachea swab samples were taken for PCR analysis. In order to determine 
the anti-OppA antibody immune response elicited by the ostriches, blood samples were 
taken during each sampling and analysed using ELISA.  
 Materials and methods 
 Ethical clearance and approval for vaccine trial 
Before the start of the trial, ethical clearance was obtained from the Stellenbosch 
University Animal Ethics Committee (SU-ACUM13-00019). Approval was also obtained 
from the Department of Agriculture, Forestry & Fisheries (DAFF), through the submission 
of a section 20 application (Reference: 12/11/1/1/3). This included permission from the 
National Executive Officer in terms of the Meat Safety Act, 2000 (Act No 40 of 2000) and 
its regulations to allow the animals to enter the human food chain after slaughter.  
 Preparation of DNA vaccines 
The oppA gene of which ten mycoplasmal TGA codons had been modified to the 
universal TGG codon, was previously sub-cloned into the pCI-neo (Promega, USA) and 
VR1020 (Vical Inc., USA) DNA vaccine plasmids by Pretorius (2009).  
Escherichia coli (E. coli) cultures containing the different plasmids were used to prepare 
overnight cultures by inoculating a 14 ml Falcon® tube containing 5 ml LB-medium and 1 
μl/ml ampicillin (100 μg/ml) for pCI-neo_oppA or 4 μl/ml kanamycin (100 μg/ml) for 
VR1020_oppA, with 10 μl of freezer culture and incubating them for 16 h at 37°C on an 
orbital shaker (150 rpm). A starter culture was prepared for both plasmids in a 50 ml 
Erlenmeyer flask containing 10 ml LB medium and 10 μl of ampicillin (100 μg/ml) for pCI-
neo_oppA or 40 μl of kanamycin (100 μg/ml) for VR1020_oppA and was inoculated with 
1 ml of the respective plasmid overnight cultures. Cultures were left to incubate at 37°C 
while shaking at 200 rpm until an OD600 of 0.6 was reached after 8 h. The respective 
starter culture mixtures were next added to a 1 L Erlenmeyer flask containing 200 ml LB-
medium and 1 μl/ml ampicillin (pCI-neo_oppA) or 4 μl/ml kanamycin (VR1020_oppA) and 
left to incubate for 16 h at 37°C while shaking at 200 rpm. Subsequent to that the plasmids 
were purified with an Endotoxin-free plasmid DNA purification kit (NucleoBond® Xtra Maxi 
plus EF, Macherey-Nagel, Germany). Yields were determined using a Nanodrop® ND 
1000 spectrophotometer (Novell®, USA) and the integrity of the plasmids confirmed by 
electrophoresis using a 1% agarose gel containing 0.5 μg/ml EtBr for visualisation of PCR 
products under UV-light. 




To ensure that the plasmid to be used for vaccination was supercoiled, each plasmid was 
digested with restriction enzymes. The pCI-neo_oppA plasmid was digested with Acc1 
(Promega, USA) and VR1020_oppA with BamH1 Fast-digest (Fermentas, USA) as 
described in section 4.2.1. All the enzyme digested products were electrophoresed on a 
1% (w/v) agarose gel containing 0.5 μg/ml ethidium bromide (EtBr) for visualisation under 
UV-light. 
The day before vaccination, the two DNA vaccines were diluted to three final 
concentrations of 100 μg/ml, 300 μg/ml and 600 μg/ml in sterile PBS buffer (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.2) and stored at 4°C until 
use. Dilutions were made under sterile conditions in 100 ml serum bottles after which 
they were sealed using 20 mm silicone rubber stoppers (Sigma Aldrich, USA) covered by 
a 20 mm Aluminium crimp seal with a tear away centre cap (Sigma Aldrich, USA). 
 Trial animals 
The vaccination trial was conducted in Fraserburg (Northern Cape Province) and 
Oudtshoorn (Western Cape Province) using 3-4 month old ostriches housed on 
commercial ostrich farms. The ostrich chicks were raised in Fraserburg until they reached 
40 kg (at week 4 of the trial), after which they were transported to Oudtshoorn. This is 
standard practice in ostrich production in order to limit exposure of ostrich chicks to 
pathogens. In Fraserburg, the trial ostriches were kept under intensive farming conditions 
as a separate group and as part of standard farming practice, each received a coloured 
tag for identification. Each tag contained a number that was unique for each ostrich. 
Upon arrival in Oudtshoorn, all ostriches including trial birds were first kept in quarantine 
for 29 days. The quarantine birds were then tested for avian influenza. This is currently 
standard practise to ensure that avian influenza is not introduced into the rest of the farm. 
In Oudtshoorn, the trial ostriches were kept under semi-intensive farming conditions and 
were therefore grouped with other ostriches not forming part of this trial. They were 
however, grouped with ostriches of the same age and weight that arrived from Fraserburg 
at the same time and from the same production farm in Fraserburg. 
The ostriches used in the trial were at all times kept under standard farming conditions in 
open air camps and were not caged. They received regular nutrition as usually given on 
the farm for production purposes and had access to water at all times. Trial ostriches 
were at all times only handled by farm personnel that were trained and had experience 




in the handling of ostriches. Ostriches were weighed at week 4, 7 and 10 during the trial 
to monitor weight gain. 
 Vaccination trial 
The trial consisted of 140 ostriches. Group one (60 ostriches) was vaccinated with pCI-
neo_oppA, group two (60 ostriches) with VR1020_oppA and group three (20 ostriches) 
acted as control and did not receive any vaccine. Each of the vaccinated groups was 
further subdivided into three groups (20 ostriches per group) with each group receiving a 
different vaccine dose. The dose per group is outlined in Table 5.1.  
The DNA vaccines were injected i.m. into the upper thigh of the ostriches at week 0 and 
7 using a single dose (1 ml) with one of the three different plasmid concentrations i.e. 100 
μg/ml, 300 μg/ml or 600 μg/ml. Blood (3 ml) was drawn from the jugular vein using 
Vacuette® Z serum sep clot activator tubes with 18G x 1” needles (Vacuette, UK) at week 
0 and 4 in Fraserburg and week 7 and 10 in Oudtshoorn. Serum was separated by low 
speed centrifugation for 10 min before the serum was transferred to 1.5 ml Eppendorf 
tubes for storage at -20°C. 
 
Table 5.1 Vaccine trial groups and dose administered 









Control No vaccination - 20 
Total   140 
* All vaccination were done using a total volume of 1 ml. 
 
 Analysis of trachea swabs by PCR 
When blood samples were taken at week 0, 4, 7, 10 and 18 of the trial, ostriches were 
tested for the presence of existing mycoplasma infections by means of trachea swabs. 




At week 18 only 66 ostriches were sampled as the rest had already reached their 
slaughter weight of 90 kg and were slaughtered before the week 18 sampling point.  
Trachea swabs were taken using dry, sterile transport swabs with a plastic applicator and 
inert, non-toxic cotton tip (Copan, ITA). Each swab was contained in a sterile 
polypropylene tube for transport purposes. Before PCR analysis each swab was rinsed 
in an Eppendorf tube containing 200 μl sterile PBS buffer.  
Samples were first tested by PCR using a generic primer pair specific for the genus 
Mycoplasma (Table 5.2). Samples that tested positive were further analysed using 
species-specific primer pairs targeting the 16S rRNA gene for each of the ostrich-infecting 
mycoplasmas, i.e. M. struthionis sp. nov. str. Ms01, Mycoplasma sp. Ms02 and M. 
nasistruthionis sp. nov. str. Ms03 (Botes et al., 2005). The sequences of the different 
primer pairs used are shown in Table 5.2. Each PCR contained 2 μl of a 10x reaction 
buffer, 2.4 μl of a 25 mM MgCl2, 0.4 μl of each primer (20 pmol/μl), 0.8 μl of a 5 mM dNTP 
mix (Kapa Biosystems, RSA), 0.05 μl of a 5 U/μl Supertherm Taq DNA polymerase (JMR 
Holdings, USA), 9.95 μl Millli-Q water and 4 μl of the PBS trachea swab sample. The 
thermal cycler (Veriti Applied Biosystems) was programed for 30 cycles of 94°C (30 sec), 
55°C (15 sec) and 68°C (1 min) followed by a single cycle of 6 min at 68°C. The same 
PCR and cycler conditions were used for all primer sets. PCR products were separated 

















Table 5.2 Primer pairs for the identification of ostrich-infecting mycoplasmas 





*GPO3F  (F) TGGGGAGCAAACAGGATTAGATACC 
272 
*MGSO   (R) TGCACCATCTGTCACTCTGTTAACCTC 
 Ms01 
Ms01Z   (F) AACATTAGTTAATGCCGGATACG 
499 
Ms01D   (R) GCCAGTATCCAAAGCGAGCC 
Ms02 
Ms02H   (F) AATATAAAAGGAGCGTTTGC 
287 
Ms02A   (R) AAGGCAATAGCATTTCCTCTACT 
Ms03 
Ms03A   (F) AGTGCTAATGCCGGATACTTATA 
521 
Ms03C   (R) CGTTAACCTCTATACAATTCTAGCG 
(F) Forward Primer; (R) Reverse Primer. 
*Obtained from Botes et al. (2005). 
 
 Weight measurements during trial 
The weight of each ostrich was measured at week 4, 7 and 10. This was to assess the 
well-being of the ostriches as well as the effect of vaccination on the ostriches, if any. 
Weight measurement also allowed dose vs weight relationships to be determined. No 
scale was available for weighing at week 0. 
 Biotinylation of rabbit anti-ostrich antibodies 
For subsequent ELISA purposes, rabbit anti-ostrich antibodies were first biotinylated. 
Anti-ostrich immunoglobulin (Ig) antibodies were previously developed in rabbits and 
provided by Dr. A. Botes, Department of Biochemistry, Stellenbosch University. For 
isolation of the rabbit anti-ostrich Ig antibodies, 0.5 ml immunised rabbit serum was 
diluted in 1 ml PBS (pH 7.2) before 1.5 ml saturated ammonium sulfate was added and 
incubated for 20 min at 4°C for precipitation to occur. The precipitate was thereafter 
centrifuged at 15 000 x g for 20 min using a Beckman Coulter Avanti J-E centrifuge. The 
pellet was dissolved in 1 ml PBS (pH 7.2) and 1.5 ml saturated ammonium sulfate again 
added followed by incubation (20 min, 4°C) and centrifugation (15 000 x g, 20 min). The 
pellet was dissolved in 0.5 ml PBS (pH 7.2) and dialysed overnight at 4°C against 1800 
ml carbonate buffer (0.1 M NaHCO3, pH 8.3). The buffer was changed once after 6 h. 
The concentration of the antibodies in the dialysate was measured at 280 nm using a 




Nanodrop® ND 1000 spectrophotometer (Novell®, USA) and diluted to 5 μg/ml of Ig in 
carbonate buffer (0.1 M NaHCO3, pH 8.3). 
Biotinylated anti-ostrich antibodies were required for use as secondary antibody in the 
ELISA to determine the immune response elicited by each of the DNA vaccines. The 
biotinylation of 3 ml diluted (5 μg/ml) Ig was performed by slowly adding 1 ml of 
biotinylation reagent (2 mg/ml, biotinamidocaproate N-hydroxysuccinimide ester in N,N 
dimethylformamide) and incubating for 2 h at room temperature while stirring. This was 
followed by dialysis against PBS (pH 7.2) overnight at 4°C with a single buffer change. 
An equal volume of glycerol was subsequently added to the biotinylated antibodies, 
mixed and stored at -20°C for no longer than 10 months. 
 Optimization of ELISA for analysis of anti-OppA immune response 
Boinformatic analysis using ProtParam (http://web.expasy.org/cgi-
bin/protparam/protparam) was done on the OppA protein to reveal the hydrophobicity 
index of the protein. Based on this, two different Nunc, 96-well microtitre plates were used 
during optimization of the ELISA, namely Maxisorp and Medisorp (Nunc, Denmark). Both 
plates’ surfaces are made from polystyrene, with Maxisorp having a high affinity for polar 
groups and Medisorp binding molecules of an intermediate hydrophobic/hydrophilic 
nature. 
The OppA-GST protein was purified as described in section 3.2.2. The purified OppA-
GST protein was diluted with carbonate buffer (50 mM NaHCO3, pH 9.6), and used for 
coating columns of microtitre plates at 3 different concentrations i.e. 1 μg/ml, 5 μg/ml and 
10 μg/ml protein respectively. Rows A and B received 1 μg/ml protein in each well, C and 
D 5.0 μg/ml in each well, and E and F 10.0 μg/ml protein in each well. The protein was 
left to incubate for 18 h at 4°C. The OppA solution was removed and 300 μl/well casein 
buffer (154 mM NaCl, 10 mM Tris-HCl, 0.02% Thiomersal and 0.5% casein, pH 7.6) was 
added to all the wells and left to incubate at 37°C for 1 h to block non-specific binding. 
Afterwards all the wells were washed 5-10 times with PBS-Tween (PBS buffer (pH 7.2) 
containing 0.1% (v/v) Tween® 20). To further reduce background finding, the PBS-Tween 
wash was combined with a 3 times distilled water (dH2O) wash. Week 0 and 
corresponding week 3 sera drawn from the VR1020_oppA 600 μg/ml immunised 
ostriches were diluted 1:20 with casein-Tween (casein buffer containing 0.1% (v/v) 
Tween® 20) and subsequently used as primary antibody. A dilution series of the sera was 
made starting at 1:20 (100 μl/well) in column 2 up to  1:40 960 in column 12. The antibody 




was left to incubate for 1 h at 37°C before it was washed 5-10 times with PBS-Tween and 
3 times with distilled water. The secondary antibody (biotinylated rabbit anti-ostrich Ig) 
was diluted 1:100 in casein-Tween and 100 μl/well added followed by incubation for 1 h 
at 37°C. The plate was subsequently washed 10 times with PBS-Tween and 3 times with 
distilled water. Thereafter 100 μl/well of HRP-conjugate (Invitrogen) (2 ml streptavidin 
HRP, 3 ml 0.5% casein buffer, 40 ml glycerol) was added and left to incubate for 1 h, 
37°C and washed 10 times with PBS-Tween and 3 times with distilled water. Finally 100 
μl/well ABTS substrate solution, 0.015% H2O2 in 0.1 M citrate buffer, pH 5) was added to 
each well. Absorbance was measured at 405 nm after 30 minutes of incubation at 37°C 
on a Titertek Multicsan spectrophotometer (Labsystems, Finland).  
 ELISA analysis of vaccination trial 
After determining the optimal coating concentration as 10 μg/ml on Maxisorp (Nunc, 
Denmark) plates, the ELISA was used to determine the antibody levels in sera of the 
vaccinated ostriches. Thereafter, Maxisorp (Nunc, Denmark) 96-well plates, coated with 
10.0 μg/ml/well purified OppA-GST protein, were used for all analysis. Week 0 and 
corresponding week 4, 7 and 10 sera drawn from immunised ostriches were diluted 1:100 
with casein-Tween and tested in triplicate. The procedure followed was described in 
5.2.8.  
There were two instances in which blood and swab samples could not be collected from 
all ostriches. Firstly, due to the loss of tags from some ostriches during the course of the 
trial and secondly ostriches not reaching 40 kg at week 4 of the vaccination trial causing 
them not to be transported to Oudtshoorn with the rest of the trial ostriches. Only sera of 
ostriches from which all 4 blood samples (week 0, 4, 7 and 10) could be collected were 
used for ELISA analysis. All trial results are given in Addendum A. 
 Statistical analysis of the ELISA results 
The ELISA results and weight data obtained during the vaccination trial were used for an 
analysis of variance (ANOVA) using the General Linear Modal (GLM) procedure using 
the Agrobase Generation II® (Agronomix Software Inc.) software and the least significant 
difference (LSD) value was calculated. A significance level of P < 0.05 was chosen for 
analysis. Analyses were only performed on data for ostriches for which blood samples 
could be obtained throughout the trial period. The input data is given in Addendum A. 





 Preparation of DNA vaccines  
The two DNA-vaccines were successfully isolated and a total of 46954.83 μg 
pCI-neo_oppA was obtained from 13 plasmid isolations and 51396.30 μg VR1020_oppA 
from 9 plasmid isolations. From Figure 5.1 it can be seen that the majority of the plasmids 
were in the supercoiled configuration after isolation with a low level of plasmid in the 
nicked configuration. There is also some nicked plasmid seen. The configuration was 
further confirmed by enzyme digestion of each vaccine vector (Figure 5.2). On the gel 
image shown in Figure 5.2 (lane 1) undigested supercoiled VR1020_oppA appears at 
approximately 5000 bp, compared to lane 2 where the plasmid was digested with BamH1. 
Digestion resulted in two bands, one corresponding to the linear VR1020 plasmid (5044 
bp) and the other to the oppA insert (2829 bp). Similarly undigested supercoiled pCI-
neo_oppA (lane 3) produced a band size of about 5000 bp. When pCI-neo_oppA was 
digested with Acc1 it resulted in one linear band at 8300 bp, representing the 5472 bp of 
the pCI-neo plasmid and the 2829 bp of the oppA insert (linear DNA). The digestion was, 




Figure 5.1 A 1% agarose gel electrophoresis image of the two DNA vaccines pCI-neo_oppA (A) 
and VR1020_oppA (B) isolated using a Endotoxin-free plasmid DNA purification kit. Lane L: 
GeneRulerTM (Fermentas). Lane 1-5 (A): Isolated pCI-neo_oppA plasmid diluted 1:100 in Milli-Q 
H2O. Lane 1-7 (B): Isolated VR1020_oppA plasmid diluted 1:100. 
 








 Analysis of trachea swabs by PCR 
The different mycoplasma infections detected amongst the trial ostriches are shown in 
Table 5.3. Only the results from ostriches for which serum samples could be obtained 
throughout the trial are shown. The PCR test indicated the presence of ostrich-infecting 
mycoplasmas during the trial. Band sizes of 500, 290 and 520 indicated the presence of 
the positive controls Ms01, Ms02 and Ms03 in samples as indicated by Figure 5.3. Some 
of the bands are more intense than others and could be an indication of the level of 
mycoplasma infection present in the sample.  
During week 0-4, when the ostriches were kept in Fraserburg, less mycoplasma 
infections were detected when compared to week 7, 10 and 18, when they were kept in 
Oudtshoorn. At the week 7 sampling point, ostriches had already been in Oudtshoorn for 
about 21 days. Results indicated that Ms02 and Ms03 were the more dominant 
mycoplasma infections throughout the trial and were detected amongst ostriches in all 
trial groups. The highest number of infections (Ms02 and Ms03) detected was at week 
10. Overall at week 10, less Ms02 and Ms03 co-infections were detected in the 
VR1020_oppA vaccinated groups, compared to the pCI-neo_oppA vaccinated groups, 
but infections were much less for both groups, compared to the control group at week 10. 
On average 98.2% of birds tested at week 7 had no infections (Ms01, MS02 and Ms03) 
compared to only 23.2% at week 10 and 51.5% at week 18. All ostriches were however 
Figure 5.2 Enzyme digestions of the two DNA vaccine vectors. Lane L: GeneRulerTM 
(Fermentas). Lane 1: VR1020_oppA plasmid diluted 1:100. Lane 2: VR1020_oppA digested with 
BamH1. Lane 3: pCI-neo_oppA plasmid diluted 1:100. Lane 4: pCI-neo_oppA plasmid digested 
with Acc1. 




not tested at week 18 which could have caused the increase in the percentage of negative 
birds. 
An Ms01 infection was only detected once during week 10 in an ostrich from the pCI-
neo_oppA 300 μg/ml group. This ostrich was not tested again at week 18 as it had 
reached its slaughter weight before this date and was therefore already slaughtered.  
Amongst the mycoplasma positive ostriches that received the pCI-neo_oppA vaccine the 
Ms02 infections increased dramatically amongst the averages of the vaccinated groups 
from week 7 (5%) to week 10 (73.7%). This became less during week 18 (41.2%) but the 
fact that not all ostriches from the pCI-neo_oppA vaccinated groups were tested at week 
18 could have influenced the number of detected infections. The ostriches that received 
the VR1020_oppA vaccine had 5% Ms02 infections at week 7, which increased to 52% 
at week 10. Infections again decreased by week 18 to only 34,3%, but once again not all 
birds were tested, which could have influenced the number of infections detected. The 
control group had 25% Ms02 infections during week 0 that decreased to 5% at week 7 
before it increased to 84% at week 10. This became less in week 18 (55%). During week 
10 both the pCI-neo_oppA 600 μg/ml and VR1020_oppA 600 μg/ml groups had the 
lowest amount of Ms02 infections followed by the groups that received a dose of 100 
μg/ml and 300 μg/ml. Although not all the ostriches were tested at week 18, the pCI-
neo_oppA 100 μg/ml group had the least amount of infections followed by the 300 μg/ml 
and 600 μg/ml groups, while the VR1020_oppA 100 μg/ml and 600 μg/ml groups had the 
least amount of Ms02 infections followed by the 300 μg/ml. 
The pCI-neo_oppA vaccinated groups showed no Ms03 infections at week 7 but at week 
10, 47.3% of the ostriches tested positive for Ms03. Infections dropped slightly to 42.2% 
by week 18 but not all ostriches were tested. The VR1020_oppA vaccinated groups also 
had no Ms03 infections detected at week 7, but infections increased to 52% during week 
10. Infections again decreased to 20% at week 18, but again not all the birds were tested, 
which could have influenced the number of infections detected. The control group had 
only one ostrich positive for Ms03 during week one. This increased dramatically during 
week 10 to 84% before it decreased to 22% by week 18. During week 10 the pCI-
neo_oppA and VR1020_oppA 600 μg/ml groups had the lowest amount of Ms03 
infections followed by 100 μg/ml and then 300 μg/ml groups. During week 18 the pCI-
neo_oppA 100 μg/ml group had no Ms03 infections followed by the 600 μg/ml and 100 




μg/ml groups witch did have infections. While the VR1020_oppA 100 μg/ml and 600 μg/ml 


























Table 5.3 Results of PCR analysis of trachea swabs.  
 
Infections detected  
 
Ms01 Ms02 Ms03 
Experimental group in which 
individuals tested positive 
Week 0 - 5/20* (25%) 1/20 (5%) Control group 
Week 4 - -  -  
Week 7 
- 1/20 (5%) - pCI-neo_oppA 100 μg/ml 
- 1/20 (5%) - VR1020_oppA 100 μg/ml 
Week 10 
- 11/13 (84%) 11/13 (84%) Control group 
- 8/10 (80%) 5/10 (50%)  pCI-neo_oppA 100 μg/ml 
1/13 11/13 (85%) 8/13 (62%) pCI-neo_oppA 300 μg/ml 
- 9/15 (60%) 5/15 (33%) pCI-neo_oppA 600 μg/ml 
- 8/15 (53%) 7/15 (47%) VR1020_oppA 100 μg/ml 
- 11/17 (65%) 12/17 (71%) VR1020_oppA 300 μg/ml 
- 6/16 (38%) 6/16 (38%) VR1020_oppA 600 μg/ml 
Week 18 
- 5/9 (55%) 2/9 (22%) Control group 
- - - pCI-neo_oppA 100 μg/ml 
- 2/7 (29%) 3/7 (43%) pCI-neo_oppA 300 μg/ml 
- 5/10 (50%) 4/10 (40%) pCI-neo_oppA 600 μg/ml 
- 3/10 (30%) 1/10 (10%) VR1020_oppA 100 μg/ml 
- 6/15 (40%) 5/15 (33%) VR1020_oppA 300 μg/ml 
- 3/10 (30%) 1/10 (10%) VR1020_oppA 600 μg/ml 
*Number of ostriches that tested positive per total of birds tested in the relevant experimental group. 
Group sizes decreased over the duration of the trial.  
In week 0-4 the ostriches were housed in Fraserburg and from week 7 and onwards in Oudtshoorn. 





Figure 5.3 An image of the PCR products obtained when analysing the swab samples of the 
ostriches that were electrophoresed on a 1% agarose gel. Ten random samples were tested for 
Ms01, Ms02 and Ms03. Lane L: GeneRulerTM (Fermentas). The respective positive controls are 
indicated in Lane +. Lane 1-10: Ten randomly selected samples. 
 
 Ostrich weights during the trial 
The weight of the ostriches was measured at each sampling point except at week one 
and 18. The results of the average weight gained over time of the different experimental 
groups are shown in Table 5.4. There was a consistent increase in the average weight 
throughout the trial and the weight increase of vaccinated ostriches did not differ 
significantly from the control group as shown by an ANOVA analysis (see Addendum A). 
Vaccination thus had no effect on the growth of the ostriches nor did the transfer of the 
ostriches between Fraserburg and Oudtshoorn. There were 6 ostriches that did not reach 
40 kg at week 4, and were not transported to Oudtshoorn with the rest of the trial 
ostriches. These include one ostrich that received pCI-neo_oppA (100 μg/ml), one 
receiving pCI-neo_oppA (300 μg/ml), one receiving pCI-neo_oppA (600 μg/ml) and three 
ostriches that received VR1020_oppA (100 μg/ml). These birds were excluded from the 
rest of the trial.  
 




Table 5.4 The average weight of the ostriches in the different experimental groups as measured 
at the different sampling times during the vaccination trial. 
 
 Optimization of ELISA for analysis of anti-OppA immune response 
The OppA-GST protein was purified and based on Bradford analysis, the highest 
concentration that could be achieved was 0.837 mg/ml. To ensure that all ELISA analyses 
could be done from a single batch of isolated OppA-GST protein, the yield was increased 
by incubating the protein solution on the glutathione agarose column for three hours 
instead of one hour before washing and eluting the protein.  
According to a ProtParam analysis the OppA protein has a grand average hydrophobicity 
(GRAVY) score of -0.499, which indicates an overall hydrophilic structure (polar). An 
increasing positive score indicates greater hydrophobicity (Kyte et al., 1982). Despite this, 
no significant difference was observed in terms of antibody titre or ELISA background 
values between the Maxisorp and Medisorp microtitre plates. The Maxisorp microtitre 
plates were therefore chosen for further analysis as they are more commonly used 
according to the literature (Hopfe and Henrich, 2004; Medi et al., 2005; Kennedy et al., 
2006; Lassaux et al., 2013).  
ELISA optimization revealed that the biotinylated anti-ostrich antibody was successful in 
identifying the antibodies produced by the ostriches in response to vaccination. A 
graphical representation of the results for serial dilutions of the serum using different 
coating concentrations on Maxisorp microtitre plates is shown in Figure 5.4. From these 
results a final coating concentration of 10 μg/ml was chosen as it gave the greatest 
difference in absorbance values when week 0 sera were compared to week 3 sera. A 
final dilution of 1:100 (indicated with a vertical line on graph) was chosen as it gave a 
better resolution between week 0 sera and week 3 sera and was therefore the dilution 
factor that was used in previous field trials. The background was reduced from an average 












Week 0 No weight measurements taken. 
Week 4 60.1 57.7 55.3 53.1 49.5 57.0 56.4 
Week 7 65.5 63.5 61.3 59.4 56.5 61.5 61.6 
Week 10 73.3 69.6 68.7 68.7 65.6 69.6 69.5 




absorbance (A405) of 0.8 to 0.3 by incorporating a 10x PBS-Tween wash, followed by a 





















Figure 5.4 ELISA optimization for the three different protein coating concentrations. 
VR1020_oppA 600 μg/ml serum collected during week 0 and week 3 was used for optimization. 
Plates were coated with 1 μg/ml (A), 5 μg/ml (B) and 10 μg/ml (C) of purified OppA-GST protein. 
The 1:100 dilution factor is indicated on each graph with a vertical line. 
 
 ELISA analysis of vaccination trial 
From the graphical results of pCI-neo_oppA (Figure 5.5) it could be seen that the control 
group, which received no vaccine, revealed a slight decrease in average titre values up 
to week 4, followed by an increase from week 7-10, but on average the titre values were 
in the same range over the period of 10 weeks. The overall ELISA results indicated much 
higher titre values for the control group when compared to the pCI-neo_oppA vaccinated 
groups. The pCI-neo_oppA 100 μg/ml dose showed a slight increase in average titre 
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300 μg/ml and 600 μg/ml doses gave similar responses with an increase in average titre 
values towards week 7, followed by a decrease towards week 10. The average titre 
values did not increase after the booster injection at week 7. 
 
Figure 5.5 Immune response elicited by each of the different concentrations of the pCI-neo_oppA 
vaccine as determined by an ELISA using 10 μg/ml purified OppA-GST protein for coating. Three 
different ostriches groups were vaccinated with 1 ml of pCI-neo_oppA 100 μg/ml, pCI-neo_oppA 
300 μg/ml and pCI-neo_oppA 600 μg/ml, respectively during week 0 and a booster administered 
during week 7 indicated with arrows. The control group received no immunisations. Blood 
sampling was done during week 0, 4, 7 and 10. 
 
Compared to the titre values of the VR1020_oppA vaccination groups, the control group 
also had the highest average titre value at week 0 (Figure 5.6). The VR1020_oppA 100 
μg/ml vaccine dose resulted in a consistent increase in titre values from week 4 through 
to week 7. After receiving a booster injection at week 7 a further increase in average titre 
values was observed at week 10. However, these values did not differ significantly from 
the control group.  
In the 300 μg/ml dose group there was one ostrich sample that gave a high titre value 
(1.078) relative to the rest of the group at week 0, which increased the average titre from 
0.440 to 0.482. Despite this high value, the average of the 300 μg/ml dose group was still 
below the control group. After the first immunisation with VR1020_oppA 300 μg/ml there 
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week 10 there was a slight decrease in titre values compared to week 7 in spite of the 
booster injection being given at week 7.  
Vaccination with VR1020_oppA at 600 μg/ml resulted in a similar increase in average 
titre values after the first vaccination with the average titre reaching a maximum value at 
week 7. After administering a booster vaccination at week 7, there was a slight decrease 
in average titre values towards week 10.  
The ANOVA analysis of the VR1020_oppA vaccination results indicated no significant 
treatment x time interaction (P = 0.1074) for the data as a whole. The calculated LSD 
(0.1759) was subsequently used as basis for a pairwise comparison between the immune 
responses of each of the vaccinated groups and the control, in order to determine 
statistically significant differences. Only the VR1020_oppA 300 μg/ml and 600 μg/ml 
treatment groups differed significantly from the control and this applied for all time points, 
except week 0.  
 
Figure 5.6 Immune response elicited by each of the different concentrations of the VR1020_oppA 
vaccine as determined by an ELISA using 10 μg/ml purified OppA-GST protein for coating. Three 
different ostriches groups were vaccinated with 1 ml of VR1020_oppA 100 μg/ml, VR1020_oppA 
300 μg/ml and VR1020_oppA 600 μg/ml respectively during week 0 and a booster administered 
during week 7 indicated with arrows. The control group received no immunisations. Blood 
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Mycoplasma infections are a commonly encountered problem in the Oudtshoorn district. 
Day old ostrich chicks are raised in remote areas such as Fraserburg up to about 3 
months of age after which they are transported back to Oudtshoorn. In Fraserburg there 
are fewer ostrich diseases and neighbouring farms are far apart from one another, limiting 
the spread of infection. This could be seen from the PCR results where during their time 
in Fraserburg, only a few cases of mycoplasma infections were detected. When the 
Ostriches reached 40 kg they were moved back to Oudtshoorn where they were first kept 
in quarantine for 29 days before they were moved to a semi-intensive feeding system. 
Within a semi-intensive feeding system about 300 ostriches are kept in a 2-5 hectare 
environment. This is the feeding system preferred by farmers as the availability and cost 
of land are limiting factors in the Klein Karoo (Shanawany and Dingle, 1999; Wheeler et 
al., 2015). Within a camp there are 5-7 feeding bowls, which are washed out with 
Virkon®S disinfectant on a weekly basis in an attempt to limit bacterial infections (personal 
communication with farmer). Despite this, once they were introduced into these feeding 
systems the mycoplasma infections increased dramatically. This was probably due to the 
close proximity in which they housed aiding the spread of infection (Nicholas and Ayling, 
2003; Fox et al., 2005). Except for one of the ostriches there were none that tested 
positive for Ms01 during the course of the trial. The control group, however, also did not 
have any Ms01 infections and therefore it cannot be concluded that the lack of Ms01 
infections was due to the vaccination with the Ms01 VR1020_oppA vaccine. There are 
no cross reactions between the anti-Ms01 OppA antibodies and the Ms02 and Ms03 
OppA proteins (Chapter 3). This may explain the presence of Ms02 and Ms03 throughout 
the trial as the DNA vaccines developed against Ms01 would have no effect against Ms02 
and Ms03. To combat all of the mycoplasma infections encountered simultaneously one 
could develop a DNA vaccine containing a gene that will lead to the production of 
antibodies that shows higher cross reactivity between Ms01, Ms02 and Ms03.  
The ostriches were tagged on the neck with coloured tags that resulted in them pecking 
at each other’s tags due to the colour of the tags drawing their attention. Loss of tags in 
some birds resulted in birds being lost from the trial. In future DNA vaccine trials tagging 
the ostriches underneath their wings might prevent the loss of tags and subsequent loss 
of data. 
Two DNA vaccines, pCI-neo and VR1020, were previously developed that each contain 
the oppA gene of Ms01. It has been reported that DNA vaccines can lead to long-term 




protection of animals against pathogens when delivered at the appropriate concentration 
(Davis et al., 2001; Khan, et al., 2010). This led to the decision of administering the DNA 
vaccines at three different concentrations at week one followed by a booster at week 7. 
For an immune response to be elicited by these vaccines after i.m. injection, the plasmid 
has to be internalised into the muscle cells. To ensure internalisation, both plasmids were 
produced in the supercoiled configuration since supercoiled plasmid is the desired 
configuration for ensuring better internalisation of the plasmid (Maucksch et al., 2009; 
Norregaard et al., 2013).  
Once the DNA vaccine is internalised into the muscle cell, the plasmid uses the host’s 
cellular machinery in order to reach the nucleus, or to transfect local cells, where the 
antigen is expressed. This would trigger the B-cells of the immune system to produce 
antibodies against the expressed antigen (Oshop et al., 2002; Kutzler and Weiner, 2008; 
Faurez et al., 2010). If a first vaccination results in a primary immune response with 
memory cells being produced, the secondary immune response (after the booster 
vaccination) should increase to a greater extent compared to the primary immune 
response (Klinman et al., 1998; Njongmeta et al., 2012). 
Anti-OppA antibodies produced in response to the pCI-neo_oppA and VR1020_oppA 
plasmids were evaluated using an ELISA developed for this purpose. No significant 
average titre increases could be seen when the different dose groups vaccinated with 
pCI-neo_oppA when compared to the control group. Thus, it appears that the different 
pCI-neo_oppA doses in combination with a booster vaccination ultimately failed to induce 
an anti-OppA immune response. The inability of the vaccine to elicit an immune response 
could indicate that it was either not expressed or it was expressed at such low levels that 
it did not evoke an immune response. In the cell culture investigation in this study, the 
pCI-neo_oppA DNA vaccine also did not lead to OppA protein production, supporting this 
conclusion. 
Ostriches vaccinated with the VR1020_oppA vaccine were able to produce an anti-OppA 
immune response. The VR1020_oppA 100 μg/ml vaccine, on average, failed to induce 
an immune response of significant increased value when compared to the control group. 
Vaccination with VR1020_oppA at 300 μg/ml and 600 μg/ml resulted in a statistically 
significant immune response after the initial i.m. injection when compared to the control 
group. VR1020 contains a tPa-signal sequence upstream from the oppA gene, which 
assists with the excretion of newly synthesised proteins and could be the reason for the 




significant titre increases as a result of vaccination with the VR1020_oppA plasmid. After 
receiving the booster at week 7, the response did not increase further but rather 
decreased during week 10 although this decrease was not significant. Also, the average 
titre value was still statistically significant higher if compared to the control.  
It may be that the concentration of the booster injected at this point was not high enough, 
due to the average heavier weight of the ostriches at week 7 (61.3 kg) when compared 
to week 0 (not measured but estimated to be approximately 46.5 based on average 
weight gain). Thus an increase in DNA vaccine concentration might be needed after the 
ostriches reach a weight of 60 kg. If an immune response was produced, several factors 
could have influenced the observed lack of a secondary immune response after 
administering the booster vaccination. Firstly, the booster vaccination could have been 
administered too early. Ostriches typically respond maximally to vaccination within 2-3 
weeks after vaccination (Pretorius, 2009). However, in such instance the immune system 
is directly confronted with the antigen. In the case of a DNA vaccine the antigen still needs 
to be produced which could add time to the production of an immune response. Secondly, 
blood samples were only collected up to week 10. A further sampling point at week 13 
and week 16 could have led to a better understanding of the immune response 
encountered after the booster was administered. Memory may have been induced, but 
due to sampling that only included week 10, it cannot be confirmed. 
No significant impact was seen throughout the trial on the average weight of the different 
experimental groups when compared to the control group. Therefore neither the 
administered vaccine nor the transport of the ostriches during the trial had a negative 
affect on the growth or health of the ostriches. Thus significant progress has been made 
in this study in the development of a DNA vaccine against Ms01, but future trials are still 
required to optimize booster vaccinations with regard to timing and dosage.  




 Concluding remarks and future perspectives  
 
During this study the aim was to re-evaluate three previously developed DNA vaccines 
against Mycoplasma struthionis sp. nov. str. Ms01, firstly by in vitro expression in a 
mammalian cell culture based system and secondly in a vaccination field trial to 
determine the ability of these vaccines to elicit immune responses in ostriches. This 
required the preparation of the Ms01 OppA protein as well as the production of rabbit 
anti-OppA antibodies. OppA was successfully produced by recombinant expression and 
purified using affinity chromatography and produced in sufficient quantity for subsequent 
rabbit anti-OppA antibody production. 
Supercoiled DNA vaccine plasmids were used to transfect a COS-1 cell line and lysed 
with either Trizol® or Trypsin for RNA expression analysis and RTB or RIPA for protein 
translation analysis. Both the RNA isolation methods proved equally efficient and could 
be used to show that the oppA gene was being transcribed from all the DNA vaccine 
plasmids. Detecting translation of the oppA gene to the OppA protein by SDS-PAGE 
analysis proved difficult and was only detected after transfection with the VR1020_oppA 
vaccine and only after combining and concentrating the samples of a 6 well plate and 
analysing them 24 h after lysis with RIPA. This might be due to the low levels of translation 
or that the protein is degraded soon after production even after the addition of a protease 
inhibitor to the RIPA buffer. The protein could also be detected with the rabbit anti-OppA 
antibodies in western blot analysis using a highly sensitive chemiluminescence detection 
method, but not when using a colorimetric method of detection. This was only observed 
for the VR1020_oppA DNA vaccine and not for the pCI-neo_oppA and VR1012_oppA. 
This difference could be due to the presence of the tPa-signal sequence in the VR1020 
plasmid causing the expressed protein to be exported from the cell. The OppA protein 
was however not detected in the cell culture medium, possibly due to low concentrations 
of protein produced. In future by evaluating the expression of the DNA vaccines in primary 
ostrich cells, a better indication of whether these DNA vaccines would lead to OppA 
protein expression once they are injected into ostriches, may be obtained.  
The isolated Ms01 OppA protein proved to be efficient as coating antigen in the ELISA 
analysis of the immune responses elicited by the DNA vaccines. Producing a sufficient 
concentration of the OppA protein was problematic and several batches of the protein 
had to be prepared during the course of the ELISA analysis. In future studies the purified 
OppA-GST protein yield from the glutathione column could be increased by increasing 




the incubation time of the protein on the column for up to 3 hours. A higher yield would 
ensure that all ELISA’s are done using the same isolated fraction, ensuring increased 
consistency and accuracy. 
During the DNA vaccine trial on ostriches, the presence of mycoplasmas was evaluated 
at each sampling date by means of PCR. Raising the ostrich chicks in Fraserburg proved 
beneficial to their well-being as less mycoplasma infections were encountered during 
their time in Fraserburg.  
The pCI-neo_oppA vaccine administered at three different concentrations was 
unsuccessful in eliciting an immune response. The VR1020_oppA vaccine administered 
at three different concentrations, gave better immune responses when compared to pCI-
neo_oppA. The VR1020_oppA 300 μg/ml and 600 μg/ml doses elicited statistically 
significant immune responses in comparison to the control. The titre values, however, did 
not increase after a booster was administered. It might be that a secondary immune 
response could have occurred, but due to sampling that ended at week 10, it was not 
observed. These results obtained for the two DNA vaccines were similar as observed 
during Chapter 4 and again emphasises the importance of the tPa-signal peptide which 
results in extracellular protein expression. 
In future including serum samples at week 13 as well as week 15 of the vaccine trials 
would give a better indication of whether the booster immunisation would in fact be able 
to produce a secondary immune response and therefore induce immune memory. 
Including a serum sample well beyond week 15 could also determine the long-term 
response of the antibodies circulating the blood. 
Although there were still high levels of mycoplasma infections uncounted across all the 
groups, the focus of the thesis was to prove that the vaccinated animals show an antibody 
response towards the vaccine. This was however proven, but the efficacy of these 
developed DNA vaccines was also not evaluated and further studies are required to 
determine the optimal dose for eliciting a protective immune response against Ms01. 
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 Addendum A 
Statistical analysis data of an ostrich vaccination trial using Agrobase Generation 
II® 
The anti-OppA humoral immune response elicited by the DNA vaccines 
The humoral immune response elicited by the ostriches that were vaccinated with the 
VR1020_oppA and pCI-neo_oppA vaccines was analysed using ELISA as described in 
section 5.2.9. The data obtained was subsequently used for an analysis of variance 
(ANOVA) and subsequent least significant difference (LSD) calculations using the 
Agrobase Generation II® (Agronomix Software Inc.) software.  
ANALYSIS OF VARIENCE 
Bertie, VR1020, 2015 
 
Variable: Response to DNA vaccine VR1020_oppA 
 
Source df SS MS F-value Pr>F 
Total   243 18.921    
FAC_A 3 1.389 .463 7.62 0.0010 
FAC_B 3 2.784 0.928 15.27 0.0000 
FAC_A by FAC_B 9 0.892 0.099 1.63 0.1074 
Residual 228 13.856 0.061   
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares; 
F- value =  
Grand mean = 0.646 R-squared = 0.2677 C.V = 38.16% 
C.V. = coefficient of variation 
LSD for FAC_A = 0.0880 S.E.D = 0.0446 r = 61.0 
t (2-sided a=0.050, 228 df) = 1.9704 MSE = 0.06077 
LSD = Least significant difference; S.E.D = Standard Error of Difference 





Level Y Cv Rank 
    
3 0.72 49.5 1 VR1020 (600) 
2 0.71 36.7 2 VR1020 (300) 
4 0.61 42.8 3 Control  











LSD for FAC_B = 0.0880 S.E.D = 0.0446 r = 61.0 
t (2-sided a=0.050, 228 df) = 1.9704 MSE = 0.06077 
LSD = Least significant difference; S.E.D = Standard Error of Difference 





Level Y Cv Rank 
    
6 0.75 40.3 1 Week 7 
9 0.74 41.1 2 Week 10 
3 0.60 38.3 3 Week 4  
0 0.49 33.5 4  
 
 
LSD for FAC_A*FAC_B = 0.1759 S.E.D = 0.0893 r = 15.3 
t (2-sided a=0.050, 228 df) = 1.9704 MSE = 0.06077 
LSD = Least significant difference; S.E.D = Standard Error of Difference 
MSE = Mean Squared Error  
 
Two-way table for FAC_A*FAC_B, n=15 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.470 0.000 0.000 0.586 0.000 0.000 0.656 
2 0.000 0.000 0.718 0.000 0.000 0.838 0.000 0.000 0.816 
3 0.000 0.000 0.659 0.000 0.000 0.889 0.000 0.000 0.873 
4 0.000 0.000 0.542 0.000 0.000 0.690 0.000 0.000 0.628 
          
 
  




ANALYSIS OF VARIENCE 




Source df SS MS F-value Pr>F 
Total   182 15920.277    
FAC_A 3 1298.027 432.676 7.71 0.0001 
FAC_B 2 5004.695 2502.348 44.57 0.0000 
FAC_A by FAC_B 6 16.488 2.748 0.05 0.9995 
Residual 171 9601.066 56.147   
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares; 
F- value =  
Grand mean = 62.587 R-squared = 0.3969 C.V = 11.97% 
C.V. = coefficient of variation 
LSD for FAC_A = 3.0925 S.E.D = 1.5797 r = 45.0 
t (2-sided a=0.050, 171 df) = 1.9739 MSE = 56.14659 
LSD = Least significant difference; S.E.D = Standard Error of Difference 




Level Y Cv Rank 
    
4 66.10 13.1 1 control 
2 63.13 13.9 2 VR1020 (300) 
3 62.75 16.0 3 VR1020 (600) 




LSD for FAC_B = 2.6782 S.E.D = 1.3568 r = 61.0 
t (2-sided a=0.050, 228 df) = 1.9739 MSE = 56.14659 
LSD = Least significant difference; S.E.D = Standard Error of Difference 





Level Y Cv Rank 
    
9 69.42 11.2 1 Week 10 
6 61.7 12.5 2 Week 7 
3 56.64 13.9 3 Week 4  
 
 




LSD for FAC_A*FAC_B = 5.3564 S.E.D = 2.7136 r = 15.3 
t (2-sided a=0.050, 171 df) = 1.9739 MSE = 56.1459 
LSD = Least significant difference; S.E.D = Standard Error of Difference 
MSE = Mean Squared Error  
 
Two-way table for FAC_A*FAC_B, n=15 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 52.000 0.000 0.000 57.467 0.000 0.000 65.633 
2 0.000 0.000 57.353 0.000 0.000 62.471 0.000 0.000 69.559 
3 0.000 0.000 56.969 0.000 0.000 62.063 0.000 0.000 69.219 
4 0.000 0.000 60.231 0.000 0.000 64.808 0.000 0.000 73.269 
          
The trial input data follows for the VR1020_oppA vaccine. On each page the data is 
arranged in two columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response gained using ELISA analysis (resp) and weight of the ostriches, 
read from top to bottom and left to right.  
 
*Ostrich TRT TIME RESP WEIGHT 
81 1 0 0.498 -9.00 
83 1 0 0.368 -9.00 
84 1 0 0.461 -9.00 
85 1 0 0.488 -9.00 
86 1 0 0.455 -9.00 
87 1 0 0.495 -9.00 
88 1 0 0.356 -9.00 
90 1 0 0.408 -9.00 
91 1 0 0.424 -9.00 
92 1 0 0.449 -9.00 
95 1 0 0.508 -9.00 
96 1 0 0.491 -9.00 
97 1 0 0.427 -9.00 
99 1 0 0.431 -9.00 
100 1 0 0.442 -9.00 
101 2 0 0.553 -9.00 
103 2 0 0.484 -9.00 
104 2 0 0.285 -9.00 
106 2 0 1.078 -9.00 
107 2 0 0.391 -9.00 
108 2 0 0.32 -9.00 
109 2 0 0.346 -9.00 
110 2 0 0.44 -9.00 
111 2 0 0.474 -9.00 
112 2 0 0.357 -9.00 
113 2 0 0.385 -9.00 
*Ostrich TRT TIME RESP WEIGHT 
114 2 0 0.49 -9.00 
115 2 0 0.424 -9.00 
116 2 0 0.776 -9.00 
117 2 0 0.523 -9.00 
118 2 0 0.562 -9.00 
119 2 0 0.392 -9.00 
122 3 0 0.649 -9.00 
123 3 0 0.365 -9.00 
124 3 0 0.416 -9.00 
126 3 0 0.293 -9.00 
127 3 0 0.525 -9.00 
128 3 0 0.204 -9.00 
129 3 0 0.666 -9.00 
130 3 0 0.407 -9.00 
131 3 0 0.382 -9.00 
133 3 0 0.442 -9.00 
135 3 0 0.411 -9.00 
136 3 0 0.472 -9.00 
137 3 0 0.496 -9.00 
138 3 0 0.573 -9.00 
139 3 0 0.435 -9.00 
140 3 0 0.496 -9.00 
1 4 0 0.681 -9.00 
2 4 0 0.664 -9.00 
4 4 0 1.099 -9.00 
7 4 0 0.521 -9.00 




*Ostrich TRT TIME RESP WEIGHT 
8 4 0 0.725 -9.00 
9 4 0 0.24 -9.00 
10 4 0 0.405 -9.00 
15 4 0 0.442 -9.00 
16 4 0 0.687 -9.00 
17 4 0 0.44 -9.00 
18 4 0 0.83 -9.00 
19 4 0 0.403 -9.00 
20 4 0 0.461 -9.00 
81 1 3 0.537 45.50 
83 1 3 0.241 46.00 
84 1 3 0.455 38.00 
85 1 3 0.354 57.50 
86 1 3 0.828 57.00 
87 1 3 0.428 56.50 
88 1 3 0.471 52.00 
90 1 3 0.543 61.00 
91 1 3 0.746 49.00 
92 1 3 0.558 54.50 
95 1 3 0.28 55.00 
96 1 3 0.386 50.00 
97 1 3 0.468 46.00 
99 1 3 0.435 55.00 
100 1 3 0.303 57.00 
101 2 3 0.78 66.00 
103 2 3 0.668 55.00 
104 2 3 0.752 57.00 
106 2 3 0.542 57.00 
107 2 3 0.389 65.50 
108 2 3 0.555 60.00 
109 2 3 0.361 65.00 
110 2 3 0.574 63.00 
111 2 3 0.835 63.50 
112 2 3 0.624 54.50 
113 2 3 0.783 42.50 
114 2 3 0.729 51.00 
115 2 3 0.754 41 
116 2 3 1.33 49 
117 2 3 0.676 60.50 
118 2 3 0.848 65.00 
119 2 3 1.005 59.50 
122 3 3 1.047 54.00 
123 3 3 0.769 78.00 
124 3 3 0.728 54.50 
126 3 3 0.424 61.00 
127 3 3 0.986 53.00 
*Ostrich TRT TIME RESP WEIGHT 
128 3 3 0.468 62.50 
129 3 3 0.81 45.00 
130 3 3 0.533 61.00 
131 3 3 0.745 71.00 
133 3 3 0.671 50.50 
135 3 3 0.414 52.00 
136 3 3 0.422 48.00 
137 3 3 0.788 50.00 
138 3 3 0.583 58.50 
139 3 3 0.389 60.00 
140 3 3 0.758 53 
1 4 3 0.468 48.00 
2 4 3 0.637 59 
4 4 3 1.215 58 
7 4 3 0.474 50.50 
8 4 3 0.547 60.50 
9 4 3 0.254 66.00 
10 4 3 0.544 68.00 
15 4 3 0.304 52.00 
16 4 3 0.762 59.50 
17 4 3 0.66 59.50 
18 4 3 0.383 74.00 
19 4 3 0.515 64.50 
20 4 3 0.287 64.00 
81 1 6 0.575 49.50 
83 1 6 0.403 66.00 
84 1 6 0.455 44.50 
85 1 6 0.495 57.50 
86 1 6 0.494 62.00 
87 1 6 1.003 58.50 
88 1 6 0.594 60.00 
90 1 6 0.552 68.50 
91 1 6 0.743 53.00 
92 1 6 0.755 56.50 
95 1 6 0.442 57.50 
96 1 6 0.625 53.50 
97 1 6 0.573 50.50 
99 1 6 0.548 59.50 
100 1 6 0.533 65.00 
101 2 6 0.749 71.50 
103 2 6 0.935 60.50 
104 2 6 0.695 59.00 
106 2 6 0.645 64.00 
107 2 6 0.587 69.50 
108 2 6 0.802 64.50 
109 2 6 0.499 67.50 




*Ostrich TRT TIME RESP WEIGHT 
110 2 6 0.792 70.50 
111 2 6 1.065 66.50 
112 2 6 1.238 62.50 
113 2 6 0.929 49.00 
114 2 6 1.102 57.50 
115 2 6 0.471 46.00 
116 2 6 1.263 57.50 
117 2 6 0.866 63.50 
118 2 6 0.496 68.00 
119 2 6 1.092 64.50 
122 3 6 0.956 62.50 
123 3 6 1.133 82.50 
124 3 6 0.752 60.00 
126 3 6 0.566 67.00 
127 3 6 0.873 54.00 
128 3 6 0.55 64.50 
129 3 6 0.929 49.00 
130 3 6 0.823 67.50 
131 3 6 0.745 77.00 
133 3 6 2.254 56.00 
135 3 6 0.855 55.50 
136 3 6 0.695 54.00 
137 3 6 0.569 56.00 
138 3 6 0.992 62.50 
139 3 6 0.754 66.50 
140 3 6 0.769 58.50 
1 4 6 0.747 53.50 
2 4 6 0.774 65.50 
4 4 6 1.311 59.00 
7 4 6 0.573 58.00 
8 4 6 0.566 64.50 
9 4 6 0.429 70.00 
10 4 6 0.593 70.00 
15 4 6 0.643 56.50 
16 4 6 1.225 62.00 
17 4 6 0.546 67.50 
18 4 6 0.554 80.00 
19 4 6 0.707 68.50 
20 4 6 0.304 67.50 
81 1 9 0.77 57.00 
83 1 9 0.645 74.00 
84 1 9 0.533 51.50 
85 1 9 0.822 65.50 
86 1 9 0.496 73.00 
87 1 9 0.561 60.00 
88 1 9 0.575 72.50 
*Ostrich TRT TIME RESP WEIGHT 
90 1 9 0.458 76.00 
91 1 9 1.068 62.00 
92 1 9 0.652 67.50 
95 1 9 0.634 65.50 
96 1 9 0.409 62.00 
97 1 9 0.548 59.50 
99 1 9 0.574 69.50 
100 1 9 1.088 69.00 
101 2 9 0.837 75.00 
103 2 9 0.772 68.00 
104 2 9 0.44 66.50 
106 2 9 0.544 74.00 
107 2 9 0.722 75.00 
108 2 9 0.473 72.50 
109 2 9 0.733 74.00 
110 2 9 0.626 77.00 
111 2 9 1.098 80.00 
112 2 9 0.73 67.50 
113 2 9 1.131 57.00 
114 2 9 0.735 62.00 
115 2 9 1.176 55.00 
116 2 9 0.856 62.50 
117 2 9 1.111 71.00 
118 2 9 0.949 74.00 
119 2 9 0.933 71.50 
122 3 9 1.113 67.00 
123 3 9 1.185 92.00 
124 3 9 0.534 66.00 
126 3 9 0.73 77.00 
127 3 9 0.683 66.00 
128 3 9 0.545 75.00 
129 3 9 0.951 53.00 
130 3 9 0.673 76.50 
131 3 9 1.095 80.00 
133 3 9 2.257 61.50 
135 3 9 0.642 66.50 
136 3 9 0.614 63.00 
137 3 9 0.542 63.00 
138 3 9 0.84 65.00 
139 3 9 0.72 72.50 
140 3 9 0.835 63.50 
1 4 9 0.4 65.00 
2 4 9 1.166 74.00 
4 4 9 0.932 64.50 
7 4 9 0.51 71.50 
8 4 9 0.806 73.00 




*Ostrich TRT TIME RESP WEIGHT 
9 4 9 0.488 76.00 
10 4 9 0.705 77.00 
15 4 9 0.42 64.00 
16 4 9 0.876 72.00 
*Ostrich TRT TIME RESP WEIGHT 
17 4 9 0.484 75.00 
18 4 9 0.377 87.00 
19 4 9 0.824 77.00 
20 4 9 0.161 76.50 
* Entry – ostrich name; TRT – Treatment received; TIME – time in weeks; RESP – Titre response; 
WEIGHT – weight of ostrich at relevant week. 
 




ANALYSIS OF VARIENCE 
Bertie, pCI-neo, 2015 
 
Variable: Response to DNA vaccine pCI-neo_oppA 
 
Source df SS MS F-value Pr>F 
Total   199 7.774    
FAC_A 3 2.229 0.743 26.83 0.0000 
FAC_B 3 0.375 0.125 4.51 0.0044 
FAC_A by FAC_B 9 0.073 0.008 0.29 0.9759 
Residual 184 5.096 0.028   
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares; 
F- value =  
 
 
Grand mean = 0.444 R-squared = 0.3444 C.V = 37.48% 
C.V. = coefficient of variation 
LSD for FAC_A = 0.0657 S.E.D = 0.0333 r = 50.0 
t (2-sided a=0.050, 184 df) = 1.9729 MSE = 0.02770 
LSD = Least significant difference; S.E.D = Standard Error of Difference 





Level Y Cv Rank 
    
4 0.62 44.0 1 Control 
2 0.43 23.9 2 VR1020 300 
3 0.42 30.9 3 VR1020 600  




LSD for FAC_B = 0.0657 S.E.D = 0.0333 r = 50.0 
t (2-sided a=0.050, 184 df) = 1.9729 MSE = 0.02770 
LSD = Least significant difference; S.E.D = Standard Error of Difference 




Level Y Cv Rank 
    
6 0.51 40.4 1 Week 7 
9 0.46 44.0 2 Week 10 
0 0.42 43.5 3  
3 0.39 44.5 4 Week 4 
 
 




LSD for FAC_A*FAC_B = 0.1313 S.E.D = 0.0666 r = 12.5 
t (2-sided a=0.050, 184 df) = 1.9729 MSE = 0.02770 
LSD = Least significant difference; S.E.D = Standard Error of Difference 
MSE = Mean Squared Error  
 
Two-way table for FAC_A*FAC_B, n=15 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.308 0.000 0.000 0.333 0.000 0.000 0.323 
2 0.000 0.000 0.343 0.000 0.000 0.518 0.000 0.000 0.454 
3 0.000 0.000 0.363 0.000 0.000 0.484 0.000 0.000 0.434 
4 0.000 0.000 0.542 0.000 0.000 0.690 0.000 0.000 0.628 
          
 
  




ANALYSIS OF VARIENCE 





Source df SS MS F-value Pr>F 
Total   149 11695.766    
FAC_A 3 602.172 200.724 3.98 0.0093 
FAC_B 2 4114.389 2057.194 40.82 0.0000 
FAC_A by FAC_B 6 24.017 4.003 0.08 0.9980 
Residual 138 6955.189 50.400   
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares; 
F- value =  
 
Grand mean = 63.065 R-squared = 0.4053 C.V = 11.26% 
C.V. = coefficient of variation 
LSD for FAC_A = 3.2418 S.E.D = 1.6506 r = 37.0 
t (2-sided a=0.050, 138 df) = 1.9773 MSE = 50.39992 
LSD = Least significant difference; S.E.D = Standard Error of Difference 




Level Y Cv Rank 
    
4 66.10 13.1 1 Control 
1 63.23 12.4 2 VR1020 100 
2 61.96 14.9 3 VR1020 300 




LSD for FAC_B = 2.8075 S.E.D = 1.4199 r = 50.0 
t (2-sided a=0.050, 138 df) = 1.9773 MSE = 50.39992 
LSD = Least significant difference; S.E.D = Standard Error of Difference 





Level Y Cv Rank 
    
9 70.03 9.8 1 Week 10 
6 61.97 11.5 2 Week 7 
3 57.20 13.2 3 Week 4  
 
 




LSD for FAC_A*FAC_B = 5.6150 S.E.D = 2.8397 r = 12.5 
t (2-sided a=0.050, 138 df) = 1.9773 MSE = 50.39992 
LSD = Least significant difference; S.E.D = Standard Error of Difference 
MSE = Mean Squared Error  
 
Two-way table for FAC_A*FAC_B, n=15 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 57.600 0.000 0.000 62.450 0.000 0.000 69.650 
2 0.000 0.000 56.208 0.000 0.000 61.208 0.000 0.000 68.458 
3 0.000 0.000 54.767 0.000 0.000 59.400 0.000 0.000 68.733 
4 0.000 0.000 60.231 0.000 0.000 64.808 0.000 0.000 73.269 
          
The trial input data follows for the pCI-neo_oppA vaccine. On each page the data is 
arranged in two columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response gained using ELISA analysis (resp) and weight of the ostriches, 
read from top to bottom and left to right. 




ENTRY TRT TIME RESP WEIGHT 
21 1 0 0.263 -9.00 
23 1 0 0.395 -9.00 
25 1 0 0.252 -9.00 
29 1 0 0.290 -9.00 
30 1 0 0.182 -9.00 
31 1 0 0.427 -9.00 
33 1 0 0.265 -9.00 
34 1 0 0.308 -9.00 
37 1 0 0.297 -9.00 
38 1 0 0.292 -9.00 
41 2 0 0.292 -9.00 
44 2 0 0.356 -9.00 
46 2 0 0.347 -9.00 
47 2 0 0.445 -9.00 
48 2 0 0.397 -9.00 
50 2 0 0.380 -9.00 
51 2 0 0.418 -9.00 
52 2 0 0.366 -9.00 
53 2 0 0.443 -9.00 
55 2 0 0.358 -9.00 
56 2 0 0.489 -9.00 
60 2 0 0.472 -9.00 
62 3 0 0.320 -9.00 
63 3 0 0.353 -9.00 
64 3 0 0.383 -9.00 
66 3 0 0.277 -9.00 
68 3 0 0.615 -9.00 
70 3 0 0.297 -9.00 
71 3 0 0.284 -9.00 
72 3 0 0.369 -9.00 
73 3 0 0.387 -9.00 
74 3 0 0.385 -9.00 
75 3 0 0.546 -9.00 
77 3 0 0.255 -9.00 
78 3 0 0.419 -9.00 
79 3 0 0.484 -9.00 
80 3 0 0.429 -9.00 
1 4 0 0.681 -9.00 
2 4 0 0.664 -9.00 
4 4 0 1.311 -9.00 
7 4 0 0.521 -9.00 
8 4 0 0.725 -9.00 
9 4 0 0.240 -9.00 
10 4 0 0.405 -9.00 
15 4 0 0.442 -9.00 
16 4 0 0.687 -9.00 
17 4 0 0.440 -9.00 
18 4 0 0.830 -9.00 
19 4 0 0.403 -9.00 
20 4 0 0.461 -9.00 
ENTRY TRT TIME RESP WEIGHT 
21 1 3 0.329 57.00 
23 1 3 0.243 49.00 
25 1 3 0.266 65.00 
29 1 3 0.172 62.50 
30 1 3 0.173 59.50 
31 1 3 0.426 60.50 
33 1 3 0.206 65.00 
34 1 3 0.398 54.00 
37 1 3 0.430 61.50 
38 1 3 0.431 42.00 
41 2 3 0.183 55.50 
44 2 3 0.336 69.50 
46 2 3 0.362 52.50 
47 2 3 0.389 46.50 
48 2 3 0.422 41.00 
50 2 3 0.332 56.50 
51 2 3 0.256 56.00 
52 2 3 0.408 62.50 
53 2 3 0.362 56.00 
55 2 3 0.376 63.50 
56 2 3 0.326 64.50 
60 2 3 0.361 50.50 
62 3 3 0.405 57.00 
63 3 3 0.276 54.00 
64 3 3 0.182 57.00 
66 3 3 0.562 58.50 
68 3 3 0.435 40.00 
70 3 3 0.222 61.00 
71 3 3 0.373 58.50 
72 3 3 0.219 48.50 
73 3 3 0.437 52.00 
74 3 3 0.304 46.00 
75 3 3 0.388 56.50 
77 3 3 0.285 60.00 
78 3 3 0.385 62.00 
79 3 3 0.480 44.50 
80 3 3 0.474 66.00 
1 4 3 0.468 48.00 
2 4 3 0.637 59 
4 4 3 1.215 58 
7 4 3 0.474 50.50 
8 4 3 0.547 60.50 
9 4 3 0.254 66.00 
10 4 3 0.544 68.00 
15 4 3 0.304 52.00 
16 4 3 0.762 59.50 
17 4 3 0.660 59.50 




ENTRY TRT TIME RESP WEIGHT 
18 4 3 0.383 74.00 
19 4 3 0.515 64.50 
20 4 3 0.287 64.00 
21 1 6 0.343 64.00 
23 1 6 0.442 55.50 
25 1 6 0.231 69.00 
29 1 6 0.273 65.00 
30 1 6 0.305 62.50 
31 1 6 0.304 61.50 
33 1 6 0.201 69.50 
34 1 6 0.478 56.00 
37 1 6 0.404 64 
38 1 6 0.363 57.50 
41 2 6 0.609 58.00 
44 2 6 0.623 69.50 
46 2 6 0.597 58.50 
47 2 6 0.510 51.50 
48 2 6 0.646 44.50 
50 2 6 0.470 65.00 
51 2 6 0.368 62.00 
52 2 6 0.405 67.50 
53 2 6 0.535 62.00 
55 2 6 0.469 71.00 
56 2 6 0.424 69.50 
60 2 6 0.545 55.50 
62 3 6 0.390 62.00 
63 3 6 0.475 59.50 
64 3 6 0.241 54.50 
66 3 6 0.383 66.50 
68 3 6 0.637 47.00 
70 3 6 0.554 65.00 
71 3 6 0.440 64.00 
72 3 6 0.464 53.50 
73 3 6 0.550 52.50 
74 3 6 0.280 52.50 
75 3 6 0.477 62.50 
77 3 6 0.610 64.00 
78 3 6 0.695 65.50 
79 3 6 0.612 49.50 
80 3 6 0.450 72.50 
1 4 6 0.747 53.50 
2 4 6 0.774 65.50 
4 4 6 1.311 59.00 
7 4 6 0.573 58.00 
8 4 6 0.566 64.50 
9 4 6 0.429 70.00 
ENTRY TRT TIME RESP WEIGHT 
10 4 6 0.593 70.00 
15 4 6 0.643 56.50 
16 4 6 1.225 62.00 
17 4 6 0.546 67.50 
18 4 6 0.554 80.00 
19 4 6 0.707 68.50 
20 4 6 0.304 67.50 
21 1 9 0.453 71.00 
23 1 9 0.226 62.00 
25 1 9 0.197 75.00 
29 1 9 0.242 73.50 
30 1 9 0.584 71.00 
31 1 9 0.304 75.00 
33 1 9 0.228 73.50 
34 1 9 0.346 66.00 
37 1 9 0.236 72.50 
38 1 9 0.406 57.00 
41 2 9 0.552 66.00 
44 2 9 0.536 76.50 
46 2 9 0.378 66.00 
47 2 9 0.361 59.00 
48 2 9 0.534 54.00 
50 2 9 0.335 70.00 
51 2 9 0.447 66.50 
52 2 9 0.354 74.50 
53 2 9 0.666 69.50 
55 2 9 0.387 79.50 
56 2 9 0.437 76.50 
60 2 9 0.451 63.50 
62 3 9 0.225 72.50 
63 3 9 0.422 62.50 
64 3 9 0.208 71.50 
66 3 9 0.404 72.00 
68 3 9 0.696 57.00 
70 3 9 0.433 73.50 
71 3 9 0.455 72.00 
72 3 9 0.326 63.00 
73 3 9 0.399 62.50 
74 3 9 0.289 62.50 
75 3 9 0.572 69.50 
77 3 9 0.475 73.50 
78 3 9 0.424 73.50 
79 3 9 0.716 62.00 
80 3 9 0.453 83.50 
1 4 9 0.400 65.00 
2 4 9 1.166 74.00 




ENTRY TRT TIME RESP WEIGHT 
4 4 9 0.932 64.50 
7 4 9 0.510 71.50 
8 4 9 0.806 73.00 
9 4 9 0.488 76.00 
10 4 9 0.705 77.00 
15 4 9 0.420 64.00 
16 4 9 0.876 72.00 
17 4 9 0.484 75.00 
18 4 9 0.377 87.00 
19 4 9 0.824 77.00 
20 4 9 0.161 76.50 
* Entry – ostrich name; TRT – Treatment received; TIME – time in weeks; RESP – Titre response; 
WEIGHT – weight of ostrich at relevant week. 
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